BEFORE THE

INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

VOLUME II

LOCATION: STANFORD UNIVERSITY

ARRILLAGA ALUMNI CENTER

MC GAW HALL, 326 GALVEZ STREET

STANFORD, CALIFORNIA

DATE: AUGUST 13, 2008

9: 41 A. M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 79817

INDEX ITEM **DESCRIPTION** PAGE NO. CALL TO ORDER 153 ROLL CALL 155 CONTINUED CONSIDERATION OF RECOMMENDATIONS 157 FROM GRANTS WORKING GROUP ON NEW FACULTY AWARDS II APPLICATIONS. CONSIDERATION OF CIRM LOAN POLICY. 274 CONSIDERATION OF NAMES FOR CIRM-FUNDED 267 MAJOR FACILITIES. CONSIDERATION OF RECOMMENDATIONS ON RFA 302 APPLICANT POLICIES. CONSIDERATION OF POLICY REGARDING 219 EXTRAORDINARY PETITIONS FOR ICOC CONSIDERATION OF APPLICATIONS FOR FUNDING. PUBLIC COMMENT 323 **ADJOURNMENT** 325

1	STANFORD, CALIFORNIA; WEDNESDAY, AUGUST 13, 2008
2	09: 41 A. M.
3	
4	CHAIRMAN KLEIN: GOOD MORNING. IF WE CAN
5	BRING THE MEETING TO ORDER. WE HAD A WONDERFUL
6	PRESENTATION THIS MORNING ON BATTEN'S DISEASE, AND I
7	RECOMMEND IT STRONGLY TO THE BOARD AS THE FILM IS
8	DEVELOPED AND THE VIDEO IS INTEGRATED TO PLEASE TAKE
9	A LOOK AT IT. IT'S A WONDERFUL EXAMPLE OF
10	EXTRAORDINARY SCIENCE AND CLINICAL WORK COMBINED TO
11	DEAL WITH A TRAGIC DISEASE, KILLING MOST CHILDREN
12	AFFLICTED WITH IT BY THE TIME THEY'RE 12.
13	IF YOU HAVE A CHANCE AND HE'S STILL HERE,
14	TONY FARRANDINO CAME ALL THE WAY FROM PENNSYLVANIA.
15	HE'S THE FATHER OF A YOUNG BOY DREW WHO IS AFFLICTED
16	WITH THE DISEASE. IT IS AN EXTRAORDINARY EFFORT
17	THAT IS A MODEL OF HOW WE NEED TO PROCEED WITH
18	REPLACEMENT CELL THERAPIES. AND I RECOMMEND THE
19	FILM THAT WE'LL BE PRODUCING TO EACH OF THE BOARD
20	MEMBERS.
21	I'D LIKE TO OPEN
22	DR. POMEROY: BOB, BEFORE YOU GO ON, COULD
23	I MAKE A COMMENT?
24	CHAIRMAN KLEIN: YES. DR. CLAIRE POMEROY.
25	DR. POMEROY: I WOULD JUST LIKE TO THANK
	153

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	MR. FARRANDINO FOR TAKING THIS LONG TRIP. AS A
2	BOARD MEMBER, WE COME TO THESE MEETINGS. AND WHEN
3	WE HEAR THE STORIES LIKE DREW'S STORY, IT REMINDS US
4	ALL WHY WE'RE WORKING SO HARD. SO ON BEHALF OF MY
5	INSTITUTION, ON BEHALF OF ICOC, I'D LIKE TO REALLY
6	THANK MR. FARRANDINO AGAIN FOR TELLING US DREW'S
7	STORY AND FOR MOTIVATING US AND INSPIRING US TO KEEP
8	WORKING SO HARD IN THIS IMPORTANT FIELD. SO THANK
9	YOU VERY MUCH.
10	(APPLAUSE.)
11	CHAIRMAN KLEIN: CLEARLY OUR GREAT
12	ADMIRATION AND THANKS GOES OUT TO STEM CELL, INC.
13	AND THEIR TREMENDOUS STAFF AND LEADERSHIP IN MOVING
14	FORWARD COURAGEOUSLY, SAFELY WITH THE DEVELOPMENT OF
15	THIS THERAPY. IT'S A GREAT MODEL FOR ALL OF US TO
16	STUDY.
17	WITH THAT, I'D LIKE TO MOVE FORWARD INTO
18	THE FORMAL MEETING. MELISSA IS NOT HERE AT THE
19	MOMENT BECAUSE I THINK SHE'S TRYING TO WORK WITH A
20	BOARD MEMBER. BUT IF, JAMES HARRISON, MAYBE YOU
21	COULD CALL THE ROLL, AND THEN WE WILL HAVE THE
22	PLEDGE OF ALLEGIANCE FOLLOW THAT.
23	MR. HARRISON: WE ARE STILL SHY OF A
24	QUORUM BY ONE. SO PERHAPS WE SHOULD BEGIN WITH THE
25	PLEDGE OF ALLEGIANCE AND THEN MOVE ON AND TAKE THE

	DARRISTERS REPORTING SERVICE
1	ROLL ONCE WE HAVE A QUORUM ESTABLISHED.
2	CHAIRMAN KLEIN: THAT'S FINE. MR.
3	HARRISON, WOULD YOU LIKE TO SPECIFICALLY INTRODUCE
4	THE NEW ALTERNATE THAT WE HAVE THIS MORNING?
5	MR. HARRISON: YES. DR. NANCY MILLIKEN
6	FROM UCSF HAS JOINED US AS DR. HAWGOOD'S ALTERNATE,
7	AND WE ARE EXTREMELY GRATEFUL TO HER GIVEN OUR
8	QUORUM CHALLENGES.
9	(APPLAUSE.)
10	MR. HARRISON: WE NOW HAVE A QUORUM.
11	CHAIRMAN KLEIN: YES. GREAT. SO AT THIS
12	POINT IF WE COULD CALL THE ROLL. WE WILL CALL THE
13	ROLL AND THEN DO THE PLEDGE OF ALLEGIANCE.
14	MS. KING: ABSOLUTELY.
15	DONALD DAFOE.
16	DR. DAFOE: HERE.
17	MS. KING: ROBERT PRICE.
18	DR. PRI CE: HERE.
19	MS. KING: FLOYD BLOOM.
20	DR. BLOOM: HERE.
21	MS. KING: DAVID BRENNER.
22	DR. BRENNER: HERE.
23	MS. KING: JACOB LEVIN.
24	DR. LEVIN: HERE.
25	MS. KING: MARSHA CHANDLER. MARCY FEIT.
	155

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

	BARRISTERS' REPORTING SERVICE
1	MI CHAEL FRIEDMAN.
2	DR. FRIEDMAN: HERE.
3	MS. KING: LEEZA GIBBONS. MICHAEL
4	GOLDBERG.
5	MR. GOLDBERG: HERE.
6	MS. KING: NANCY MILLIKEN.
7	DR. MILLIKEN: HERE.
8	MS. KING: BOB KLEIN.
9	CHAIRMAN KLEIN: HERE.
10	MS. KING: SHERRY LANSING.
11	MS. LANSING: HERE.
12	MS. KING: GERALD LEVEY. TED LOVE.
13	DR. LOVE: HERE.
14	MS. KING: TINA NOVA. ED PENHOET.
15	DR. PENHOET: HERE.
16	MS. KING: PHIL PIZZO.
17	DR. PI ZZO: HERE.
18	MS. KING: CLAIRE POMEROY.
19	DR. POMEROY: HERE.
20	MS. KING: FRANCISCO PRIETO. ROBERT
21	QUI NT.
22	DR. QUINT: HERE.
23	MS. KING: JOHN REED. DUANE ROTH.
24	MR. ROTH: HERE.
25	MS. KING: JOAN SAMUELSON.
	156
	100

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	MS. SAMUELSON: HERE.
2	MS. KING: DAVID SERRANO-SEWELL. JEFF
3	SHEEHY.
4	MR. SHEEHY: HERE.
5	MS. KING: JON SHESTACK. OSWALD STEWARD.
6	DR. STEWARD: HERE.
7	MS. KING: AND WE HAVE A QUORUM. PLEASE
8	STAND IF YOU ARE ABLE.
9	(THE PLEDGE OF ALLEGIANCE.)
10	CHAIRMAN KLEIN: TO MAKE CERTAIN WE HAVE A
11	FULLY INFORMED QUORUM THIS MORNING, MIKE YAFFE,
12	COULD YOU GO BACK THROUGH THE BASIC CRITERIA UNDER
13	WHICH WE ARE TO JUDGE THIS GRANT BY THE TERMS OF THE
14	RFA THAT WAS SENT OUT AND AUTHORIZED BY THE BOARD
15	AND IMPLEMENTED BY THE STAFF?
16	DR. YAFFE: JUST GO STRAIGHT TO THE
17	CRITERIA THAT WERE USED BY THE GRANTS WORKING GROUP
18	TO JUDGE THIS SET OF APPLICATIONS. AND THE
19	APPLICATIONS WERE JUDGED IN THREE KEY AREAS. EACH
20	OF THESE THREE CRITERIA WAS VIEWED AS EQUALLY
21	I MPORTANT.
22	FIRST, RESEARCH PLAN. THESE ARE RESEARCH
23	GRANTS. THE REVIEWERS JUDGED THE RESEARCH PLAN FOR
24	THE SIGNIFICANCE AND INNOVATION OF THE PROPOSED
25	PROJECT AS WELL AS THE DESIGN AND THE FEASIBILITY OF
	157

1	THE EXPERIMENTS.
2	SECOND AREA OF CONSIDERATION WAS THE
3	PRINCIPAL INVESTIGATOR, THE APPLICANT. HERE THE
4	REVIEWERS ASSESSED THE QUALIFICATIONS AS WELL AS THE
5	POTENTIAL FOR LEADERSHIP IN THE STEM CELL AND
6	REGENERATIVE MEDICINE FIELDS. ADDITIONALLY, THEY
7	EXAMINED PLANS FOR MENTORING AND CAREER DEVELOPMENT.
8	AND THE THIRD KEY AREA WAS THE
9	INSTITUTION, THE APPLICANT'S INSTITUTION. HERE THE
10	REVIEWERS ANALYZED THE COMMITMENT OF THE INSTITUTION
11	TO THE INVESTIGATOR, THE TRACK RECORD OF THE
12	INSTITUTION IN THE PROMOTION AND SUPPORT OF YOUNG
13	FACULTY, AS WELL AS THE FUTURE PLANS OF THE
14	INSTITUTION FOR FURTHER GROWTH IN STEM CELL SCIENCE.
15	CHAIRMAN KLEIN: THANK YOU VERY MUCH. AND
16	I'M GOING TO TURN THIS OVER TO JEFF SHEEHY AS WE GO
17	THROUGH LOOKING AT THESE GRANTS. I WOULD LIKE TO
18	SAY AS A MACRO ISSUE THAT WE NEED TO REMEMBER THAT
19	WHEN WE'RE LOOKING AT THE PERCENTAGE OF THESE GRANTS
20	THAT WE FUND, THEY HAVE ALREADY BEEN TRIAGED DEEPLY
21	AT THE INSTITUTIONS, WHO ARE LIMITED IN THE NUMBER
22	OF NOMINATIONS. AND UNLIKE MORE NARROWLY DEFINED
23	GRANT REQUESTS THAT MAY HAVE A VERY SPECIFIC FOCUSED
24	TOPIC AS NEW CELL LINES OR TOOLS, THIS IS A VERY
25	LARGE UNIVERSE THAT THESE APPLICATIONS CAME FROM
	150

1	BECAUSE IT'S THE ENTIRE SPECTRUM OF EMBRYONIC AND
2	ADULT, OF ALL CELL TYPES, FETAL CELL, ETC. SO WE
3	HAVE A LARGE UNIVERSE THAT WAS DEEPLY TRIAGED
4	INSTITUTIONALLY BEFORE IT GOT TO THIS LEVEL.
5	SO WHEN WE LOOK AT THESE, WE NEED TO
6	UNDERSTAND THE RELATIVE SCORING OF THESE WITH THAT
7	MACRO PICTURE AND HOPEFULLY LOOK AT THE SCIENCE AND
8	THE QUALITY OF THE CANDIDATE AND THE INSTITUTIONAL
9	COMMITMENT, INDEPENDENTLY MAKING DECISIONS WITHOUT
10	BEING AS CONSTRAINED AS WE OTHERWISE MIGHT BE IN A
11	NORMAL GRANT CYCLE BY THE PERCENTAGE OF THOSE GRANTS
12	WHICH ARE FUNDED. JEFF SHEEHY.
13	MR. SHEEHY: THANK YOU, BOB. JUST TO
14	RECAP WHAT WE DID LAST NIGHT, WE HAVE APPROVED
15	PROVISIONALLY ALL THE APPLICATIONS THAT THE WORKING
16	GROUP HAD RECOMMENDED FOR TIER 1. SO IF WE COULD
17	PUT UP TIER 3, I THINK OUR NEXT STEP WILL BE TO LOOK
18	AT THE APPLICATIONS THAT ARE IN TIER 3 AND SEE IF
19	THERE ARE ANY OF THOSE APPLICATIONS WE WOULD LIKE TO
20	MOVE UP TO TIER 1 OR HAVE SOME OTHER DISPOSITION
21	WI TH.
22	CHAIRMAN KLEIN: YOU ARE GOING TO TIER 3
23	FIRST?
24	MR. SHEEHY: AND THEN AFTER THIS, WE'LL GO
25	TO TIER 2, AND THOSE APPLICATIONS WE WILL EITHER
	150

1	MOVE INTO TIER 1 OR INTO TIER 3. THEY'LL EITHER GET
2	FUNDED OR NOT, BUT I THINK PROBABLY BEST RIGHT NOW
3	TO DISPOSE OF TIER 3.
4	SO IF BOARD MEMBERS WILL TAKE A MINUTE TO
5	LOOK AT THE APPLICATIONS IN TIER 3, WHICH ARE YELLOW
6	IN YOUR BOOK, AND SEE IF THEN I WOULD TAKE A
7	MOTION TO MOVE ANY OF THOSE APPLICATIONS INTO TIER 1
8	IF THERE IS SUCH A MOTION.
9	MR. ROTH: JEFF, COULD I JUST ASK. DURING
10	THE REVIEW OF THE TIER 3, WERE THERE ANY
11	APPLICATIONS IN THERE THAT RESULTED IN LENGTHY
12	DISCUSSIONS PRO OR CON?
13	MR. SHEEHY: NO. TIER 3, IT WAS I'M
14	GLAD THAT BOB MADE HIS INTRODUCTORY REMARKS. IF YOU
15	TAKE THE LARGER VIEW OF THIS APPLICATION CYCLE, WE
16	REALLY HAD A LOT OF VERY GOOD SCIENCE, A LOT OF VERY
17	GOOD SCIENTISTS IN THIS PROCESS. SO WE STARTED OFF
18	ABOVE THE PAYLINE IN TIER 1. AND THEN IN TIER 2 WE
19	HAD AN ENORMOUS NUMBER OF GOOD APPLICATIONS TOO.
20	AND SO REALLY GOING INTO TIER 3 WAS NOT SOMETHING
21	THAT GOT MUCH ATTENTION BECAUSE WE HAD ALMOST AN
22	ABUNDANCE, OVERABUNDANCE OF GOOD SCIENCE. WE WERE
23	WAY BEYOND WHAT WE HAD BUDGET AUTHORITY FOR TO BEGIN
24	WITH, SO OUR CHALLENGE WAS REALLY TRYING TO WINNOW
25	IT DOWN.

I THINK THAT'S A FAIR REPRESENTATION OF
WHAT HAPPENED.
CHAIRMAN KLEIN: AND JEFF.
MR. SHEEHY: TIER 3 DID NOT REALLY GET
MAYBE THE SAME EXAMINATION IT MIGHT HAVE HAD IN
DI FFERENT ROUNDS.
MR. ROTH: THAT'S WHY I RAISED THE
QUESTION JUST GIVEN THE EXPERIENCE WE HAVE, THAT
SOMETIMES THERE'S CONTROVERSY AND WE GET IT WRONG.
BEFORE WE JUST WIPE THESE ALL OUT
CHAIRMAN KLEIN: IN TERMS OF DUANE'S
QUESTION, JEFF, THERE'S NO APPLICATION IN TIER 3
THAT I WANT TO MOVE, WHICH WAS YOUR INITIAL
QUESTION; BUT IN TERMS OF THE CONTEXT OF DUANE'S
QUESTION, THERE IS AN APPLICATION IN TIER 3 THAT I
DON'T THINK THAT I HAVE ADEQUATE INFORMATION TO DEAL
WITH A DECISION ON. AND I'D LIKE TO ACTUALLY ASK IF
WE CAN BRING IT BACK AT A LATER MEETING WITH MORE
INFORMATION BECAUSE IT'S APPLICATION NO. 937. AND I
DON'T WANT GO INTO AN EXAMINATION OF IT AT THIS
POINT BECAUSE I'M NOT I'M LACKING BASIC
INFORMATION, WHICH I THINK THE PEER GROUP LACKED,
AND THAT THERE WAS A QUESTION THAT AROSE AS TO
WHETHER THERE WAS SUFFICIENT TISSUE OF A VERY
SPECIFIC TYPE TO DO THE SCIENCE PROPOSED.
161

1	AND I RECALL THAT THE SCIENCE WAS
2	DOWNGRADED ON THAT, AND THE SCORE IS REFLECTIVE OF
3	THAT DOWNGRADING, WHICH MAY BE VERY APPROPRIATE, BUT
4	THERE WASN'T INFORMATION AT THE PEER REVIEW
5	SUFFICIENT TO DETERMINE WHETHER THERE WAS SUFFICIENT
6	TISSUE OF THIS TYPE TO DO AVAILABLE TO THIS
7	INSTITUTION TO DO THE RESEARCH. SO I WOULD JUST ASK
8	THAT 937 BE LOOKED AT BY THE STAFF, BE BROUGHT BACK
9	IN SEPTEMBER SO WE HAVE ENOUGH INFORMATION. AND THE
10	STAFF MAY COME BACK AND SAY WE DON'T THINK, FROM OUR
11	CONSIDERATION, THERE WOULD BE ANY CHANGES. FINE.
12	BUT JUST INFORMATIONALLY, I THINK WE'D BE BETTER
13	SERVED ON THAT APPLICATION GETTING ADDITIONAL
14	I NFORMATION.
15	MR. SHEEHY: WELL, LET ME JUST DO ONE
16	THING FIRST. CAN WE GET THE CONFLICTS SO THAT
17	JAMES, I THINK IF WE'RE GOING TO HAVE ANY
18	DISCUSSION, AND I WANT TO MAKE SURE I'M NOT
19	CONFLI CTED.
20	MR. HARRISON: YOU'RE NOT. IT'S DR.
21	FRI EDMAN.
22	MR. SHEEHY: BOB, IF YOU WANT TO MAKE A
23	MOTION TO THAT, IT SEEMS VERY REASONABLE. I DON'T
24	THINK THE APPLICANT WILL BE HURT BY THIS BECAUSE THE
25	APPLICANT IS CLEARLY IN TIER 3. SO I SUSPECT THAT

1	IT'S NOT GOING TO GO ANYWHERE, SO IF YOU WANT TO A
2	MAKE MOTION.
3	CHAIRMAN KLEIN: I'D MAKE A MOTION THAT WE
4	DEFER ACTION ON 937 UNTIL SEPTEMBER AND ASK THE
5	STAFF JUST TO GIVE US AN EVALUATION IN SEPTEMBER
6	WHETHER THERE'S SIGNIFICANT INFORMATION THAT WOULD
7	POTENTIALLY CHANGE THE EVALUATION OF WHETHER THE
8	TISSUE MATERIAL THAT WAS IN QUESTION WOULD BE
9	AVAILABLE AND WOULD, THEREFORE, IMPACT THE
10	SCIENTIFIC EVALUATION OF THE ABILITY TO COMPLETE THE
11	EXPERIMENT AS WELL AS THE OTHER CONSIDERATION OF THE
12	APPLI CATI ON.
13	BASICALLY THE MOTION IS DEFER ACTION ON
14	937 UNTIL SEPTEMBER, ASK THE STAFF TO REPORT BACK TO
15	US WITH THEIR RECOMMENDATION AT THAT TIME.
16	MR. SHEEHY: IS THERE A SECOND TO THAT
17	MOTION?
18	MS. SAMUELSON: I'LL SECOND IT.
19	MR. SHEEHY: WE HAVE A SECOND FROM JOAN
20	SAMUELSON.
21	DR. PENHOET: I JUST HAVE A QUESTION. ON
22	WHAT BASIS DO WE MAKE THIS JUDGMENT? YOU HAVE SOME
23	INFORMATION THAT THE REST OF US DON'T HAVE ABOUT
24	937.
25	CHAIRMAN KLEIN: AS A MEMBER OF THE PEER
	163

103

1	REVIEW GROUP, I'M RESPONDING TO DUANE'S POINT. I'M
2	JUST POINTING OUT THAT I THINK WE NEED MORE
3	INFORMATION. I DON'T THINK IT'S APPROPRIATE TO
4	BRING THIS INTO A DISCUSSION UNTIL WE HAVE THAT
5	INFORMATION. AND AT THAT TIME, BASED UPON THE
6	ADVICE OF THE SCIENTIFIC STAFF, THE WHOLE BOARD
7	COULD DECIDE TO DISCUSS IT OR NOT DISCUSS IT. SO IN
8	SEPTEMBER THE WHOLE BOARD WOULD HAVE THE INFORMATION
9	AVAILABLE TO IT TO MAKE A DECISION.
10	DR. PENHOET: I UNDERSTAND WHAT YOU JUST
11	SAID. YOU HAVE INFORMATION I DON'T HAVE, SO I'M
12	JUST TRYING TO FIGURE OUT HOW I MAKE AN INFORMED
13	VOTE WHETHER WE SHOULD DELAY 937 OR NOT BECAUSE I'M
14	SURE THE REST OF THE PEOPLE AROUND THE TABLE ARE IN
15	THE SAME POSITION I'M IN. I DON'T KNOW WHAT YOU'RE
16	TALKING ABOUT.
17	CHAIRMAN KLEIN: IN PLAIN LANGUAGE, IT'S
18	JUST IT'S A REQUEST THAT WE OBTAIN INFORMATION,
19	WHICH SHOULDN'T BE A DIFFICULT ISSUE. I'M JUST
20	ASKING THAT SO THAT WE MAKE SURE WE'RE THOUGHTFULLY
21	LOOKING AT EVERY GRANT. I DON'T BELIEVE THAT
22	THERE'S ENOUGH INFORMATION OUT THERE TO PRESENT IT
23	AT THIS POINT, AND SO I THINK THAT WE SHOULD HAVE
24	THE ABILITY FOR THE STAFF, WHEN WE LACK INFORMATION,
25	TO EXAMINE IT AND COME BACK AT A SUBSEQUENT MEETING.

1	DR. PRICE: I JUST WONDER ISN'T THERE AN
2	EQUITY ISSUE INVOLVED? THERE MAY BE OTHERS OF THESE
3	GRANTS IN THIS CATEGORY WHERE MORE INFORMATION
4	CHAIRMAN KLEIN: SO, DR. PRICE, IF YOU
5	THINK THAT THERE IS ANOTHER APPLICATION THAT NEEDS
6	INFORMATION FOR US TO MAKE A DECISION, I WOULD
7	SUGGEST THAT YOU ASK FOR IT.
8	DR. PRICE: I DON'T WANT US TO HAVE TO GO
9	BACK INTO EXECUTIVE SESSION WHILE WE EXAMINE EVERY
10	ONE OF THESE.
11	MR. SHEEHY: LET ME JUST PUT A CONTEXT
12	TOO. WE'RE IN KIND IF A MIDDLE PERIOD, SO I THINK
13	THIS IS KIND OF AN INTERESTING PLACE TO BE IN. WE
14	HAVE LATER ON THE AGENDA A FORMAL PROCESS FOR AN
15	APPLICANT TO ASK FOR A RE-REVIEW.
16	THE LAST MEETING WE HAD A LOT OF RATHER
17	I DON'T KNOW IF IT WAS REALLY EQUITABLE. WHOEVER
18	HAPPENED TO HAVE GOTTEN THEIR TEN CENTS IN SEEMED TO
19	HAVE GOTTEN ANOTHER BITE AT THE APPLE. SO WE'RE IN
20	BETWEEN WHAT HAPPENED LAST MEETING AND WHAT'S GOING
21	TO HAPPEN FOLLOWING. IN THAT CONTEXT, I HAVE DUANE
22	AND THEN I HAVE SHERRY.
23	CHAIRMAN KLEIN: I WOULD SAY IN THIS
24	CONTEXT, JEFF, THE APPLICANT DID NOT CONTACT ME. SO
25	I HAVE NO INFORMATION FROM THE APPLICANT.
	165

1	MR. ROTH: IF I COULD JUST CLARIFY AGAIN.
2	THAT'S EXACTLY WHY I ASKED THE QUESTION, THAT I HOPE
3	WE'RE GOING TO ADDRESS THIS, BUT AT THE LAST
4	MEETING, THERE WERE SOME GRANTS THAT WERE SCORED LOW
5	BECAUSE THE REVIEWERS DIDN'T BELIEVE THAT THERE WERE
6	ENOUGH OOCYTES AVAILABLE. I DON'T REMEMBER THE
7	DETAIL; BUT IF THERE WERE ANY OF THOSE IN THE REVIEW
8	WHERE THERE WAS SOMETHING MATERIAL THAT WAS
9	DISBELIEVED, BECAUSE WE DON'T HAVE THE NEW PROCESS
10	IN PLACE, JUST TELL US WHICH GRANTS THOSE WERE AND
11	LET'S HAVE A LOOK AT THEM LIKE THIS ONE.
12	MS. LANSING: WELL, I'M VERY RESPECTFUL OF
13	AN APPLICANT OR A MEMBER OF THE BOARD COMING IN AND
14	ASKING FOR A REVIEW OF SOMETHING. AND I BELIEVE
15	THAT LATER IN THE DAY, WE ALL HAVE IT IN OUR BOOKS,
16	WE'RE GOING TO PRESENT, OR JEFF IS, A PROCESS. SO I
17	RESPECTFULLY THINK THAT WE SHOULD PRESENT THE
18	PROCESS, AND ANYBODY, INCLUDING THE BOARD MEMBER,
19	THAT HAS A PROBLEM SHOULD DO THE PROCESS. AND I
20	THINK, THEREFORE, CHAIRMAN KLEIN, IF THAT'S
21	COMFORTABLE WITH YOU AT THAT TIME, WE COULD BRING
22	THIS ONE UP.
23	CHAIRMAN KLEIN: SURE. THE PROCESS IS FOR
24	A PETITION FROM THE APPLICANT.
25	MS. LANSING: CAN'T IT ALSO BE A
	166
	100

1	PROCESS SHOULDN'T WE WHEN WE GET TO IT A PROCESS
2	THAT WE WOULD ALSO DO AS WELL BECAUSE WHAT I THINK
3	EVERYBODY IS FEELING, AND I'M VERY RESPECTFUL OF
4	WHAT YOU'RE SAYING, I DON'T KNOW WHAT THIS SPECIFIC
5	APPLICANT, WHY WE'RE DOING IT. THEREFORE, IT MAKES
6	ME FEEL WHAT BOB SAID, WELL, MAYBE WE THEN SHOULD
7	LOOK AT ALL OF THEM. WE DON'T WANT TO DO THAT. SO
8	THE QUESTION IS
9	CHAIRMAN KLEIN: BRINGING IT UP IN THE
10	CONTEXT OF THIS
11	MS. LANSING: OF THIS NEW PROCESS. I
12	THINK THAT WOULD BE MAKE EVERYBODY FEEL GOOD
13	ABOUT IT. THEN IT WOULD GO THROUGH THE PROCESS AND
14	COME BACK TO US.
15	CHAIRMAN KLEIN: ABSOLUTELY FINE.
16	MR. SHEEHY: TED.
17	DR. LOVE: I THINK I WAS GOING TO
18	EMPHASIZE THE POINT THAT ED WAS MAKING, WHICH I'M A
19	LITTLE BIT UNCOMFORTABLE IN PULLING THIS GRANT OUT
20	UNLESS I KNOW MORE. THE LAST SENTENCE OF THE REVIEW
21	SAYS, "IN SUMMARY, REVIEWERS FELT THAT THIS WAS A
22	WEAK PROPOSAL FROM A MODERATELY PROMISING
23	CANDIDATE." WHEN IT ENDS THAT WAY, I HAVE A HARD
24	TIME FEELING LIKE THIS IS ONE THAT WE SHOULD PULL
25	OUT FOR SPECIAL ATTENTION UNLESS THERE'S A BASIS
	4.7

1	THAT YOU CAN ARTICULATE.
2	CHAIRMAN KLEIN: IN TERMS OF THAT
3	TERMINOLOGY, TOO, ONE THING THAT WE'VE UNDERUTILIZED
4	IN THE SYSTEM IS MINORITY REPORTS. MY RECOLLECTION
5	IS THERE WAS A GREAT DEAL OF DISCREPANCY AMONG THE
6	REVIEWERS SO THAT WE HAD CADRES WHO WERE STRONGLY
7	SUPPORTIVE AND CADRES THAT WERE NOT. AND IF WE HAVE
8	A MORE AS WE GAIN REFINEMENT AND HAVE MINORITY
9	REPORTS, WE WILL GET INSIGHT INTO THESE OPTIONS.
10	NEVERTHELESS, I THINK WE'VE POSTPONED THIS AS SHERRY
11	I NDI CATED.
12	MR. SHEEHY: SO DOES THAT MEAN YOU'RE
13	TAKING YOUR MOTION
14	CHAIRMAN KLEIN: I'M WITHDRAWING THE
15	MOTION.
16	MR. SHEEHY: THAT'S OKAY WITH THE SECOND?
17	MS. SAMUELSON: SURE.
18	MR. SHEEHY: SO DO WE HAVE ANY OTHER
19	MOTIONS RELATED TO APPLICATIONS IN TIER 3?
20	DR. PENHOET: I JUST WANTED TO MAKE A
21	POINT FOR THE AUDIENCE, THAT ALL OF THE GRANTS,
22	INCLUDING THOSE IN TIER 3, RECEIVED THE SAME LEVEL
23	OF THOUGHTFUL, THOROUGH REVIEW IN THE PROCESS BEFORE
24	ANY RANKING OCCURRED. YOUR COMMENT MIGHT BE TAKEN
25	BY SOME, JEFF, THAT THOSE IN TIER 3 DIDN'T GET A
	160

168

1	HARD LOOK BECAUSE
2	MR. SHEEHY: I THINK MAYBE I SHOULD HAVE
3	BEEN CLEAR WHEN I WAS ANSWERING DUANE. THAT WAS
4	SOLELY IN THE CONTEXT OF PROGRAMMATIC REVIEW. EVERY
5	APPLICATION GOT FULL REVIEW; BUT IN PROGRAMMATIC
6	REVIEW IS WHEN WE ASSIGN APPLICATIONS TO THEIR
7	TIERS. AND THERE IS A TENDENCY TO REALLY FOCUS ON
8	THOSE THAT SCORED VERY WELL OR NEARLY VERY WELL.
9	AND ESPECIALLY WHEN WE HAVE A LIMITED AMOUNT OF
10	MONEY TO WORK WITH, I THINK THAT'S WHERE MOST OF THE
11	ATTENTION IS GOING TO BE FOCUSED IN PROGRAMMATIC
12	REVIEW, AND WE WERE WELL OVER OUR STATED BUDGET OR
13	STATED PAYLINE WHEN WE GOT THROUGH WITH TIER 1. SO
14	THAT DID KIND OF IMPACT HOW MUCH WE FELT WE COULD
15	INTRODUCE PROGRAMMATIC CONSIDERATIONS INTO THE
16	REVIEW AT THAT POINT FOR SOME OF THOSE APPLICATIONS
17	IN TIER 3.
18	SO, AGAIN, IF THERE'S NO MOTION TO MOVE
19	ANYTHING IN TIER 3, THEN PERHAPS WE COULD LOOK AT
20	TIER 2, WHICH IS THE GRAY AREA IN YOUR BOOKS.
21	PUBLIC COMMENT NOW IS FINE, IF YOU'D LIKE.
22	MR. SIMPSON: JOHN SIMPSON FROM CONSUMER
23	WATCHDOG. I JUST WANTED TO SECOND WHAT DR. LOVE
24	SAID IN THIS PARTICULAR REGARD. I'VE BEEN READING
25	THE PUBLIC REVIEW HERE. IT SEEMS TO ME THAT, BASED
	160

1	ON WHAT IS IN THE PUBLIC REVIEW OF THE THING YOU'RE
2	TALKING ABOUT, THERE'S NO WAY THAT THIS SHOULD EVEN
3	BE HELD OVER. PUBLICATION RECORD IS POOR, ETC.,
4	ETC. AND I JUST I THINK YOU NEED TO MAINTAIN
5	SOME HIGH STANDARDS.
6	MR. SHEEHY: THANK YOU. SO, AGAIN,
7	LOOKING NOW AT TIER 2, WHICH IS THE GRAY AREAS IN
8	YOUR BOOKS, AND MAYBE WE COULD PUT TIER 2. WE GOT
9	TIER 2 UP YET?
10	MS. LANSING: I THINK I CAN SPEAK EVEN
11	THOUGH I MAY OR MAY NOT BE CONFLICTED ON TIER 2 AS A
12	GROUP; IS THAT CORRECT?
13	MR. HARRISON: IF YOU'RE MAKING A VERY
14	GENERAL COMMENT.
15	MS. LANSING: I'M MAKING A VERY GENERAL
16	COMMENT. OKAY. SO SINCE WE ALL BELIEVE THAT
17	THESE THAT THIS PARTICULAR SERIES OF GRANTS IS
18	EXTREMELY IMPORTANT, AND SINCE WE ALSO HAVE SOME
19	CARRY-FORWARD MONEY, I WOULD LIKE TO SUGGEST I
20	WANT TO MAKE SURE I'M DOING THIS CORRECTLY THAT
21	WE LOOK
22	MR. HARRISON: I THINK THAT YOU NEED TO
23	REFRAIN FROM MAKING ANY COMMENTS OR SUGGESTIONS WITH
24	RESPECT TO HOW THE BOARD TREATS THE APPLICATIONS IN
25	TIER 2. I'M SORRY.

1	MS. LANSING: SO WHO CAN TALK ON THIS? I
2	DON'T KNOW. AM I CONFLICTED ON 71, 72, AND 76? I
3	HAVE NO IDEA. I'M SORRY. I DIDN'T MEAN THAT. 05,
4	52, 02.
5	MR. SHEEHY: WELL, I THINK DUANE IS NOT
6	CONFLICTED. MAYBE HE MIGHT BE ABLE TO MAKE SOME OF
7	THE POINTS YOU WANT TO MAKE.
8	MS. LANSING: SORRY.
9	MR. HARRISON: IT MIGHT, JEFF, BEFORE WE
10	PROCEED, MAKE SENSE FOR ME TO JUST READ THE
11	CONFLICTS ON THOSE APPLICATIONS SO THAT WE ALL KNOW
12	WHO CAN.
13	MR. SHEEHY: ON THOSE THREE?
14	MR. HARRISON: YES. 905, 952, AND 902 THE
15	CONFLICTS ARE AS FOLLOWS: BRENNER, MILLIKEN,
16	SHEEHY, DAFOE, LANSING. THOSE ARE THE CONFLICTS.
17	MR. SHEEHY: OKAY. NOW, I DON'T THINK
18	THAT WE'RE AT A POINT WE'RE ACTUALLY DISCUSSING
19	THOSE APPLICATIONS RIGHT NOW, SO I THINK IT'S OKAY
20	IF I GO AHEAD AND CONTINUE TO CHAIR AND LET DUANE
21	MAKE HIS COMMENTS.
22	MR. ROTH: THANK YOU. SO GIVEN THE
23	IMPORTANCE OF YOUNG NEW INVESTIGATORS TO THE STATE
24	OF CALIFORNIA IN THIS PARTICULAR AREA, ESPECIALLY IN
25	TERMS OF RETENTION OF TALENT AND THE SIGNAL IT WILL
	474

1	SEND TO RECRUITMENT OF NEW TALENT TO COME INTO THE
2	STATE, I WOULD RECOMMEND THAT WE BE FAIRLY GENEROUS
3	IN FOLLOWING THE RECOMMENDATIONS TO FUND AS MANY OF
4	THESE PROGRAMS AS WE FEEL APPROPRIATE. AND THE FACT
5	THAT WE DO HAVE EXTRA FUNDS THAT WE'VE CARRIED
6	FORWARD, I CAN'T THINK OF A BETTER AREA AND A TIMELY
7	AREA TO GET WHAT WE REALLY WANTED OUT OF THE
8	TALENTED PEOPLE LOCATING IN THE STATE OF CALIFORNIA
9	AND STAYING HERE.
10	AND, FURTHERMORE, AND, ALAN, I WOULD LIKE
11	TO PICK UP ON OUR CONVERSATION AT THE END OF THE
12	EVENING. I WOULD BE EVEN MORE ENTHUSIASTIC IN
13	FUNDING THESE IF I KNEW THAT WE DIDN'T HAVE TO FUND
14	THEM TO THE MAX OR THAT THERE WAS SOME INTERACTION
15	BEFORE THAT WAS DONE BECAUSE I DO HAVE A PROBLEM
16	WITH A SCORE THAT IS 20 POINTS UNDER ASKING FOR \$3
17	MILLION VERSUS SOMETHING IN THE TOP TIER IS ONE AND
18	A HALF TO TWO MILLION.
19	I DON'T THINK I WOULD BE AS ENTHUSIASTIC
20	TO GIVE A FULL REWARD FOR SOMETHING THAT'S WELL DOWN
21	THE LIST. ON THE OTHER HAND, I WOULD LIKE TO
22	ENCOURAGE THEM TO GO FORWARD AND PERHAPS COME BACK
23	FOR ANOTHER GRANT DOWN THE ROAD, BUT NOT TO DO THE
24	FULL AMOUNT. AND THAT CAN BE DISCUSSED. WE CAN SAY
25	THAT'S NOT A GOOD IDEA, VOTE ON THEM UP OR DOWN, BUT

1	I'D BE MORE ENTHUSIASTIC TO GO DEEPER IF WE DID
2	THAT.
3	DR. PIZZO: I WANT TO JUST FOLLOW UP ON
4	THAT. I THINK THAT IS A VERY IMPORTANT DISCUSSION.
5	AND I APPRECIATE THE POINT YOU ARE MAKING ABOUT
6	EMPHASIZING QUALITY. BUT AT THE SAME TIME, I THINK
7	WE WANT TO PROVIDE AWARDS THAT WILL ALSO DO AS MUCH
8	AS WE CAN TO ASSURE SUCCESS. SO PARTICULARLY FOR
9	NEW INVESTIGATORS, THIS IS AN IMPORTANT OPPORTUNITY
10	TO BRIDGE THAT PERIOD OF TIME. AND SO IF WE
11	INADVERTENTLY TRUNCATE THE AWARDS, WE MIGHT ACTUALLY
12	NEGATIVELY IMPACT THEIR PROGRESSION. SO I THINK WE
13	JUST NEED TO BE MINDFUL OF THAT TRADE-OFF.
14	FOR MYSELF, I WOULD RATHER PROVIDE FEWER
15	GRANTS AT THE HIGHER AWARD LEVEL THAN REDUCE
16	AWARDS REDUCE THE AMOUNTS OF AWARDS AND
17	POTENTIALLY HAVE A NEGATIVE IMPACT ON OUTCOME.
18	DR. TROUNSON: THERE'S ONE MATTER THAT
19	MIGHT HELP THE DISCUSSIONS, CHAIR, THAT BUILT INTO
20	OUR ASSESSMENT OF THE PROJECTS IS UNSATISFACTORY
21	PERFORMANCE, FOR WHICH WE CAN TERMINATE THE PROJECT.
22	NOW, UNSATISFACTORY PERFORMANCE, WE'VE
23	ONLY JUST GOT INTO RECEIVING THE ANNUAL REPORTS AND
24	SETTING UP A PROCESS. BUT IT'S IN THE GAP, AND IF
25	NEEDS TO BE, WE CAN HAVE TAMAR, YOU KNOW, DESCRIBE
	170

THAT SPECIFICALLY FOR YOU, BUT IT'S THERE. AND IT'S
INTENDED TO IDENTIFY THAT WE'RE SERIOUS ABOUT OUR
MONEY BEING SPENT IN THE WAYS THAT WE'VE
ANTI CI PATED.
SO I HAVE SOME SYMPATHY, DUANE, THAT IF
THINGS ARE NOT GOING RIGHT, WE SHOULDN'T WASTE THE
MONEY. THIS IS VERY IMPORTANT MONEY, AND WE SHOULD
SAY, "OKAY. LET'S STOP THIS. AND YOU COME BACK AT
ANOTHER TIME." AND I THINK THAT'S A REASONABLE
PROCESS. IT'S ALREADY BUILT IN.
NOW, WHETHER THAT HELPS THE ARGUMENT OR
NOT, CHAIR, I THINK IT DOES SAY THAT WE CAN, IF
THINGS ARE NOT GOING WELL, THAT WE CAN DRAW BACK ON
THEM.
MR. ROTH: COULD I FOLLOW UP ON THAT,
ALAN? LET'S JUST HYPOTHETICALLY SAY THAT WE WOULD
APPROVE IT CONDITIONALLY, SO THE FIRST THREE YEARS
ARE LOCKED IN, BUT THERE WOULD BE SOMEONE WHO WOULD
APPROVE THE LAST TWO. SO WE DO THE FULL FIVE YEARS;
BUT INSTEAD OF JUST SAYING YOU'RE IN
DR. TROUNSON: WE DO THAT ANNUALLY ANYWAY.
THAT'S PART OF WHAT OUR GAP REQUIRES US TO DO. BUT
IF YOU FEEL THAT IT'S, YOU KNOW, IN THIS GRAY
AREA
MR. ROTH: IT'S A FAIRNESS ISSUE TO ME
174

1	THAT GIVES A SIGNAL TO THE PEOPLE WHO SCORED
2	EXTREMELY WELL THAT THEY'RE NOT TREATED THE OTHER
3	GROUP IS GOING TO BE TREATED A LITTLE BIT DIFFERENT.
4	IT'S JUST A SIGNAL THAT SAYS THAT'S A CONDITIONAL
5	APPROVAL. AND IT MEANS THE SAME THING. THREE
6	YEARS, IT'S GOING TO BE LOOKED AT VERY THOROUGHLY
7	BEFORE YOU GET THE LAST TWO.
8	DR. PIZZO: I WAS GOING TO MAKE A SIMILAR
9	ALTERNATE SUGGESTION, SO I AGREE WITH YOU. I THINK
10	WHAT I WOULD LIKE NOT TO SEE WOULD BE A REDUCTION
11	DURING THOSE EARLY YEARS, BUT IT IS PERFECTLY FINE
12	TO HAVE FULL FUNDING WITH THE EXPECTATION THAT THERE
13	WILL BE A CRITICAL REVIEW. AND IF PROGRESS ISN'T
14	BEING MADE, YOU KNOW, THEN SO BE IT. AT LEAST THAT
15	OPTIMIZES THE CONDITIONS AND ALLOWS CIRM TO MANAGE
16	THE GRANT AND THE FACULTY MEMBER AS WELL. GREAT.
17	MR. SHEEHY: MAYBE A GOOD PROCESS GOING
18	FORWARD, THEN, IS JUST TO TAKE MOTIONS ON INDIVIDUAL
19	GRANTS. AND THOSE GRANTS THAT, AS DUANE HAS SAID,
20	THERE IS SOME CONCERN, BUT YOU STILL WANT TO DO
21	SOMETHING WITH, MAKE THE MOTION THAT'S APPROPRIATE,
22	WHICH WOULD PROBABLY BE SOMETHING ALONG THE LINES TO
23	FUND FOR THREE YEARS.
24	MR. ROTH: THREE PLUS TWO.
25	MR. SHEEHY: THAT SOUNDS IT'S UP TO THE

175

1	REST OF US WHETHER WE VOTE YES OR NO ON THAT, AND
2	THEN WE DON'T HAVE TO REALLY SOLVE THE WHOLE POLICY
3	ISSUE. WE'RE GOING TO TAKE IT ON A CASE-BY-CASE
4	BASIS BECAUSE THAT'S HOW WE HAVE TO DO IT ANYWAY.
5	CHAIRMAN KLEIN: COULD I ASK A QUESTION
6	HERE? DUANE, DO YOU DIFFERENTIATE THE TOP THREE IN
7	THE SECOND CATEGORY WHO WERE MOVED DOWN FOR PURPOSES
8	OF PROGRAMMATIC PRIORITY? THEY HAVE SCORES THAT ARE
9	HIGHER THAN THE BOTTOM OF THE FIRST CATEGORY, SO
10	MAYBE THEY MIGHT BE TREATED THE SAME WAY AS THE TOP
11	CATEGORY.
12	MR. ROTH: SO I THINK WE WOULD DO OUR
13	NORMAL PROCESS AND MOVE THINGS UP THAT WOULD BE
14	FULLY FUNDED, IF IT'S APPROPRIATE. AND THEN THERE
15	MAY BE A GROUP WHICH WE COME TO THAT WE SAY THREE
16	PLUS TWO.
17	MR. SHEEHY: SO I THINK, BECAUSE THESE MAY
18	BE MORE COMPLICATED MOTIONS, A LITTLE MORE
19	TIME-CONSUMING THAN USUAL, CAN WE GO AHEAD AND START
20	TAKING MOTIONS BECAUSE I THINK WE MAY WANT TO GO
21	THROUGH THE BULK OF THESE TWELVE ONE BY ONE.
22	MS. SAMUELSON: JEFF, I HAVE A SUGGESTION
23	FOR A WAY TO DO IT. SINCE I'M NOT CONFLICTED AT
24	ALL, AND ALL THE SECOND TIER WAS RECOMMENDED BY THE
25	WORKING GROUP TO BE FUNDED IF FUNDS ARE AVAILABLE,

1	WE HAVE THAT RECOMMENDATION, I WOULD MOVE THAT WE
2	FUND ALL OF THOSE IN TIER 2 WITH THAT PROCEDURAL
3	CHECK.
4	DR. PIZZO: IS THE PROCEDURAL CHECK THE
5	THREE PLUS TWO?
6	MS. SAMUELSON: YES.
7	MR. SHEEHY: FIRST OF ALL, I THINK WE NEED
8	TO HEAR FROM COUNSEL JUST ON WHETHER IT'S REALLY
9	FEASIBLE TO TRY TO DEAL WITH THAT MANY APPLICATIONS
10	AT ONCE GIVEN CONFLICT ISSUES. AND THEN I WOULD
11	LIKE TO LET CLAIRE HAVE HER COMMENT RIGHT AFTER
12	THAT. WHILE YOU HAVE INSERTED YOUR MOTION, I HAVE A
13	FEELING WE'RE GOING TO HEAR IT'S VERY DIFFICULT TO
14	HANDLE IT IN THAT FASHION.
15	MS. SAMUELSON: IT WILL BE EASIER.
16	MR. HARRISON: IT DOES PRESENT SOME
17	CHALLENGES BECAUSE TYPICALLY WE'VE CONSIDERED
18	APPLICATIONS IN TIER 2 ON AN INDIVIDUAL BASIS. BUT
19	AS YOU KNOW, ULTIMATELY, ONCE ALL MOTIONS HAVE BEEN
20	EXHAUSTED, WE THEN CONSIDER THE ULTIMATE ARRAY OF
21	APPLICATIONS EN BLOC SO THAT THE PREFERENCE
22	GENERALLY IS TO CONSIDER THE APPLICATIONS ON AN
23	INDIVIDUALIZED BASIS SO THAT ANY DISCUSSION CAN
24	OCCUR, AND WE CAN ENSURE THAT THOSE WHO HAVE AN
25	INTEREST IN THE APPLICATION DON'T PARTICIPATE.
	177

1	MR. SHEEHY: LET ME DO TWO THINGS. JOAN,
2	SINCE YOU MADE A MOTION, CAN WE REALLY CLARIFY YOUR
3	MOTION, SEEK A SECOND, AND THEN WE'LL GO DIRECTLY TO
4	CLAIRE FOR HER COMMENT IF WE HAVE OTHER COMMENTS
5	BECAUSE I DON'T WANT TO KEEP CLAIRE WAITING.
6	MS. SAMUELSON: IT'S MADE IN LIGHT OF ALL
7	OF DUANE'S COMMENTS AND PHIL'S AND NOW I'M
8	FORGETTING WHO ELSE, THAT THE FUNDS ARE AVAILABLE,
9	THAT THIS IS AN IMPORTANT THING TO BE FUNDING
10	BECAUSE OF THE NIH SITUATION AND BECAUSE WE WANT OUR
11	OWN RESEARCH PORTFOLIO TO GET GOING WITH GUSTO. AND
12	THAT IN DEFERENCE TO THE RECOMMENDATIONS OF THE
13	WORKING GROUP, WHICH RECOMMENDED THAT IF FUNDS WERE
14	AVAILABLE, THEY BE CONSIDERED FOR FUNDING, AND THE
15	FACT THAT WE HAVE THE FUNDS, FOR ALL THOSE REASONS,
16	IT FEELS APPROPRIATE TO GO AHEAD AND TAKE THE
17	WORKING GROUP'S RECOMMENDATION AND DECIDE TO FUND
18	ALL OF THOSE IN TIER 2.
19	MR. SHEEHY: IS THERE A SECOND FROM A
20	NONCONFLICTING
21	MS. SAMUELSON: SO IT'S NOT THAT THEY
22	HAVEN'T BEEN REVIEWED. WE'RE DOING THIS ON THE
23	BASIS OF THE WORKING GROUP'S RECOMMENDATION.
24	MR. ROTH: JOAN, COULD I OFFER A
25	MODIFICATION? AND INSTEAD OF TAKING THEM ALL AS A
	170

1	BLOCK, MAYBE TAKE THREE BLOCKS. THE FIRST THREE
2	GRANTS, 905, 952, 902, AND RECOMMEND THOSE BE MOVED
3	TO TIER 1. THEN DEAL WITH 36 THROUGH 18, AND THEN
4	DECIDE IF THE ONES THAT ARE UNSCORED SHOULD BE DONE
5	SO THAT WE DON'T TRY TO MOVE THE ENTIRE THING UP?
6	START WITH THE THREE AT THE STOP AND MOVE THOSE TO
7	TIER 1 AND SEE THERE'S IF ANY DISCUSSION.
8	MS. SAMUELSON: OKAY. IT'S THE WISH OF
9	THE GROUP. I DON'T SEE DISTINCTIONS BETWEEN THEM
10	THAT CONCERN ME.
11	MR. SHEEHY: IT'S REALLY A MECHANICAL
12	ISSUE. IF YOU WANT TO GO AHEAD AND MAKE THAT YOU
13	HAVE A SECOND IN THAT CASE FOR THE FIRST THREE. AND
14	THAT WOULD ALLOW US TO KIND OF MOVE FORWARD. I
15	THINK IT WOULD BE A LITTLE EASIER. TAKING THEM ALL
16	IN ONE CHUNK MAKES IT VERY DIFFICULT TO HAVE A
17	CONVERSATION BECAUSE OF THE CONFLICTS.
18	IF THAT'S ACCEPTABLE, DUANE HAS MADE THE
19	SECOND. I WANT TO GO AHEAD AND GIVE CLAIRE HER
20	OPPORTUNI TY.
21	MR. HARRISON: IF WE COULD JUST CHECK.
22	THERE'S A MOTION ON THE TABLE. AGAIN, LET ME
23	REITERATE THE CONFLICTS AS TO THIS MOTION, AND,
24	AGAIN, THIS MOTION WOULD JUST GO TO APPLICATIONS
25	905, 952, AND 902, ARE BRENNER, MILLIKEN, SHEEHY,

1	DAFOE, AND LANSING.
2	MR. SHEEHY: SINCE WE'RE IN THE CONTEXT OF
3	A MOTION, I THINK YOU SHOULD REALLY TAKE OVER.
4	CHAIRMAN KLEIN: ALL RIGHT. SO AS TO THIS
5	MOTION, AS I UNDERSTAND PRECISELY, THIS MOTION IS TO
6	MOVE THOSE THREE WITHOUT ANY CONDITION ON A
7	REEXAMINATION OF A MILESTONE TEST, ALTHOUGH THERE IS
8	GENERAL OVERSIGHT IN THE ADMINISTRATION OF GRANTS
9	REGARDLESS. RI GHT?
10	SO AS TO THIS MOTION, WITH KNOWLEDGE OF
11	WHO IS IN CONFLICT, DEBATE AS TO THIS MOTION?
12	DR. STEWARD: I REALLY THINK IT'S GOING TO
13	BE EASIER AND QUICKER TO DO THESE ONE AT A TIME
14	BECAUSE THESE THREE HAVE DIFFERENT ISSUES ASSOCIATED
15	WITH THEM, AND WE ACTUALLY COULD HAVE ALREADY DONE
16	TWO OF THEM IN THE TIME THAT WE'VE DISCUSSED THIS
17	BATCHI NG.
18	CHAIRMAN KLEIN: OKAY. ANY ADDITIONAL
19	OPI NI ON?
20	DR. POMEROY: BOB, THIS IS THE GENERAL
21	POINT THAT I'VE BEEN TRYING TO MAKE. THINGS GOT
22	MOVED FOR TWO BASIC REASONS THAT I COULD ASCERTAIN.
23	ONE WAS A FEELING THAT THERE WAS LACK OF
24	QUALIFICATION AS A NEW FACULTY INVESTIGATOR, AND THE
25	SECOND WAS MORE SCIENTIFIC CONCERNS.
	180
	100

1	AND I THINK THAT THE DECISIONS FOR THE
2	PEOPLE WHO DON'T FALL CLEARLY INTO THE CATEGORY AS A
3	NEW FACULTY ARE VERY DIFFERENT DECISIONS THAN THE
4	ONES WHERE THERE WERE SCIENTIFIC QUESTIONS. SO
5	SINCE THIS FIRST MOTION FOR WHICH I AM NOT
6	CONFLICTED CONTAINS BOTH OF THOSE ISSUES, I WOULD
7	NOT BE ABLE TO VOTE EN BLOC ABOUT THESE THREE.
8	CHAIRMAN KLEIN: ALL RIGHT. ADDITIONAL
9	POINTS OF VIEW?
10	MR. HARRISON: DR. DAFOE, YOU HAVE AN
11	INTEREST IN THE MOTION.
12	DR. DAFOE: I KNOW I DO.
13	CHAIRMAN KLEIN: YOU CAN'T ADDRESS IT.
14	DR. CSETE: IN ANSWER TO DR. POMEROY'S
15	COMMENT, THERE IS A PROCEDURE IN OUR GAP WHERE WE GO
16	BACK AND CHECK FACULTY ELIGIBILITY FOR THE SPECIFIC
17	RFA AFTER YOU'VE ALL VOTED ON IT. AND IF THERE IS
18	AN ACTUAL ISSUE WITH ELIGIBILITY, WE HAVE THAT AS A
19	BACKUP CHECK.
20	DR. POMEROY: WELL, I APPRECIATE THAT, BUT
21	THERE ARE INSTANCES IN WHICH THERE'S NOT A TECHNICAL
22	VIOLATION, BUT IT IS NOT FELT THAT THERE'S AN
23	APPROPRIATE NEED FOR MENTORING, FOR EXAMPLE. SO
24	TECHNICALLY THIS PERSON MIGHT QUALIFY, AND I DON'T
25	KNOW IF THEY DO, BUT THERE WERE CONCERNS BY THE
	4.04

1	REVIEWERS THAT IT WASN'T APPROPRIATE TO HAVE THEM
2	MENTORING RELATIONSHIPS.
3	DR. CSETE: WE CAN'T CHECK THE SPIRIT
4	EXCEPT AGAINST THE REVIEWS, BUT THERE ARE TECHNICAL
5	CHECKS.
6	DR. POMEROY: SO THAT WOULD BE OUR JOB TO
7	LISTEN TO THE REVIEWERS ABOUT WHETHER THIS WAS AN
8	APPROPRIATELY DESIGNED MENTORING PLAN.
9	CHAIRMAN KLEIN: ALL RIGHT. ADDITIONAL
10	POINTS OF VIEW?
11	DR. STEWARD: JUST IN THE INTEREST OF
12	GETTING THINGS GOING, I WONDER IF THE BOARD WOULD
13	ACCEPT A FRIENDLY AMENDMENT WHICH IS TO CONSIDER
14	THINGS ONE AT A TIME STARTING WITH 905 ON WHICH I AM
15	NOT IN CONFLICT.
16	CHAIRMAN KLEIN: THE REQUEST IS MADE, SO
17	ASK THE MAKER OF THE MOTION, DO YOU WISH TO HAVE A
18	VOTE ON YOUR MOTION AS STATED, OR DO YOU WISH TO
19	ACCEPT AN AMENDMENT?
20	MS. SAMUELSON: I PREFER TO DO IT THE WAY
21	I SUGGESTED FOR SEVERAL REASONS. ONE IS I DON'T SEE
22	HOW WE CAN COMPLETELY RECONSIDER ALL OF THE PROS AND
23	CONS AND DIFFERENT ISSUES INVOLVED THAT THE WORKING
24	GROUP INCLUDED, WHICH INVOLVED THE THINGS THAT YOU
25	TALKED ABOUT, CLAIRE, BUT ALSO OTHER ISSUES OF HOW
	182

1	INNOVATIVE THE GRANT WAS, HOW COMPELLING, AND
2	IMPORTANT THAT ADVANCE WOULD BE RELATIVE TO OTHERS.
3	THERE WERE A VARIETY OF THINGS, AND THEY WERE WELL
4	CONSIDERED. SO I WOULD LEAN TOWARD JUST TAKING THAT
5	ON ITS FACE. I ALSO THINK THIS IS GOING TO TAKE A
6	VERY LONG TIME.
7	CHAIRMAN KLEIN: ALL RIGHT.
8	MS. SAMUELSON: JUST PRACTICALLY SPEAKING,
9	BUT I'M A PRAGMATIST. I DON'T THINK I GOT THE VOTE.
10	SO I'M NOT INCLINED TO PUSH IT. SO I JUST WANT TO
11	DO THIS IN A WAY THAT WILL WORK.
12	CHAIRMAN KLEIN: YES. SO IT HAS BEEN
13	SUGGESTED BY THE MAKER OF THE MOTION THAT SHE'D LIKE
14	A VOTE ON THE MOTION. IS THERE COMMENTS ON THAT,
15	DR. PRI CE?
16	DR. PRICE: JUST A POINT OF INFORMATION.
17	IF THIS MOTION IS VOTED DOWN, WE CAN GO BACK AND
18	TAKE THEM ONE AT A TIME.
19	CHAIRMAN KLEIN: THAT'S RIGHT. PUBLIC
20	COMMENT? OKAY. PUBLIC COMMENT? SEEING NO PUBLIC
21	COMMENT, MR. HARRISON, I BELIEVE WE'RE GOING TO NEED
22	A ROLL CALL VOTE, AND ALL OF THOSE WHO HAVE A
23	CONFLICT WILL NEED TO INDICATE THEY'RE VOTING YEA OR
24	NAY EXCEPT FOR THOSE FOR WHICH THEY HAVE A CONFLICT.
25	ANY ADDITIONAL INSTRUCTIONS?

183

1	MR. HARRISON: THAT'S CORRECT. ONE I
2	HESITATE TO MAKE THIS MORE COMPLICATED, BUT GIVEN
3	OUR QUORUM SITUATION, AS YOU KNOW, THE BOARD
4	CONDITIONALLY APPROVED ALL THE APPLICATIONS IN TIER
5	1 YESTERDAY. SO IN THE EVENT THAT WE LOSE A QUORUM,
6	ONE WAY TO ENSURE THAT, IF THERE'S A POSITIVE VOTE
7	ON THIS MOTION, THAT IT WOULD BE SUSTAINED WOULD BE
8	TO FUND THESE APPLICATIONS RATHER THAN SIMPLY TO
9	MOVE THEM TO TIER 1, WHICH WOULD THEN REQUIRE
10	ANOTHER VOTE.
11	CHAIRMAN KLEIN: SO YOU'RE BEGINNING TO
12	LIKE MY CONDITIONAL APPROVAL. SO WE ARE
13	CONDITIONALLY FUNDING UNLESS WE LATER ACT TO AMEND
14	THAT.
15	AND I WOULD LIKE TO POINT OUT TO THE BOARD
16	THAT I'VE JUST BEEN INFORMED THAT THERE'S AN
17	INTERNATIONAL FLIGHT THAT HAS HAD TO BE RESCHEDULED
18	FOR ONE OF OUR BOARD MEMBERS. SO WE'RE GOING TO
19	LOSE A QUORUM POTENTIALLY, UNLESS I CAN NEGOTIATE
20	SOMETHING SEPARATELY WITH THE AIRLINES OR SOMEONE
21	ELSE, IN ABOUT 25 MINUTES. SO PLEASE BEAR IN MIND
22	WHAT WE HAVE HERE IS SOME VERY IMPORTANT DECISIONS
23	TO MAKE. LET'S TRY AND DO IT EFFICIENTLY. ALL
24	RIGHT. CALL THE ROLL, PLEASE.
25	MS. KING: DONALD DAFOE. SO SORRY.
	184
	191

1	ROBERT PRICE.
2	MR. HARRISON: YOU CAN VOTE YES OR NO
3	EXCEPT AS TO THOSE IN WHICH YOU HAVE AN INTEREST.
4	MS. LANSING: WE'RE VERY CONFUSED.
5	CHAIRMAN KLEIN: LET'S RESTATE THE MOTION.
6	MS. LANSING: I LEFT THE ROOM BECAUSE I
7	THOUGHT LISTENING TO THIS WAS GOING TO BE A PROBLEM.
8	WILL YOU JUST TELL US WHAT THE MOTION IS?
9	CHAIRMAN KLEIN: THE MOTION IS TO
10	JOAN'S MOTION, SECONDED BY DUANE, I BELIEVE, IS THAT
11	CORRECT, IS TO MOVE THE TOP THREE UP TO FUND,
12	CONDITIONALLY APPROVING THEM UNLESS WE LATER CHANGE
13	IT, INTO THE FUNDING CATEGORY, JUST THE TOP THREE IN
14	THE MIDDLE CATEGORY.
15	MS. LANSING: SO I HAVE A QUESTION.
16	CHAIRMAN KLEIN: AND YOU CAN YOU'RE
17	MOVING THEM UP TO TIER 1. AND WHAT IS YOUR
18	QUESTI ON?
19	MS. LANSING: THE MOTION IS TO MOVE THE
20	TOP THREE UP TO TIER 1. I HAVE A QUESTION. WHAT IF
21	WE WANT TO EVALUATE EACH AND EVERY ONE OF THE TOP
22	THREE? WHAT WOULD WE VOTE THEN?
23	MR. HARRISON: NO, EXCEPT AS TO THOSE IN
24	WHICH YOU HAVE AN INTEREST.
25	CHAIRMAN KLEIN: MY UNDERSTANDING, JAMES,
	185
	100

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

-	
1	IS WE'RE AUGMENTING TIER 1. WE ARE NOT CHANGING ANY
2	OF THE PRIOR APPROVALS ON TIER 1.
3	MR. HARRISON: THAT'S CORRECT.
4	DR. DAFOE: I HAVE A QUESTION. IT'S MORE
5	OF A PROCEDURAL ONE. I'M VOTING ON THIS, YET I'M
6	NOT ALLOWED TO COMMENT. I'M MUZZLED IN THE COMMENT
7	PERIOD, YET I CAN VOTE ON IT. IT JUST SEEMS TO BE
8	KIND OF CONTRADICTORY.
9	CHAIRMAN KLEIN: FOR PURPOSES OF A QUORUM,
10	TO THE EXTENT THAT YOU'RE NOT IN CONFLICT WITH ALL
11	THREE AND YOU WISH TO CAST A VOTE, YOU CAN VOTE YEA
12	OR NAY EXCEPT FOR THOSE WITH WHICH YOU ARE IN
13	CONFLICT. SO THAT GIVES YOUR VOTE AN IMPACT. OKAY.
14	MS. KING: DONALD DAFOE.
15	CHAIRMAN KLEIN: MR. HARRISON, ARE WE
16	APPROPRIATELY INFORMED?
17	MR. HARRISON: YES.
18	CHAIRMAN KLEIN: THANK YOU, SIR. MELISSA,
19	CALL THE ROLL.
20	MS. KING: DONALD DAFOE.
21	DR. DAFOE: APPROVE EXCEPT FOR THOSE WITH
22	WHICH I HAVE A CONFLICT.
23	MS. KING: ROBERT PRICE.
24	DR. PRICE: NO.
25	MS. KING: FLOYD BLOOM.
	186
	100

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

	DARRISTERS REPORTING SERVICE
1	DR. BLOOM: APPROVE EXCEPT FOR THOSE WITH
2	WHICH I HAVE A CONFLICT.
3	MS. KING: DAVID BRENNER.
4	DR. BRENNER: APPROVE EXCEPT FOR THOSE
5	WITH WHICH I HAVE A CONFLICT.
6	MS. KING: MICHAEL FRIEDMAN.
7	DR. FRIEDMAN: NO, EXCEPT FOR THOSE WITH
8	WHICH I HAVE A CONFLICT.
9	MS. KING: MICHAEL GOLDBERG.
10	MR. GOLDBERG: YES, EXCEPT FOR THOSE WITH
11	WHICH I HAVE A CONFLICT.
12	MS. KING: NANCY MILLIKEN.
13	DR. MILLIKEN: NO, EXCEPT FOR THOSE FOR
14	WHICH I MIGHT HAVE A CONFLICT.
15	MS. KING: BOB KLEIN.
16	CHAIRMAN KLEIN: YES.
17	MS. KING: SHERRY LANSING.
18	MS. LANSING: CAN I ABSTAIN? I'M SO
19	CONFUSED.
20	MS. KING: TED LOVE.
21	DR. LOVE: YES.
22	MS. KING: ED PENHOET.
23	DR. PENHOET: YES.
24	MS. LANSING: OKAY. I KNOW MY VOTE. NO.
25	MR. HARRISON: EXCEPT FOR THE
	187
	107

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

BARRISTERS' REPORTING SERVICE
APPLICATION
MS. LANSING: EXCEPT FOR THOSE FOR WHICH I
HAVE A CONFLICT. I WANT TO TALK ABOUT, SO I'M
ADDING THAT.
MS. KING: PHIL PIZZO.
DR. PI ZZO: YES.
MS. KING: CLAIRE POMEROY.
DR. POMEROY: NO.
MS. KING: ROBERT QUINT.
DR. QUINT: YES.
MS. KING: DUANE ROTH.
MR. ROTH: YES.
MS. KING: JOAN SAMUELSON.
MS. SAMUELSON: YES.
MS. KING: JEFF SHEEHY.
MR. SHEEHY: YES, EXCEPT FOR THOSE WITH
WHICH I HAVE A CONFLICT.
MS. KING: OSWALD STEWARD.
DR. STEWARD: NO.
CHAIRMAN KLEIN: WHILE THEY'RE TALLYING
THEM, DOES ANYONE HAVE A MOTION THAT GOES BEYOND
THESE THREE?
MR. HARRISON: MR. CHAIR, COULD I
INTERRUPT FOR ONE MOMENT. WE NEGLECTED TO CALL
MEMBER LEVIN IN THE ROLL CALL. MEMBER LEVIN.
188

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	DR. LEVIN: NO.
2	CHAIRMAN KLEIN: IF WE CAN HAVE DISCUSSION
3	WHILE THEY'RE TALLYING THE VOTE, IS THERE
4	MS. LANSING: I WOULD LIKE TO SAY
5	SOMETHI NG.
6	CHAIRMAN KLEIN: SHERRY LANSING, YOU HAVE
7	THE FLOOR.
8	MS. LANSING: I ACTUALLY WANT TO SAY THAT
9	WHATEVER THE VOTE IS I'M COMFORTABLE WITH IT, BUT
10	WHAT I REALLY WANT TO SAY IS THAT IT'S FRUSTRATING
11	TO ME THAT IN 25 MINUTES WE WON'T HAVE A QUORUM.
12	AND I THINK THAT WE REALLY HAVE TO EITHER IN THE
13	GOVERNANCE COMMITTEE HAVE TO ADDRESS THESE ISSUES
14	BECAUSE WE SHOULDN'T BE VOTING BECAUSE THERE'S ONLY
15	25 MINUTES LEFT TO MAKE A DECISION. AND THAT'S
16	WHAT'S FRUSTRATING TO ME. AND I'M NOT IN ANY WAY
17	CRITICIZING ANY MEMBERS OF THE BOARD. WE'VE ALL
18	WORKED VERY, VERY, VERY HARD, BUT I THINK WE HAVE A
19	RESPONSIBILITY EITHER TO HAVE AN ALTERNATE OR MAYBE
20	WE HAVE TO LOOK AT GOVERNANCE IN SOME WAY SO THAT WE
21	NEVER ARE VOTING BECAUSE WE ONLY HAVE 25 MINUTES
22	LEFT.
23	CHAIRMAN KLEIN: SHERRY, I WOULD AGREE
24	WITH THAT. AND, IN FACT, DR. FRIEDMAN HAS MADE SOME
25	IMPORTANT INNOVATIVE SUGGESTIONS OF HOW

189

1	TELEPHONICALLY WE CAN CREATE SOME BACKUPS THAT WOULD
2	BE VERY HELPFUL. AS CHAIR OF GOVERNANCE, I WOULD
3	HOPE THAT YOU WILL TAKE THIS ON YOUR NEXT GOVERNANCE
4	MEETI NG.
5	MS. LANSING: SO, MELISSA, I'D LIKE YOU TO
6	SCHEDULE A MEETING BECAUSE IN THE WORLD TODAY WITH
7	VISUAL CONFERENCING, AND WE'VE TALKED ABOUT THIS AS
8	WELL, WITH VISUAL CONFERENCING, WE COULD ACTUALLY
9	LOOK AT EACH OTHER AND WE COULD BE ON THE PHONE, AND
10	I THINK REALLY, REALLY DO A REAL SERVICE TO OUR
11	COMMITTEE AND REALLY GET FULL ATTENDANCE THAT WAY
12	BECAUSE IT IS HARD, YOU KNOW, TO TAKE TWO TO
13	SOMETIMES THREE DAYS TO ATTEND A MEETING AS
14	FREQUENTLY AS WE DO MEET. IF YOU WILL SCHEDULE THAT
15	RATHER SOON.
16	CHAIRMAN KLEIN: THANK YOU VERY MUCH FOR
17	THAT LEADERSHIP. AND REMEMBER OUR CHALLENGE IS
18	GOING TO BE THAT THOSE WHO ARE ON A PHONE PROBABLY
19	NEED TO BE AN EXCEPTION BECAUSE WE CAN'T HAVE AN
20	EXECUTIVE SESSION WHERE WE SEND STAFF ALL AROUND THE
21	STATE TO DEAL WITH THE PROPRIETARY SCIENTIFIC
22	ISSUES, BUT IT WOULD BE A HUGE BENEFIT TO HAVE SOME
23	BACKUP WHO CAN BE THERE TELEPHONICALLY SO THAT WE
24	CAN HAVE A VERY STABLE QUORUM, PARTICULARLY IN TIMES
25	OF THE YEAR WHERE WE HAVE MANY PEOPLE OUTSIDE THE
	100

1	STATE OR OUTSIDE THE COUNTRY.
2	MR. HARRISON: SO THE MOTION TO
3	CONDITIONALLY FUND APPLICATIONS 905, 952, AND 902
4	CARRIES WITH A VOTE OF 12 TO 7.
5	CHAIRMAN KLEIN: THANK YOU VERY MUCH. IS
6	THERE A MOTION THAT GOES BEYOND THOSE THREE?
7	MR. ROTH: SO I WOULD MOVE THAT APPLICANTS
8	936 THROUGH 918 BE APPROVED ON A THREE/TWO
9	CONDITIONAL APPROVAL.
10	CHAIRMAN KLEIN: SO RECONSTITUTE THAT
11	STATEMENT, MY UNDERSTANDING IS THEY'D BE APPROVED
12	FOR THE FULL FIVE YEARS, BUT THERE WOULD BE A
13	SPECIFIC MILESTONE ANALYSIS OF PROGRESS AT THREE
14	YEARS. AND THIS IS IN ADDITION TO THE NORMAL
15	OVERSIGHT OF THE STAFF TO LOOK AT THE ANNUAL REPORTS
16	AND MAKE SURE THAT REASONABLE PROGRESS IS BEING
17	MADE; IS THAT CORRECT?
18	MR. ROTH: YES.
19	CHAIRMAN KLEIN: ALL RIGHT. SO THE MOTION
20	THAT IS BEING MADE HERE, LET ME ASK WHO THE
21	CONFLICTS WOULD BE.
22	MR. HARRISON: THE CONFLICTS WOULD BE
23	BLOOM, PRICE, LANSING, AND POMEROY. LET ME JUST
24	POINT OUT ONE OF THE CHALLENGES MOTIONS LIKE THIS
25	PRESENT IS THAT THOSE MEMBERS WHO ARE CONFLICTED
	191
	171

CAN'T SPEAK TO THE MOTION AT ALL EVEN IF THEY HAVE A
COMMENT AS TO AN APPLICATION IN WHICH THEY DON'T
HAVE AN INTEREST. SO IT DOES PRESENT CHALLENGES.
CHAIRMAN KLEIN: CAN I ASK THE MAKER OF
THE MOTION, TO PROMOTE DISCUSSION, IS IT POSSIBLE TO
BREAK THIS GROUP INTO HALF?
MR. ROTH: I WOULD BE HAPPY TO ACCEPT
THAT.
CHAIRMAN KLEIN: SO POTENTIALLY
MR. ROTH: THERE ARE FIVE GRANTS.
CHAIRMAN KLEIN: WANT TO TAKE THE FIRST
THREE? WOULD THAT SUBSTANTIALLY REDUCE CONFLICTS,
MR. HARRISON AND SCOTT TOCHER?
MR. TOCHER: IF YOU TOOK THE FIRST THREE,
THAT WOULD REDUCE THE LANSING AND POMEROY COULD
PARTICIPATE. OTHERWISE, IT WOULD STILL BE BLOOM AND
PRI CE.
CHAIRMAN KLEIN: OKAY. COULD WE DO THAT?
MR. ROTH: YES.
CHAIRMAN KLEIN: CAN WE TAKE THE FIRST
THREE? THIS WOULD SAY 936, 914, 943 ARE UNDER
CONSIDERATION. THE MOTION IS MADE BY DUANE ROTH.
IS THERE A SECOND?
MS. SAMUELSON: I'LL SECOND.
CHAIRMAN KLEIN: JOAN IS THE SECOND.
192

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	THOSE THREE ARE UNDER DISCUSSION. YES, DR. LEVIN.
2	DR. LEVIN: I'D JUST LIKE TO ASK I
3	THINK I'M ALLOWED TO ASK ON WHAT BASIS THESE
4	GRANTS ARE BEING SINGLED OUT FROM THE OTHER ONES IF
5	MERELY THE SCIENTIFIC SCORES, NOT ANY OF THE
6	DISCUSSIONS THAT HAVE BEEN HAD, SO IT'S A SCORE THAT
7	TO SOME EXTENT IS ARBITRARY IN THAT DIFFERENT
8	WORKING GROUPS HAVE DIFFERENT SLIGHTLY DIFFERENT
9	SCORING SYSTEMS, SO TO HAVE ONE OR TWO OR THREE
10	POINTS
11	CHAIRMAN KLEIN: SURE. IT IS ONE WORKING
12	GROUP THAT SCORED ALL OF THESE, SO WE HAVE A
13	CONSISTENCY OF THE SAME WORKING GROUP SCORING THEM
14	ALL. BUT I THINK YOUR POINT IS THAT THERE'S VERY
15	LITTLE GRADIENT DIFFERENCES IS THESE SCORES. AND
16	THE ONLY REASON THAT THEY'RE BEING TAKEN IN A
17	SMALLER GROUP IS SO THAT WE CAN HAVE VOTES WITH
18	FEWER CONFLICTS. BUT THE INTENT OF THE PARTIES IS
19	TO ADDRESS THE ONES THAT FOLLOW THIS AS WELL, AND
20	THE QUESTION IS AT WHAT POINT IS THERE A CUTOFF ON
21	SCIENTIFIC SCORES OR BASED UPON ANY OTHER DISCUSSION
22	OF THE BOARD.
23	DR. LEVIN: AND WE'RE DOING THEM IN GROUPS
24	LIKE THIS RATHER THAN LOOKING AT THE MERITS AND
25	SHORTCOMINGS OF INDIVIDUAL GRANTS, JUST BASED ON OUR
	100

1	TIME?
2	CHAIRMAN KLEIN: NO. WE CAN IF YOU
3	FEEL THAT THERE IS A PARTICULAR GRANT IN HERE THAT
4	SHOULD BE EXCLUDED FROM THIS MOTION BASED UPON
5	MERITS, YOU SHOULD CALL OUT THAT GRANT, AND WE
6	SHOULD DISCUSS THAT GRANT. THAT IS A POINT OF
7	DISCUSSION, AND IT MAY INFLUENCE THE BOARD TO DEFEAT
8	THE MOTION BECAUSE THEY DON'T WANT TO BLOCK APPROVE
9	THE THREE.
10	DR. LEVIN: I DON'T HAVE ENOUGH
11	INFORMATION ON THE INDIVIDUAL GRANTS, BUT IT JUST
12	SEEMS LIKE A BETTER WAY TO ADDRESS THAT A LOT OF
13	WORK WENT INTO EVALUATING THE GRANTS AND ALL OF THE
14	DIFFERENT STRENGTHS AND PROBLEMS.
15	CHAIRMAN KLEIN: VERY SPECIFICALLY, THE
16	BOARD BY PRACTICE, IF THERE IS A GRANT IN THE GROUP
17	THAT SOMEONE HAS A SPECIFIC ISSUE WITH, THEY
18	EFFECTIVELY TAKE THE POSITION OF CALLING THAT TO THE
19	ATTENTION OF ALL THE MEMBERS AND ASKING THAT IT BE
20	TAKEN OUT OF THE GROUP.
21	MS. PACHTER: BECAUSE THIS MOTION REQUIRES
22	STAFF TO DO CERTAIN THINGS DIFFERENTLY, I WOULD JUST
23	ASK THAT THE MOTION BE RESTATED SO THAT STAFF WILL
24	UNDERSTAND EXACTLY WHAT'S GOING TO BE REQUIRED IN
25	TERMS OF FUNDING, THE CONDITIONAL PART OF IT.
	104

CHAIRMAN KLEIN: IN TERMS OF A SUMMARY,
DUANE, WOULD YOU LIKE TO RESTATE YOUR MOTION?
MR. ROTH: I DON'T HAVE THE EXACT WORDS,
BUT THE INTENT IS THAT IT WOULD BE APPROVED ON A
THREE-YEAR WITH A REVIEW BY STAFF BEFORE THE FINAL
TWO YEARS ARE FUNDED. WHILE THIS EXISTS ALREADY,
IT'S A MORE FORMAL REVIEW AT THE END OF THREE YEARS.
CHAIRMAN KLEIN: DUANE, I THINK YOU'RE
APPROVING FOR FIVE YEARS WITH A STOP AT THREE YEARS
IF, IN FACT, THE STAFF DOES NOT BELIEVE THAT
ADEQUATE PROGRESS IS BEING MADE.
MS. PACHTER: STAFF COULD JUST STOP THE
FUNDING AT THREE YEARS, OR COULD IT STOP IT EARLIER?
MR. ROTH: CAN STOP IT WELL, UNDER ANY
PROCEDURE, IT CAN STOP, EXISTING PROCEDURES. BUT
THIS ONE WE'RE ASKING FOR A SPECIFIC REVIEW AT THREE
YEARS AS TO THE PROGRESS AND PERHAPS A REPORT BACK
TO THE I COC ON THE PROGRESS ON THESE GRANTS.
MS. PACHTER: THEN THE ICOC WILL DECIDE
WHETHER TO CONTINUE FOR THE NEXT TWO YEARS?
MR. ROTH: NO. I THINK THAT CAN BE THE
JUDGMENT OF STAFF THAT THEY'RE MAKING PROGRESS. I'M
SIMPLY TRYING TO MAKE SURE WE GIVE A MESSAGE TO
THOSE APPLICANTS THAT THERE HAS TO BE REAL PROGRESS
HERE. THIS ISN'T GOING TO BE SORT OF AN AUTOMATIC
195

1	ANNUAL REVIEW, YOU SEND IN YOUR PAPER.
2	CHAIRMAN KLEIN: SINCE THIS WAS ORIGINALLY
3	RAISED WITH A COMMENT OF DR. PIZZO, DR. PIZZO, IS
4	THAT CONSISTENT WITH YOUR
5	DR. PIZZO: YES, IT'S CONSISTENT.
6	DR. PENHOET: I DON'T WANT TO BELABOR THE
7	POINT. I'D BE MORE COMFORTABLE IF IT WAS A
8	THREE-YEAR GRANT WITH A POSSIBILITY OF A TWO-YEAR
9	EXTENSION SO THERE'S AN AFFIRMATIVE REQUIREMENT THAT
10	THEY QUALIFY FOR AN ADDITIONAL TWO YEARS RATHER THAN
11	STAFF HAVE TO TAKE AWAY SOMETHING FROM THEM THAT
12	THEY THOUGHT THEY HAD IN A FIVE-YEAR GRANT. SO I'M
13	NOT SURE
14	MR. ROTH: I WOULD ACCEPT THAT.
15	CHAIRMAN KLEIN: WHAT WOULD BE THE
16	CRITERIA FOR THE EXTENSION AND WHO WOULD MAKE THE
17	DECISION?
18	DR. PENHOET: I'M PERFECTLY HAPPY TO HAVE
19	STAFF MAKE THE DECISION, BUT THAT THE COMMUNICATION
20	IS THAT THE LAST TWO YEARS ARE ESSENTIALLY AN ADD-ON
21	TO THE FIRST THREE YEARS, RATHER THAN SAYING, LOOK,
22	YOU HAVE A FIVE-YEAR GRANT, BUT WE'RE GOING TO RENEW
23	YOUR THREE YEARS. WE'RE NOT HAPPY WITH WHAT YOU'RE
24	DOING. WE'RE GOING TO TAKE AWAY THE LAST TWO YEARS.
25	CHAIRMAN KLEIN: DR. TROUNSON, COULD YOU
	196

1	COMMENT ON YOUR PERSPECTIVE, PLEASE?
2	DR. TROUNSON: WELL, I UNDERSTAND THAT
3	THEY'RE PUTTING A CONDITIONAL PROCESS IN HERE THAT
4	WOULD BRING A MORE INTENSIVE LOOK AT THE AIMS AND
5	THE PROGRESS THAT'S BEING MADE. WE WILL BE DOING
6	THIS WITH ALL GRANTS, BUT IN THIS CASE IT WOULD BE
7	INTENTIONALLY MILESTONE DRIVEN, WELL, WE DON'T HAVE
8	MILESTONE, BUT WE HAVE AIMS, BUT IF WE'RE NOT MOVING
9	FORWARD IN ACHIEVING THE AIMS, THEN WE WOULD SAY,
10	LOOK, YOU KNOW, I DON'T THINK THIS IS PROGRESSING AT
11	THE RATE THAT'S APPROPRIATE. AND WE'RE GOING TO
12	MAKE A RECOMMENDATION TO NOT CONTINUE THE FUNDING
13	FOR THE OTHER TWO YEARS.
14	WE CAN DO THIS, AS EVERYONE HAS NOTED, YOU
15	KNOW, IF PROGRESS WAS INSUFFICIENT ANYWAY, BUT I
16	THINK THIS IS PUTTING IN AN ADDED LEVEL OF MARK, IF
17	YOU LIKE. IF YOU DO THIS, WE WOULD NOT WE WOULD
18	BASE IT ON PROBABLY A REPORT, BUT ALSO PERHAPS AN
19	INTERVIEW, A VISIT JUST TO SEE WE VISIT
20	FREQUENTLY ANYWAY, AND WE CAN INCLUDE THAT IN OUR
21	TERMS OF LOOKING AT THESE PARTICULAR PROJECTS.
22	DR. PENHOET: IT BOILS DOWN TO DO YOU HAVE
23	A THREE-YEAR GRANT WITH A POSSIBILITY OF A TWO-YEAR
24	EXTENSION, OR DO YOU HAVE FIVE-YEAR GRANT OF WHICH
25	THE LAST TWO YEARS MIGHT BE TAKEN AWAY? I'M ASKING
	107

1	HOW YOU COMMUNICATE THIS.
2	MR. ROTH: THREE AND TWO.
3	DR. TROUNSON: I UNDERSTOOD IT WAS A
4	FIVE-YEAR GRANT, BUT IT WAS CONDITIONAL ON
5	APPROPRI ATE PROGRESS AT THE THREE YEARS.
6	MR. ROTH: I WOULD THINK ED'S APPROACH IS
7	EVEN BETTER. A THREE-YEAR GRANT WITH A TWO-YEAR
8	EXTENSION FOLLOWING A REVIEW.
9	CHAIRMAN KLEIN: SO TO BE CLEAR, WE'RE
10	APPROVING UP TO FIVE YEARS, BUT IT'S THREE YEARS AND
11	THEN WITH THE APPROVAL OF STAFF IT EXTENDS THE OTHER
12	TWO YEARS. IS THAT THE POSITION, DR. PENHOET? IS
13	THAT ACCEPTABLE ADMINISTRATIVELY, DR. TROUNSON?
14	DR. TROUNSON: YES, IT IS. IT'S SOMETHING
15	THAT WE'LL HAVE TO WORK OUR WAY THROUGH, MAKE SURE
16	THAT WE'VE GOT THINGS SUITABLY SET OUT FOR DOING
17	THIS, BUT IT'S NOTHING THAT PREVENTS US FROM GETTING
18	THAT DONE.
19	CHAIRMAN KLEIN: OKAY. THANK YOU VERY
20	MUCH.
21	DR. LOVE: I JUST HAVE A QUESTION ABOUT
22	WHETHER OR NOT THERE IS ANY UNINTENDED CONSEQUENCE
23	THAT WE'RE COMMUNICATING TO THE OTHER GROUP, THAT
24	SOMEHOW THEIR ANNUAL REVIEW IS NOT AS IMPORTANT AS
25	IT IS FOR THIS GROUP. MAYBE THAT'S WHAT WE WANT TO
	100
	198

1	DO, BUT I'M JUST TRYING TO MAKE SURE THAT WE DON'T
2	DO SOMETHING AROUND A VERY SMALL NUMBER OF GRANTS
3	THAT COULD HAVE UNINTENDED INTERPRETATIONS FOR KIND
4	OF THE WHOLE SET OF GRANTS THAT WE MAKE ON A BROADER
5	LEVEL.
6	DR. TROUNSON: DR. LOVE, IF IT'S AN
7	ALTERNATIVE BETWEEN GETTING NO FUNDING OR GETTING
8	FUNDING THAT WAS CONDITIONAL, I THINK ACTUALLY THE
9	APPLICANTS WOULD IT DEPENDS HOW IT'S PUT TO THEM.
10	I SUGGEST THAT IT WOULD BE A CHOICE BETWEEN EITHER
11	NO FUNDING OR A CONDITIONAL FUNDING EXTENDING, YOU
12	KNOW, CIRM'S ABILITY TO GET ACROSS THE WHOLE SPACE.
13	DR. POMEROY: BUT THE MESSAGE
14	CHAIRMAN KLEIN: YES. WE HAVE DR. PIZZO
15	AND THEN DR. POMEROY.
16	DR. PIZZO: SO I THINK PERHAPS THIS HAS
17	BEEN ADDRESSED, ALAN, BY YOU, BUT IT SOUNDS LIKE
18	YOU'RE GOING TO BE COMING UP WITH POLICIES FOR
19	REGULAR REVIEWS OF GRANTS, OBVIOUSLY TAKING INTO
20	ACCOUNT STAFF TIME AND RELATED ACTIVITIES.
21	PRESUMABLY THAT'S GOING TO REQUIRE SOME KIND OF
22	ANNUAL REPORT AND THAT GOES ON. SO THAT BECOMES THE
23	LANGUAGE FOR ALL GRANTS.
24	AND I THINK, TO THE POINT OF THE
25	DISCUSSION TODAY, I THINK WHAT WE WANT TO DO IS

1	SIGNAL I THINK THIS IS WHAT DUANE WAS INITIALLY
2	MOTIVATED BY THAT THERE WERE A VARIETY OF GRANTS
3	THAT WERE UNEQUIVOCALLY JUSTIFIABLE FOR WHAT THE RFA
4	WAS ABOUT, FIVE YEARS. AND THEY'RE GOING TO BE
5	ANNUALLY REVIEWED, BUT THEY'RE IN A HIGHER TIER.
6	AND THEN THERE WERE A GROUP OF GRANTS THAT, QUOTE,
7	DIDN'T HAVE THAT SAME LEVEL OF SCIENTIFIC RIGOR AND
8	QUALITY, BUT THE ICOC AND CIRM IS APPROVING THEM FOR
9	THREE YEARS, AND THERE'S A POTENTIAL FOR FULL
10	FUNDI NG.
11	I THINK IF WE STATE IT THAT WAY AND GIVE
12	THAT MESSAGE, WE'RE BEING TRUE TO TWO THINGS. ONE
13	IS WE'RE BEING CLEAR IN OUR LANGUAGE WITH RECIPIENTS
14	OF THE GRANT; AND, SECONDLY, WE'RE NOT COMPROMISING
15	ON QUALITY.
16	ONE OF THE THINGS THAT I'M WORRIED ABOUT
17	THAT OUR PRACTICE HAS BEEN OVER AND OVER AGAIN THAT
18	WE OFTENTIMES COME TO THE SECOND TIER, AND WE DO
19	APPROVE THEM. AND, YOU KNOW, I THINK IT'S A GREAT
20	THING BECAUSE WE'RE TRYING TO INFUSE FUNDING. I'M
21	MUCH MORE, AS I THINK OTHERS ARE, LENIENT ABOUT THAT
22	FOR NEW INVESTIGATORS, BUT I THINK WE WANT TO KEEP
23	THAT MESSAGE VERY CLEAR, THAT QUALITY IS IMPORTANT
24	AND THAT WE'RE SETTING A PRECEDENT THAT WILL ALLOW
25	US TO DEVIATE FROM THAT IN THE FUTURE.

1	DR. TROUNSON: MR. CHAIR, I TOTALLY
2	ENDORSE WHAT YOU'RE SAYING, DR. PIZZO. IT'S VERY
3	IMPORTANT THAT THE MESSAGE GOES BACK TO THE ENTIRE
4	COMMUNITY, THAT WE'RE AFTER THE TOP GRADE SCIENCE
5	AND THE COMMITMENT. AT TIMES PERHAPS THE GRANTS
6	COULD HAVE BEEN BETTER WRITTEN WHEN THEY'RE FALLING
7	DOWN IN THESE LEVELS. IT MIGHT INDICATE THAT IF YOU
8	GAVE A BIGGER COMMITMENT OR YOU ACTUALLY HAD MORE
9	DATA, THAT YOU WOULD BE MORE SUCCESSFUL. I THINK
10	WE'VE GOT TO MAINTAIN AS MUCH OF THE STANDARD AS IS
11	POSSIBLE WHILE BEING SENSITIVE TO WHAT WE CAN
12	ACHIEVE. SO I TOTALLY AGREE WITH WHAT YOU'RE
13	SAYI NG.
14	DR. FRIEDMAN: MR. CHAIRMAN, IF I COULD
15	ASK A QUESTION, PLEASE.
16	CHAIRMAN KLEIN: DR. POMEROY AND THEN DR.
17	FRI EDMAN.
18	DR. POMEROY: THANK YOU. I WANT TO JUST
19	REITERATE AND REMIND EVERYBODY THAT IT'S REALLY
20	IMPORTANT THAT WE SEND A MESSAGE THAT THIS FUNDING
21	IS CONDITIONAL EVERY YEAR ON EVERY GRANT.
22	AND THAT I HAVE TO ENDORSE WHAT TED SAID.
23	IT WOULD BE UNFORTUNATE TO MAKE, IN MY OPINION,
24	DIFFERENTIATION BETWEEN LEVELS OF CONDITIONALITY
25	BECAUSE IT MAY SEND A MESSAGE TO EVERYBODY THAT WE
	201

1	DON'T TAKE THE ONE-YEAR REVIEWS SERIOUSLY. SO SINCE
2	QUALITY IS THE GOAL HERE, I PERSONALLY THINK THAT
3	EVERY ANNUAL REVIEW IS IMPORTANT, EVERY ANNUAL
4	REVIEW SHOULD HAVE APPROPRIATE PROGRESS; AND WHILE
5	THESE IN THE SECOND TIER MAY BE HIGHER RISK FOR NOT
6	MAKING ADEQUATE PROGRESS, WE HAVE A PROCESS IN PLACE
7	TO DETERMINE FOR STAFF TO DETERMINE IF ADEQUATE
8	PROGRESS HAS BEEN MADE.
9	SO I WOULD PERSONALLY PREFER, IT'S NOT A
10	SWORD I'LL DIE ON, BUT I WOULD PERSONALLY PREFER
11	THAT WE USE THE EXISTING PROCESS.
12	AND THEN MY FINAL COMMENT IS THIS MIDDLE
13	CATEGORY WAS VERY SPECIFICALLY RECOMMENDED FOR
14	FUNDING IF FUNDS ARE AVAILABLE. AND BY DEFINITION,
15	NEW FACULTY GRANTS ARE HIGHER RISK THAN ESTABLISHED
16	INVESTIGATORS. AND THAT'S EXACTLY WHAT THIS RFA WAS
17	FOR AND ACTUALLY THE FIELD THAT WE'RE IN. SO I AM
18	GOING TO, IF I HAD MY IDEAL SITUATION, VOTE
19	AFFIRMATIVELY ON THESE WITH USING THE EXISTING
20	PROCESS FOR AN ANNUAL EVALUATION.
21	CHAIRMAN KLEIN: OKAY. THE EXISTING
22	MOTION IS FOR FIVE YEARS APPROVAL WITH THE STAFF
23	HAVING THE, AS I UNDERSTAND, THE AMENDED MOTION AT
24	THIS POINT FROM JOAN SAMUELSON AND DUANE ROTH
25	EXCUSE ME DUANE ROTH AND JOAN SAMUELSON IS THAT

1	IT IS A FIVE-YEAR APPROVAL. AT THREE YEARS THE
2	STAFF WILL MAKE A DECISION ON WHETHER TO CONTINUE IT
3	FOR THE LAST TWO YEARS.
4	MR. ROTH: OKAY.
5	CHAIRMAN KLEIN: BECAUSE WE HAVE TO
6	AUTHORIZE IT FOR FIVE, BUT IT'S A THREE-YEAR GRANT,
7	THAT IF THE STAFF APPROVES IT, THEY CAN EXTEND IT
8	FOR TWO; IS THAT CORRECT?
9	MR. ROTH: WHAT PHIL SAID AND OTHERS, IT'S
10	THE MESSAGE
11	CHAIRMAN KLEIN: OKAY.
12	MR. ROTH: I'M MORE CONCERNED ABOUT,
13	NOT THE PROCESS.
14	CHAIRMAN KLEIN: SO DR. POMEROY HAS MADE
15	SOME VERY GOOD COMMENTS. YOU NEED TO KEEP THOSE IN
16	MIND, BUT WE NEED TO CALL THE QUESTION HERE IF WE
17	CAN. DR. FRIEDMAN.
18	DR. FRIEDMAN: THIS WILL TAKE JUST ONE
19	SECOND. CAN STAFF PLEASE TELL ME IF WE APPROVE FOR
20	FUNDING THESE THREE ADDITIONAL GRANTS, WHAT IS THE
21	TOTAL?
22	DR. TROUNSON: TOTAL MONEY. AMY.
23	DR. FRIEDMAN: WHAT YOU TOLD US LAST NIGHT
24	WAS THAT WE HAD SET ASIDE SOME \$40 MILLION; AND IF
25	WE FUNDED ALL THE ONES THAT WERE APPROVED FOR
	203

203

1	FUNDING, IT WOULD BE ABOUT \$51 MILLION, AS I RECALL.
2	DR. TROUNSON: THAT'S CORRECT.
3	DR. FRIEDMAN: WHAT IS THE ADDITIONAL
4	INCREMENT, PLEASE?
5	DR. TROUNSON: YOU'VE AGREED TO THREE
6	ADDI TI ONAL.
7	DR. FRIEDMAN: THREE ADDITIONAL, YES.
8	CHAIRMAN KLEIN: 67.3 MILLION.
9	DR. FRIEDMAN: 67.3 MILLION. I'M SORRY.
10	I'M LOOKING AT THE SCREEN. I JUST DON'T SEE IT.
11	THANK YOU. NOW I DO. THANK YOU. 67.3.
12	MY POINT, MR. CHAIRMAN, IS THE FOLLOWING:
13	I STRONGLY, STRONGLY URGE THAT WE CONSIDER THE
14	FUTURE GRANTS INDIVIDUALLY. THE REASON I SAY THIS
15	IS I HAD THE OPPORTUNITY TO REVIEW ONE OF THE GRANTS
16	IN THE FIRST THREE, AND I THINK THERE ARE VERY
17	SUBSTANTIAL PROBLEMS WITH IT. I CAN'T SPEAK TO THE
18	OTHER TWO, AND I'M NOT MAKING CRITICISMS OF THOSE.
19	BUT I THINK IT'S A CRUDE MECHANISM FOR APPROVING
20	THEM AS BATCHES, NO. 1.
21	NO. 2, I REALLY WANT TO WARN MYSELF AND MY
22	COLLEAGUES. THERE IS GOING TO COME A TIME A YEAR OR
23	TWO FROM NOW WHEN WE'RE GOING TO WANT MORE MONEY FOR
24	BETTER IDEAS. AND I PROMISE YOU WHAT LOOKS LIKE
25	EXCESS CAPACITY TODAY, AND WE'RE GOING 27 MILLION
	204

204

1	OVER WHAT WE ANTICIPATED, LET'S NOT FOLLOW THE SAME
2	PATHWAY AT THE NIH WHERE YOU FUND EVERYTHING UP
3	FRONT, AND THEN SUDDENLY WHEN ALL THE GOOD IDEAS
4	BEGIN TO COME FORTH, YOU HAVE INSUFFICIENT RESOURCES
5	TO SUPPORT IT.
6	I'M VERY SUPPORTIVE OF YOUNG
7	INVESTIGATORS. I THINK IT'S A LEGITIMATE CONCERN
8	ABOUT THE PHYSICIAN/SCIENTIST. I AGREE WITH THE
9	POINTS THAT HAVE BEEN MADE. I'M JUST TRYING TO
10	STRIKE A BALANCE. WE DO NOT HAVE LIMITLESS FUNDS,
11	AND THERE'S GOING TO COME A TIME WHEN WE'RE GOING TO
12	BE SHORT OF MONEY.
13	CHAIRMAN KLEIN: I THINK THAT THERE'S
14	PROBABLY BROAD AGREEMENT ON THE BOARD, DR. FRIEDMAN.
15	THERE'S AN ATTEMPT TO DISTINGUISH THE GRANTS HERE
16	BECAUSE THEY ARE YOUNG INVESTIGATORS, BECAUSE IT'S
17	THE BUILDING BLOCKS OF THE SYSTEM, AND BECAUSE OF
18	THE LEAD-TIME IN THE SYSTEM. BUT WE TAKE YOUR POINT
19	VERY ACUTELY WITH GREAT ACUTE FOCUS. SHERRY.
20	MS. LANSING: AM I ALLOWED TO SPEAK ON
21	THIS? I JUST WANT TO KIND OF SECOND WHAT DR.
22	FRIEDMAN SAID. I THINK THAT WE HAVE A
23	RESPONSIBILITY WHETHER WE CAN MOVE MONEY FORWARD OR
24	NOT MOVE MONEY FORWARD TO USE THE FUNDS WISELY AND
25	NOT JUST TO SPEND IT. SO I WANT TO SECOND YOUR
	205

	BARRISTERS' REPORTING SERVICE
1	COMMENT.
2	CHAIRMAN KLEIN: OKAY. THANK YOU VERY
3	MUCH. WE HAVE A MOTION ON THE FLOOR HERE. PUBLIC
4	COMMENT ON THIS MOTION? SEEING NO PUBLIC COMMENT,
5	CAN WE CALL THE ROLL ON THIS MOTION.
6	MS. KING: DONALD DAFOE.
7	DR. DAFOE: NO.
8	MS. KING: ROBERT PRICE.
9	DR. PRICE: ABSTAIN.
10	MS. KING: DAVID BRENNER.
11	DR. BRENNER: NO.
12	MS. KING: JACOB LEVIN.
13	DR. LEVIN: NO.
14	MS. KING: MICHAEL FRIEDMAN.
15	DR. FRIEDMAN: NO.
16	MS. KING: MICHAEL GOLDBERG.
17	MR. GOLDBERG: NO.
18	MS. KING: NANCY MILLIKEN.
19	DR. MILLIKEN: NO.
20	MS. KING: BOB KLEIN.
21	CHAIRMAN KLEIN: YES.
22	MS. KING: SHERRY LANSING.
23	MS. LANSING: NO.
24	MS. KING: TED LOVE.
25	DR. LOVE: NO.
	206
	200

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	MS. KING: ED PENHOET.
2	DR. PENHOET: NO.
3	
	MS. KING: PHIL PIZZO.
4	DR. PI ZZO: NO.
5	MS. KING: CLAIRE POMEROY.
6	DR. POMEROY: YES.
7	MS. KING: ROBERT QUINT.
8	DR. QUINT: NO.
9	MS. KING: DUANE ROTH.
10	MR. ROTH: YES.
11	MS. KING: JOAN SAMUELSON.
12	MS. SAMUELSON: YES.
13	MS. KING: JEFF SHEEHY.
14	MR. SHEEHY: YES.
15	MS. KING: OSWALD STEWARD.
16	DR. STEWARD: NO.
17	CHAIRMAN KLEIN: WHILE THIS IS BEING
18	TABULATED, MAY I SUGGEST, IN THIS CATEGORY IN
19	PARTICULAR, I'M A VERY STRONG PROPONENT OF WHAT HAS
20	BEEN VOICED BY MANY MEMBERS OF THIS BOARD, WHICH IS
21	WE NEED INDIVIDUAL ANALYSIS. WHAT I'D LIKE TO DO IS
22	TAKE A POLL OF THE BOARD WITH A SUGGESTION, BECAUSE
23	I DON'T THINK THIS MOTION PASSES, THAT WE TAKE THESE
24	THAT WERE PART OF THIS MOTION, THE SUGGESTION WAS WE
25	LOOK AT THEM INDIVIDUALLY, AND THE REST OF THEM, AND
	207

1	IF WE'RE GOING TO LOSE OUR QUORUM, WE DON'T DRIVE
2	OURSELVES BY THE QUORUM. WE PUT OVER THESE AND THE
3	BALANCE OF THEM UNTIL SEPTEMBER TO GO OVER THESE
4	INDIVIDUALLY SO THAT WE CAN GIVE THEM ADEQUATE
5	CONSIDERATION ON THEIR MERITS INDIVIDUALLY.
6	MS. LANSING: BOB, I THINK WE'RE GOING
7	I JUST THINK I THINK WE'RE GOING TO HAVE A
8	PROCESS THAT WE'RE GOING TO HEAR ABOUT TO REEVALUATE
9	GRANTS THAT PEOPLE CAN BRING FORWARD, AND THAT MAYBE
10	WE'RE GOING TO ADOPT IT SO THE BOARD CAN BRING IT
11	FORWARD. I THINK WE HAVE TO FOLLOW THAT PROCEDURE.
12	I THINK THAT'S GOING TO BE PART OF OUR AGENDA. MY
13	SUGGESTION IS, YOU KNOW, PEOPLE BRING FORWARD
14	INDIVIDUAL THINGS IN THE PROCESS THAT WE'RE GOING TO
15	GET TO IN A COUPLE OF HOURS OR MAYBE THE NEXT ITEM.
16	CHAIRMAN KLEIN: THE ISSUE HERE IS WE HAVE
17	A GROUP OF GRANTS THAT ARE IN THIS CATEGORY.
18	BECAUSE WE'VE HAD FIVE DIFFERENT PEOPLE THAT HAVE
19	HAD REALLY SUBSTANTIAL PROBLEMS, INDIVIDUAL PROBLEMS
20	THEY'VE HAD TO MEET, WE HAVE A BOARD MEMBER WHO JUST
21	HAD TO LEAVE FOR AN INTERNATIONAL FLIGHT THAT IS, OF
22	COURSE, INFLEXIBLE, BUT WE HAVE AN OBLIGATION TO TRY
23	AND INDIVIDUALLY LOOK AT THESE GRANTS AND CONSIDER
24	THEM. SO THIS IS NOT A QUESTION OF AN APPEAL, WHICH
25	IS WHAT WE'RE GOING TO ADDRESS LATER. THIS IS A

1	DIFFERENT QUESTION. THIS IS A QUESTION OF GIVING
2	THESE GRANTS THAT ARE IN THE CATEGORY OF FUND IF
3	AVAILABLE A REASONABLE REVIEW.
4	MS. LANSING: WHY WOULDN'T WE DO IT WITH
5	THE TOP THREE AS WELL? I THINK I DON'T
6	UNDERSTAND OUR PROCESS. AND THAT'S I'M NOT EVEN
7	REFERRING TO THE INDIVIDUAL GRANTS. I'M REFERRING
8	TO A PROCESS. AND
9	CHAIRMAN KLEIN: I THINK THAT YOU'RE GOING
10	TO HELP OUR PROCESS GREATLY BECAUSE, AS CHAIR OF
11	GOVERNANCE, YOU'RE GOING TO COME UP WITH A PROGRAM
12	WHERE WE'RE NOT ARTIFICIALLY PUT UNDER THESE
13	PRESSURES.
14	BUT GIVEN THE SITUATION WE'RE IN IN
15	REAL-TIME, MY QUESTION TO THIS BOARD IS DO YOU
16	WANT WE'RE EFFECTIVELY IN A POSITION, I BELIEVE,
17	THAT WITH THE REST OF THE PENDING GRANTS, IF WE'RE
18	GOING TO GIVE THEM PROPER ATTENTION, DR. PRICE HAS
19	SUGGESTED AND DR. FRIEDMAN IN INDIVIDUAL
20	PRESENTATIONS THAT THEY DESERVE INDIVIDUAL
21	EXAMINATION. MY QUESTION IS DOES THE BOARD WANT TO
22	INDIVIDUALLY EXAMINE THESE IN SEPTEMBER ON THE ONES
23	WE HAVE NOT ACTED ON.
24	MS. LANSING: AND MY QUESTION IS WHY
25	WOULDN'T THE PROCESS THAT WE'RE GOING TO PUT IN
	209

1	PLACE WORK AS WELL FOR THAT, AND WHY DON'T WE ADJUST
2	THE PROCESS SO IT DOES BECAUSE I CAN GO BACK TO
3	OTHER ONES WHEN WE HAD TO VOTE BECAUSE WE HAD A
4	QUORUM.
5	DR. STEWARD: DOING WHAT YOU'RE SUGGESTING
6	REQUIRES AN AFFIRMATIVE ACTION BY THIS BOARD?
7	CHAIRMAN KLEIN: WELL, AT THIS POINT IT
8	DOESN'T REQUIRE AN AFFIRMATIVE ACTION BECAUSE
9	DR. STEWARD: BECAUSE WE CAN'T. SO IT'S A
10	MOOT DISCUSSION IS WHAT I'M SAYING. LET'S MOVE ON.
11	CHAIRMAN KLEIN: BECAUSE DURING THE
12	DISCUSSION, THE VOTE LEFT. BUT AS A PROCESS, AS A
13	PROCESS QUESTION, I'D LIKE TO ADDRESS THIS IN THAT
14	CONTEXT, THAT I WOULD HOPE WE'VE LEARNED FROM THIS
15	PARTICULAR EXPERIENCE. AND I'D LIKE DIRECTION FROM
16	THE BOARD THAT IF WE FACE THIS EXPERIENCE, I THINK
17	IT'S BEST TO JUST PUT THEM OVER TO THE NEXT MEETING,
18	SO WE CAN GET REALLY THOUGHTFUL CONSIDERATION.
19	DR. LOVE: BOB, I THINK I UNDERSTAND WHAT
20	YOU'RE TRYING TO DO. THE THING THAT I GET
21	UNCOMFORTABLE WITH IS THE SUGGESTION THAT THESE HAVE
22	NOT GOTTEN AN ADEQUATE PROCESS ALREADY. IN FACT, I
23	THINK WHAT WE'VE DEMONSTRATED OVER AND OVER AGAIN IS
24	WE DO HAVE A VERY GOOD PROCESS. THESE GRANTS HAVE
25	BEEN THOROUGHLY VETTED AND REVIEWED. THEY WERE
	210

1	RANKED AS THEY WERE RANKED FOR REASONS THAT I THINK
2	WE'VE HAD A CHANCE TO COMPREHEND. AND THE REALITY
3	IS THEY DID NOT DO AS WELL.
4	SO I'M JUST I'M A LITTLE BIT
5	UNCOMFORTABLE WITH THE SUGGESTION THAT WE HAVEN'T
6	GIVEN ADEQUATE PROCESS AND WE NOW SOMEHOW NEED TO.
7	CHAIRMAN KLEIN: WE HAVEN'T HAD THE
8	OPPORTUNITY TO DISCUSS THE ONES BELOW, WHICH THERE
9	HAVE BEEN MOTIONS. THAT'S THE ONLY THING I'M
10	FOCUSING MY DISCUSSION ON.
11	DR. PIZZO: I DO VALUE THE MOTION THAT WAS
12	MADE, BUT I'M ALSO HAVING SORT OF ADDITIONAL
13	CONCERNS ALONG THE SAME LINES THAT TED AND MIKE
14	COMMENTED ON, WHICH IS THE THREE THAT WE NOW HAVE,
15	AND THIS IS THE REASON WHY I VOTED NO, ARE JUST
16	THREE THAT WERE ARBITRARY. AND THEY WERE DRIVEN BY
17	THE FACT THAT WE HAD SOME CONFLICTS BECAUSE WE COULD
18	HAVE EITHER DRAWN THE NUMBER DOWN OR DONE EACH ONE
19	INDIVIDUALLY. AND I FEAR THAT LET ME JUST MAKE
20	MY POINT THAT IF WE FOLLOW YOUR GUIDANCE, BOB,
21	AND REVIEW EACH OF THESE INDIVIDUALLY AT THE NEXT
22	MEETING IN SEPTEMBER, THAT THERE'S NO BASIS TO
23	NECESSARILY STOP WITH THE ONES IN GRAY BECAUSE WE
24	CAN THEN EASILY SAY LET'S EXTEND THAT TO INDIVIDUAL
25	REVIEWS OF ALL THE OTHERS THAT ARE IN TIER 3.
	211

1	AND I THINK IF WE START GOING DOWN THAT
2	PATHWAY, WE'RE REALLY OPENING A CAN OF WORMS THAT'S
3	GOING TO BE VERY HARD FOR US TO BE ABLE TO
4	RECONCI LE.
5	SO IT IS A MATTER OF SORT OF FINDING SOME
6	BALANCE AROUND THIS. I WAS PARTICULARLY WORRIED IN
7	THIS GROUP I WOULD HAVE EXPRESSED IT IN THE NEXT
8	ROUND WHEN WE GOT TO THE UNSCORED ONES BECAUSE
9	THERE I THINK IS REALLY UNCHARTERED TERRITORY. SO I
10	THINK THAT WE'RE SORT OF RE-RAISING THE ISSUE OF
11	WHETHER THE PATH THAT WE WERE ON JUST A FEW MINUTES
12	AGO IS A PRUDENT ONE FOR US TO CONTINUE FOLLOWING.
13	CHAIRMAN KLEIN: ALL RIGHT. LET'S DO THIS
14	SEQUENTIALLY. JEFF SHEEHY.
15	MR. SHEEHY: I'D LIKE TO MAKE A NUMBER OF
16	POINTS, AND I DO FUNDAMENTALLY I THINK I'M COMING
17	FROM TED'S POINT. FIRST OF ALL, IF YOU LOOK AT
18	WHERE WE ARE AND YOU GO TO WHERE WE WERE IN
19	PROGRAMMATIC REVIEW, THE THREE ONES WE MOVED UP WERE
20	MOVED OUT, WERE MOVED DOWN INTO A LOWER TIER IN
21	PROGRAMMATIC REVIEW. THAT WAS AS MUCH AS ANYTHING A
22	FINANCIAL CONSIDERATION. WHEN YOU'RE HAVING, YOU
23	KNOW, TRIAGE, YOU ARE GOING TO TAKE SO THOSE
24	PROBABLY WERE THE LEGITIMATE NEXT THREE THAT SHOULD
25	GO UP. THEY STARTED OFF IN THE TOP TIER AND WERE
	212

MOVED DOWN. SO JUST IN TERMS OF CONTEXT.
SO IF YOU LOOK AT WHAT WE'VE ACCOMPLISHED
SO FAR, WE HAVE TAKEN EVERYTHING THAT THE WORKING
GROUP PUT IN TIER 1, BOTH ORIGINALLY AND FOLLOWING
PROGRAMMATIC REVIEW.
THE SECOND THING I WOULD NOTE IS THAT WE
ARE FUNDING 23 OUT OF 54, AND WE ALREADY HAVE HAD A
ROUND OF YOUNG INVESTIGATORS OR NEW INVESTIGATORS.
SO I DON'T KNOW. IT SEEMS TO ME WE MAY HAVE REALLY
COVERED THE AREA, AND I DON'T KNOW WE WILL HAVE
TO DISPOSE OF THESE GRANTS NO MATTER WHAT. WE ARE
MISSING A FUNDAMENTAL MOTION, WHICH IS TO ASSIGN
EVERYTHING THAT IS NOT FUNDED TO A NONFUNDABLE
CATEGORY. SO THEY WILL COME UP AGAIN.
I WOULD CAUTION AGAINST ANY ADDITIONAL
SCRUTINY. AS HAS BEEN SAID, THEY HAVE BEEN WELL
REVIEWED LABORIOUSLY. THEY HAVE RECEIVED
PROGRAMMATIC REVIEW. EVERYTHING THAT WAS
RECOMMENDED EITHER BY REVIEW, BY SCORE, OR
PROGRAMMATICALLY WE HAVE NOW FUNDED. SO WE REALLY
ARE TRULY IN A CATEGORY THAT IS GRAY NOW. AND SO I
WOULD NOT ENCOURAGE STAFF TO COLLECT ANY ADDITIONAL
INFORMATION. I THINK WE ARE YOU KNOW, WE CAN
DECIDE WHAT WE DO NEXT MEETING, BUT I THINK WE'VE
DONE A GOOD JOB SO FAR. I'M READY TO MOVE ON
213

1	PERSONALLY.
2	CHAIRMAN KLEIN: I WOULD JUST PUT IT IN
3	CONTEXT. A, IT IS IMPORTANT TO NOTE THAT WE HAVE
4	COMMUNICATIONS THAT HAVE BEEN RECEIVED, WHICH AS A
5	MATTER OF BAGLEY-KEENE ACT ARE PUBLIC RECORD, ON
6	SOME OF THESE APPLICATIONS IN THIS CATEGORY. WHEN
7	THOSE COME UP IN THE NEXT SESSION, PEOPLE WILL HAVE
8	A RIGHT TO INDIVIDUALLY ADDRESS THEM.
9	SO I'M TRYING TO WORK WITHIN SEVERAL
10	LAYERS OF COMPLEXITY HERE. NOW, IF THE BOARD AT THE
11	NEXT SESSION WISHES TO MOVE ALL OF THESE REMAINING
12	GRANTS INTO A NONFUNDED CATEGORY, THAT CAN BE A
13	MOTION. BUT REALIZE THAT YOU DO HAVE SOME
14	INDIVIDUAL RECORDS THAT HAVE BEEN ON FILE PUBLICLY
15	ADDRESSING SOME OF THESE GRANTS. WE ARE GOING TO,
16	AS SHERRY SAID, DISCUSS AN EXTRAORDINARY PETITION,
17	WHICH WE CAN DISCUSS IN THIS MEETING AND HOPEFULLY
18	PROGRESS THAT BECAUSE WE NEED SOME PROCESS. WE ARE
19	DEVELOPING AN APPROACH HERE TO DEAL WITH PETITIONS
20	AND REVIEWS THAT WILL BE VERY HELPFUL TO US.
21	JAMES HARRISON, DID YOU HAVE A COMMENT?
22	MR. HARRISON: I JUST WANTED TO STATE FOR
23	THE RECORD, BEFORE WE GET TOO FAR ALONG, THAT THE
24	LAST MOTION FAILED BY A VOTE OF 12 NOES, FIVE YESES,
25	AND ONE ABSTENTION.

CHAIRMAN KLEIN: THANK YOU VERY MUCH. ALL
RIGHT. SO DR. PENHOET.
DR. PENHOET: TWO ISSUES. THE LAST VOTE
WAS ON A COMPOUND PROPOSAL, ONE PIECE OF WHICH WAS
THREE PLUS TWO, THE OTHER THREE PLECE WAS THESE
THREE GRANTS TO MOVE UP. I VOTED NO BECAUSE I
DIDN'T WANT TO MOVE THE THREE UP EN BLOC. I WOULD
HAVE VOTED YES IF THEY HAD BEEN SEPARATED ON A IF
WE AGREED TO FUND ANY OF THESE, THAT THEY WOULD HAVE
BEEN FUNDED UNDER THE THREE PLUS TWO PROPOSAL THAT
DUANE MADE.
I DO AGREE WITH MICHAEL FRIEDMAN. I THINK
WE HAVE A LONG-STANDING TRADITION OF LOOKING AT EACH
OF THESE GRANTS IN THIS CATEGORY ONE BY ONE,
ASSESSING THEIR VALUE, AND MAKING A DECISION TO
EITHER MOVE THEM UP OR MOVE THEM DOWN ESSENTIALLY.
WE DON'T UNFORTUNATELY WE SEEM NOT TO HAVE A
PROSCRIBED LIMIT OF WHAT AVAILABLE FUNDING MEANS;
AND, THEREFORE, WE'RE WORKING WITH A TO SOME DEGREE
ARTIFICIAL CONSTRUCT. WE DON'T KNOW IT SAYS FUND
THESE IF FUNDS ARE AVAILABLE. WE'RE HEARING, WELL,
EITHER THEY'RE AVAILABLE OR WE'VE ALREADY SPENT TOO
MUCH MONEY. I'M NOT SURE WHICH, BUT WE HAVEN'T
DEFINED WHAT'S AVAILABLE FOR THIS CATEGORY.
SO, YOU KNOW, I THINK IN FAIRNESS TO THE
215

1	INDIVIDUALS WHO WROTE THESE GRANTS WHO DID WELL
2	ENOUGH TO GET THEMSELVES IN THIS CATEGORY, THAT WE
3	OWE IT TO THEM TO REVIEW THEM ONE BY ONE AT THE
4	APPROPRIATE TIME.
5	BUT I THINK, SHERRY, IT'S A DIFFERENT
6	ISSUE THAN THE APPEAL PROCESS. THIS IS OUR STANDARD
7	OPERATING PROCEDURE FOR DEALING WITH GRANTS. WE'VE
8	DONE IT OVER AND OVER AND OVER AGAIN. TO BE FRANK,
9	IN THE INTEREST OF TIME, TODAY I THINK WE DID LUMP
10	SOME OF THESE TOGETHER, BUT I DON'T DISAGREE WITH
11	YOU, JEFF, THAT PRIOR TO THIS MEETING, A LOT OF
12	THOUGHTFUL WORK HAS GONE INTO CREATING THESE
13	RANKINGS, ETC., BUT I THINK WE OWE IT TO THE
14	APPLICANTS TO REVIEW THESE ONE AT A TIME. THERE
15	AREN'T THAT MANY, AND WE HAVE A LONG-STANDING
16	TRADITION OF DOING THAT. I DON'T SEE ANY REASON TO
17	CHANGE THAT.
18	CHAIRMAN KLEIN: THAT WAS MY POINT
19	EARLIER. EVERY ONE OF US WILL MAKE A DECISION, AND
20	WE'RE GOING TO HAVE AN OPPORTUNITY WHEN WE RECONVENE
21	IN SEPTEMBER TO REACH INDIVIDUAL DECISIONS IN THAT
22	VOTE.
23	SO, DUANE, WOULD YOU LIKE TO MAKE COMMENT?
24	MR. ROTH: I WAS TRYING TO BE EFFICIENT
25	HERE AND MADE THE RECOMMENDATION ON THE BASIS OF
	216

1	THAT. I AM PERFECTLY WILLING TO GO THROUGH EACH
2	INDIVIDUAL GRANT. THERE IS NO INTENTION
3	CHAIRMAN KLEIN: I THINK EVERYONE
4	UNDERSTOOD IT WAS IN THAT CONTEXT YOU MADE THE
5	MOTION.
6	MR. ROTH: BOB, IF YOU COULD SHED A LITTLE
7	LIGHT. WE HAVE OVERFUNDED AND UNDERFUNDED IN THE
8	PAST BASED ON WHAT OUR BUDGET WAS. WHAT DO WE HAVE
9	AVAILABLE IN TERMS OF FUNDING?
10	CHAIRMAN KLEIN: WHAT I'D LIKE TO DO, IF
11	POSSIBLE, IS ANSWER THAT HOPEFULLY WITH SOME
12	THOUGHTFUL INTERACTION WITH THE PRESIDENT BY
13	BRINGING BACK AT THE NEXT MEETING A QUICK LOOK
14	DIAGRAMMATICALLY AT OUR OVERALL STRATEGIC PLAN AS IT
15	SITS TODAY IT'S UNDER REVISION AND SHOW YOU
16	WHERE WE ARE IN TERMS OF OUR FUNDING RELATED TO THE
17	STRATEGIC PLAN SO THAT EVERYONE IN REAL-TIME CAN BE
18	MAKING ADJUSTMENTS AND UNDERSTANDING WHAT THE
19	INTERPLAY IS BETWEEN DIFFERENT CATEGORIES OF
20	FUNDING. RATHER THAN JUST SUMMARIZING, WE'LL GIVE
21	YOU THE SUMMARY DATA IN THE NEXT SESSION.
22	I WOULD ALSO SUGGEST IF IT IS I'D LIKE
23	TO KNOW FROM THE BOARD'S PERSPECTIVE, BUT I ACTUALLY
24	THINK THAT WE CAN SAVE SOME MONEY IN THE FUTURE BY
25	HAVING SOME DISCUSSIONS WITH THE INSTITUTIONS ON A
	047

1	DYNAMIC FUNDING MODEL THAT CHANGES THE PARADIGM OF
2	HOW THEY HANDLE FUNDING WHERE THE INSTITUTIONS ON A
3	NET BASIS ARE BETTER OFF AND WE SAVE MONEY ON OUR
4	FUNDING. IT'S A PERATO-OPTIMAL APPROACH TO FUNDING.
5	I, FRANKLY, THINK HISTORICAL FUNDING PATTERNS AND
6	HOW MONEY IS DELIVERED TO INSTITUTIONS IS MEDIEVAL,
7	BUT I WOULD HOPE THAT
8	DR. TROUNSON: CHAIR, SORRY. BEFORE WE DO
9	THAT, WE PROBABLY NEED TO LOOK AT ALL THE
10	CIRCUMSTANCES AROUND THAT, PARTICULARLY IF WE'RE
11	GOING YEAR BY YEAR AND ENSURING THAT THEY ARE DOING
12	WHAT WE WANT.
13	CHAIRMAN KLEIN: OH, NO. I'M NOT TALKING
14	ABOUT CHANGING OUR RFA POLICY. I'M TALKING ABOUT
15	THE MANNER OF DELIVERING FUNDS. SO I'M NOT CHANGING
16	ANYTHING IN THE STRATEGIC PLAN OR ANYTHING IN
17	PROCESS, MERELY LOOKING AT THE STRUCTURING OF HOW
18	FUNDING OCCURS BECAUSE I THINK THERE'S WAYS TO SAVE
19	MONEY AND PROVIDE MORE FUNDING FOR MORE PROGRAMS.
20	OKAY. I'D LIKE TO FOR DISCUSSION, WE
21	HAVE A VERY IMPORTANT ITEM, AS SHERRY LANSING HAS
22	MENTIONED, THAT WE NEED TO GET TO TO MOVE THE
23	EXTRAORDINARY PETITION ISSUES. AND SINCE THAT'S
24	BEEN RAISED HERE IN CONTEXT, I'M WONDERING IF WE CAN
25	MOVE TO THAT ITEM ON THE AGENDA.

MS. SAMUELSON: POINT OF ORDER OR PROCESS
OR SOMETHING, BOB. I'M WONDERING HOW WE CAN PROCEED
WITHOUT A QUORUM.
CHAIRMAN KLEIN: BECAUSE WE CAN PROCEED
WITH DISCUSSIONS OF ITEMS SO THAT, YOU KNOW, WE HAVE
THIS IMPORTANT ITEM THAT WE HAVE RAISED HERE, THAT
SHERRY HAS BEEN REFERENCING. AND I THINK IT'S VERY
IMPORTANT WE ALSO HAVE THE LOAN POLICY TO DISCUSS SO
THAT THE BOARD IS FULLY ADVISED ON THE LOAN POLICY.
WE CAN'T TAKE AN ACTION ON THE LOAN POLICY, BUT WE
CAN HAVE A BRIEFING ON THE LOAN POLICY SO WE CAN
TAKE A FINAL ACTION IN SEPTEMBER.
BUT ITEM 17 IS THE CONSIDERATION OF POLICY
REGARDING EXTRAORDINARY PETITIONS FOR ICOC
APPLICATIONS FOR FUNDING. AND I'D LIKE TO KNOW IS
IT ACCEPTABLE TO THE BOARD, SINCE IT SEEMS TO BE
PERTINENT TO THE DISCUSSIONS WE'VE BEEN HAVING, IF
WE PROCEED TO THAT ITEM FOR DISCUSSION.
SEEING NO DISAGREEMENT, IF WE COULD GO TO
ITEM 17. FIVE-MINUTE BREAK IS REQUESTED. SO WE
WILL TAKE A FIVE-MINUTE BREAK FOR THE BENEFIT OF
STAFF. MR. PENHOET HAS REQUESTED WE MAKE THAT A
TEN-MINUTE BREAK, SO WE WILL RECONVENE IN TEN
MI NUTES.
(A RECESS WAS THEN TAKEN.)
219

1	CHAIRMAN KLEIN: ALL RIGHT. IF WE CAN
2	RECONVENE PLEASE. ALL RIGHT. THANK YOU VERY MUCH.
3	SO IF WE COULD RETRIEVE OUR OTHER MEMBERS. IF STAFF
4	COULD HELP, IT WOULD BE BENEFICIAL. JENNA, LYNN,
5	COULD YOU PLEASE RETRIEVE MEMBERS THAT ARE OUT IN
6	THE LOBBY? THANK YOU VERY MUCH.
7	SO FOR THE BENEFIT OF THE PUBLIC AND STAFF
8	AND THE REST OF THE BOARD, WHILE WE'RE REASSEMBLING,
9	THE REASON I MOVED TO ITEM 17 IS DR. PENHOET HAS
10	JUST DONE A VERY GOOD OF JOB DIFFERENTIATING BETWEEN
11	PETITIONS FOR EXTRAORDINARY PETITIONS FOR
12	APPLICANTS AS A PROCESS AS CONTRASTED WITH OUR
13	PROCESS IN REVIEWING RECOMMENDATIONS THAT COME
14	BEFORE THIS BOARD FROM THE PEER REVIEW COMMITTEE.
15	SO WITH THAT FRESH IN OUR MINDS, IT
16	APPEARS APPROPRIATE NOT TO LOSE THAT BRAIN POWER AND
17	CONTRIBUTION. THANK YOU, DR. PENHOET. AND WE WOULD
18	HOPEFULLY MOVE FORWARD TO ITEM 17.
19	I'D ALSO SAY THAT CHALLENGE IS THE MOTHER
20	OF INVENTION, SO SHERRY LANSING, WHO I KNOW IS VERY
21	INNOVATIVE, IN WORKING WITH DR. FRIEDMAN AND OTHERS,
22	WILL COME BACK TO US WITH A PROCESS THAT WILL
23	INSULATE US FROM THESE UNEXPECTED DEMANDS THAT ARE
24	MADE ON EXTRAORDINARILY IMPORTANT INDIVIDUALS WHO
25	SERVE THEIR INSTITUTIONS THAT ARE ON THIS PANEL. WE
	220

1	HAVEN'T BEEN FACED IN THE PAST WITH THE KIND OF
2	EXTRAORDINARY SITUATIONS AFFECTING THE QUORUMS. AND
3	WITH THE INNOVATION OF SHERRY LANSING, THE
4	GOVERNANCE COMMITTEE, I KNOW WE WON'T BE FACED WITH
5	THIS SAME CHALLENGE IN THE FUTURE. SO THIS IS GOING
6	TO BE THE BEGINNING OF THE NEW ERA.
7	AS ITEM 17, I'D LIKE BOARD COUNSEL, JAMES
8	HARRISON, THE PRESIDENT, DR. ALAN TROUNSON, ASKED TO
9	TAKE THE LEAD TO LEAD IN DEVELOPING THIS PROCESS TO
10	LEAD US THROUGH THIS ITEM. AND THEN I'D LIKE TO ASK
11	FOR DR. TROUNSON'S COMMENTS AND THEN GO INTO BOARD
12	DISCUSSION OF THIS ITEM.
13	AND THIS IS DR. TROUNSON INITIATED THIS
14	AT THE SPECIFIC REQUEST OF SEVERAL BOARD MEMBERS WHO
15	IN THE LAST MEETING ASKED THAT WE CREATE A PROCESS
16	SO WE COULD CREATE SOME PREDICTABILITY FOR THE BOARD
17	AND ENOUGH THOUGHTFUL EVALUATION TO HAVE A
18	MEANINGFUL RESPONSE WHEN THERE WAS AN EXTRAORDINARY
19	PETITION. EXTRAORDINARY MEANING NOT IN THE ORDINARY
20	COURSE, ONLY IF THERE IS A VERY HIGH PREPONDERANCE
21	OF PROOF CARRIED BY THE APPLICANT. MR. HARRISON.
22	MR. HARRISON: AS THE CHAIR SAID, THIS IS
23	ITEM 17, AND THE DRAFT POLICY SHOULD BE IN YOUR
24	BINDER UNDER TAB 17. AS YOU WILL RECALL AT THE LAST
25	MEETING, THE BOARD RECEIVED WRITTEN COMMUNICATION

1	FROM ONE APPLICANT IN ADDITION TO PUBLIC COMMENT BY
2	ANOTHER APPLICANT RELATING TO THE APPLICATIONS THAT
3	WERE THEN UNDER CONSIDERATION. AND WE DID HAVE SOME
4	DISCUSSION OF THE AD HOC NATURE OF THOSE
5	COMMUNICATIONS AT THE TIME OF THE LAST MEETING AND
6	THE NEED TO TRY TO ESTABLISH SOME GUIDELINES AROUND
7	COMMUNICATIONS WITH THE BOARD REGARDING APPLICATIONS
8	CONSISTENT WITH THE BAGLEY-KEENE OPEN MEETING ACT.
9	SO WITH DR. TROUNSON AND THE CIRM
10	EXECUTIVE COMMITTEE, WE HAVE TRIED TO DEVELOP A
11	POLICY THAT STRIKES A BALANCE BETWEEN THE RIGHT OF
12	APPLICANTS TO COMMUNICATE WITH THE BOARD AND THE
13	NECESSITY FOR THOROUGH, FAIR, AND THOUGHTFUL
14	CONSIDERATION OF APPLICATIONS.
15	AS YOU ALL KNOW, APPLICANTS DO HAVE THE
16	RIGHT TO COMMUNICATE WITH YOU AS MEMBERS OF THE
17	BOARD IN WRITING OR BY MAKING PUBLIC COMMENT HERE AT
18	THE MEETING UNDER THE BAGLEY-KEENE OPEN MEETING ACT.
19	BUT WE WANT TO ENSURE THAT WE HAVE A PROCESS THAT
20	PROVIDES FOR ORDERLY CONSIDERATION OF THESE
21	COMMUNICATIONS AND THAT ENSURES FAIRNESS TO ALL
22	APPLI CANTS.
23	SO WITH THAT, LET ME WALK YOU THROUGH THE
24	GUIDELINES THEMSELVES THAT WE'VE PROPOSED. FIRST,
25	WE WOULD ASK APPLICANTS OR ENCOURAGE APPLICANTS TO

1	SUBMIT A PETITION TO THE ICOC ONLY UNDER
2	EXTRAORDINARY CIRCUMSTANCES, AS THE CHAIR SAID, FOR
3	EXAMPLE, WHERE A DEMONSTRABLE ERROR OF FACT AFFECTED
4	THE OUTCOME OF THE REVIEW.
5	NEXT WE WOULD REQUIRE THAT PETITIONS BE
6	SUBMITTED IN WRITING TO THE BOARD AT LEAST FIVE DAYS
7	BEFORE THE BOARD MEETING AT WHICH THE APPLICATION
8	WILL BE CONSIDERED. THE PURPOSE OF THIS IS TO
9	PROVIDE TIME FOR STAFF TO DISTRIBUTE THE PETITION TO
10	THE MEMBERS OF THE BOARD AND ALSO FOR THE SCIENTIFIC
11	STAFF TO CONSIDER AND ANALYZE THE SUBSTANCE OF THE
12	COMMUNICATION. FOR THAT REASON AND, AGAIN TO ENSURE
13	AN ORDERLY AND FAIR PROCESS, WE WOULD NOT CONSIDER
14	PETITIONS SUBMITTED AFTER THAT DATE.
15	THE PETITIONS WOULD BE REQUIRED TO
16	SUCCINCTLY SET FORTH THE BASIS FOR THE REQUEST FOR
17	SPECIAL CONSIDERATION BECAUSE, OF COURSE, THE BOARD
18	DOES CONSIDER ALL APPLICATIONS AND MAKES A FINAL
19	DECISION ON THEM. AND WE WOULD REQUIRE THAT THE
20	APPLICANTS DO THAT IN FIVE PAGES OR LESS.
21	THE STAFF WOULD THEN DISTRIBUTE THE
22	PETITIONS TO EACH OF YOU AND POST THEM ON CIRM'S
23	WEBSITE WITH THE UNDERSTANDING THAT IT MAY BE
24	NECESSARY UNDER CERTAIN CIRCUMSTANCES TO REDACT
25	INFORMATION THAT IS EITHER PROPRIETARY IN NATURE OR

1	TO PROTECT REVIEWERS UNDER CERTAIN CIRCUMSTANCES.
2	STAFF WOULD THEN REVIEW THE PETITIONS AND
3	WOULD, IF THE BOARD REQUESTS, MAKE A RECOMMENDATION
4	REGARDING THE PETITION DURING THE BOARD'S
5	CONSIDERATION OF THE APPLICATION. IN OTHER WORDS,
6	THE BOARD WOULD NOT ROUTINELY HAVE A DISCUSSION OF
7	THESE PETITIONS. IF, HOWEVER, A MEMBER OF THE ICOC
8	BELIEVES THAT THE LETTER OR PETITION RAISES A POINT
9	THAT MERITS CONSIDERATION AND DISCUSSION, THE MEMBER
10	COULD THEN REQUEST BOARD CONSIDERATION OF THE
11	PETITION, AND STAFF WOULD THEN MAKE A RECOMMENDATION
12	REGARDING ITS VIEW OF THE MERITS OF THE PETITION.
13	THE BOARD, OF COURSE, WOULD RETAIN FULL
14	DISCRETION TO CONSIDER OR NOT CONSIDER APPLICATIONS
15	BEFORE MAKING ITS FINAL FUNDING DECISIONS.
16	THAT'S A SUMMARY OF THE GUIDELINES THAT WE
17	WOULD PROPOSE TO THE BOARD.
18	CHAIRMAN KLEIN: AND TO BE CLEAR HERE,
19	UNDER BAGLEY-KEENE SOMEONE HAS THE ABILITY TO APPEAR
20	BEFORE THIS BOARD AND MAKE A THREE-MINUTE
21	PRESENTATION. THAT'S A MATTER OF LAW. HOWEVER,
22	IT'S IMPORTANT FOR THE BOARD TO HAVE A PROCESS
23	WHEREBY WE CAN MEANINGFULLY DECIDE WHETHER THERE'S
24	SUBSTANCE TO IT. SO BY CREATING A PROCESS,
25	HOPEFULLY WE'LL COMMUNICATE THIS IS NOT A FORUM JUST
	224

1	TO BRING CASUAL ARGUMENTS TO US TO TRY AND
2	CONTRADICT A VERY SERIOUS PEER REVIEW.
3	IF WE'RE GOING TO LOOK TO SUBSTANCE OF
4	THESE ARGUMENTS, WE'RE CREATING A PROCESS WHERE
5	SOMEONE COULD SUBMIT SOMETHING, AND BY THE WAY,
6	THREE PAGES IS AN ALTERNATIVE THAT I THINK IS BEING
7	DISCUSSED ALONG WITH FIVE BECAUSE WE HAVE
8	ADMINISTRATIVE CONSTRAINTS ON HOW MUCH TIME WE HAVE
9	AND STAFF WE HAVE TO REVIEW THESE. BUT IT'S
10	IMPORTANT TO NOTE THAT THERE WOULD BE UNDER THIS
11	PROCESS A VERY HIGH BURDEN OF PROOF ON THE
12	APPLICANTS. AND IT'S GOING TO BE UP TO THE BOARD'S
13	BEHAVIOR TO DEMONSTRATE THAT WE'RE SERIOUS ABOUT THE
14	REAL DRIVING SUBSTANCE AND BURDEN OF PROOF BEING
15	MET, OR WE'RE GOING TO OVERWHELM THE STAFF AND THE
16	BOARD WITH PETITIONS.
17	DR. PIZZO: WELL, ON THIS NOTE, WHICH IS
18	THE OBVIOUS POINT TO DISCUSS, I THINK, FIRST, I
19	UNDERSTAND THE REASON FOR PROCESS AND AGREE THAT
20	THERE NEEDS TO BE AN ORGANIZED APPROACH TO THIS. MY
21	IMMEDIATE CONCERN IS THE DEFINITION OF FACT AND
22	FACTUAL DISAGREEMENT BECAUSE I COULD ENVISION
23	SOMEONE LOOKING AT A DISAGREEMENT OVER WHAT MAY BE
24	TO THEM AN IMPORTANT FACT, BUT IN REALITY A TRIVIAL
25	ONE SO THAT THE NUMBERS OF FACT-BASED REVIEWS
	225
	==-

1	WITHOUT SOME DEFINITION OF WHAT THAT REALLY MEANS
2	COULD OPEN UP ANYONE WHO'S NOT APPROVED TO APPLY.
3	SO THAT'S NO. 1.
4	NO. 2 IS I WONDER WHETHER IT IS
5	APPROPRIATE, AND THIS IS A QUESTION TO YOU, JAMES,
6	TO HAVE THESE EXPRESSED CONCERNS COME TO THE ICOC
7	DIRECTLY OR WHETHER THEY SHOULD ACTUALLY GO TO CIRM
8	AND CIRM STAFF FOR REVIEW SINCE WE'RE ASKING THEM TO
9	DO A FACT-BASED ASSESSMENT. AND THEN IF THERE'S A
10	FACT-BASED ISSUE THAT REQUIRES THE ICOC TO BE
11	INVOLVED, THAT THAT WOULD TAKE PLACE. I'M GRAPPLING
12	WITH THE BALANCE OF THE RIGHT OF SOMEONE WHO FEELS
13	THAT THEIR HIS OR HER APPLICATION WAS NOT
14	ADEQUATELY REVIEWED TO GO TO, AND GIVEN THE
15	BAGLEY-KEENE ACT, TO GO TO THE I COC.
16	CHAIRMAN KLEIN: DR. PIZZO, MAYBE DR.
17	TROUNSON COULD ADDRESS THIS BECAUSE THIS POLICY
18	ASSUMES THAT AS THE APPLICATIONS COME IN, THEY, IN
19	FACT, THEN GO TO STAFF AND STAFF ACTS AS A SCREEN.
20	DR. PIZZO: I UNDERSTOOD THAT, BUT I'M
21	TRYING TO THINK OF HOW WE SIGNAL THIS TO THOSE WHO
22	ARE OFFERING THEIR CONCERN. SO RATHER THAN THE
23	LETTER BEING ADDRESSED TO THE ICOC, IS IT
24	APPROPRIATE FOR THE LETTER TO BE ADDRESSED TO CIRM
25	AND FOR CIRM TO INFORM THE ICOC THAT THESE LETTERS
	224

1	HAVE COME IN? THIS IS THE FACT-BASED REVIEW. AND
2	THEN FOR THE ICOC TO MAKE A JUDGMENT ABOUT WHETHER
3	OR NOT IT NEEDS TO DISCUSS THEM. I'M TRYING I'M
4	THINKING OF THE SIGNALING THAT GOES ON AND THE WAY
5	WE CREATE THE RIGHT BALANCE.
6	CHAIRMAN KLEIN: IN THE ADDRESSING THIS
7	PETITION, WHAT THEY TRIED TO CAPTURE IS BY
8	ADDRESSING IT NOT TO INDIVIDUAL MEMBERS, BUT TO THE
9	CHAIRMAN AND THE PRESIDENT, IT'S INTENDED TO FUNNEL,
10	WHETHER THEY WANT TO WRITE TO THE STAFF OR THE
11	BOARD, THERE'S ONE FUNNEL, AND ALL OF THOSE GO, ONCE
12	RECEIVED, IMMEDIATELY THEN TO THE PRESIDENT TO DEAL
13	WITH.
14	DR. PIZZO: WHY NOT HAVE IT GO TO THE
15	PRESIDENT TO START WITH?
16	CHAIRMAN KLEIN: IT DOES.
17	DR. TROUNSON: I THINK MOST OF THEM DO.
18	WHAT WE'RE A LITTLE WHAT WE, I THINK, ALL A
19	LITTLE CONCERNED WITH IS YOU'RE GOING TO BE DELUGED,
20	THE ICOC MEMBERS; AND WHILE THERE'S A RIGHT FOR THE
21	PUBLIC TO COMMUNICATE WITH THE ICOC MEMBERS, WE
22	WANTED THE ICOC MEMBERS TO LET US HAVE FIVE DAYS TO
23	HAVE A LOOK AT WHAT THE ISSUES WERE.
24	GENERALLY THE ISSUES OF DISAGREEMENT HAVE
25	BEEN DISCUSSED. AND SO, YOU KNOW, WE HAVE THAT IN
	007

1	OUR NOTES, PLUS MEMORY. AND IF IT'S BEEN DISCUSSED,
2	IT'S JUST A MATTER OF DISAGREEMENT AMONGST
3	SCIENTISTS. THAT'S THE PROCESS THAT'S USED IN
4	SCIENCE ALL THE TIME, AND WE SHOULDN'T EXPECT THEM
5	TO BE DIFFERENT.
6	WHERE THERE ARE OTHER MATTERS, WE LOOK
7	INTO IT IN A WAY WHICH SOMETIMES CAN REASSURE THE
8	APPLICANT CONCERNED THAT THERE'S BEEN NO BLAS
9	BECAUSE THERE WASN'T ANY ALTERATION TO THE MARKING
10	ANYWAY IN OR OUT OF THAT PARTICULAR PERSON. WHAT WE
11	DON'T WANT TO DO IS HAVE A RAFT OF COMPLAINTS THAT
12	MIGHT TOPPLE CONTINUOUSLY INTO THE PRESS, WHICH
13	WOULD BE VERY DAMAGING, I THINK, FOR THE REVIEWERS,
14	MIGHT BE DAMAGING FOR PARTICULAR REVIEWERS, MIGHT BE
15	DAMAGING FOR THE APPLICANT WHO'S WRITING BECAUSE IT
16	COULD BECOME AN ARGUMENT AS WELL, PLUS THE
17	INSTITUTE, PLUS US.
18	SO WHAT I'M TRYING TO DO IS GET A TIME FOR
19	US ENOUGH TIME FOR US TO HAVE A CONSIDERED VIEW
20	OF IT, AND THEN COME BACK TO YOU AND SAY THERE'S
21	EITHER NO MERIT OR IF YOU WISH MORE DETAILS, WE CAN
22	GO INTO WHAT THE REASON IS THAT THERE'S NO MERIT IN
23	THE COMPLAINTS.
24	WE GENERALLY GET A LOT OF THEM. AND GIL
25	SAMBRANO AND OTHER STAFF DEAL WITH THIS
	220

1	CONTINUOUSLY. THERE IS A SCIENTISTS, LIKE OTHER
2	PEOPLE, KIND OF BELIEVE THEY LIVE IN CALIFORNIA
3	SHOULD GET A GRANT. CIRM WAS SET UP TO GIVE THEM
4	GRANTS. BUT IT'S CERTAINLY SET UP TO PUSH THE FIELD
5	IN THIS AREA, BUT NOT NECESSARILY TO GIVE THEM
6	SPECIFICALLY GRANTS NO MATTER WHAT THEIR REPUTATIONS
7	ARE.
8	SO IT'S MORE ON THE BASIS OF WHATEVER
9	THEY'VE SUBMITTED IN RESPONSE TO AN RFA. IF WE
10	THINK IT'S BEEN FAIRLY DEALT WITH GIVEN EVEN THEIR
11	ISSUES, PLUS MAKING SURE THAT THERE HAS BEEN NO REAL
12	CASE OF BLAS, THEN I THINK WE COULD MAKE THAT
13	CONCLUSION. AND IF YOU WANT TO INTERROGATE, THAT'S
14	FINE WITH US. WE'VE HAD A CHANCE TO DO THAT.
15	I THINK THERE ARE VERY OCCASIONALLY SOME
16	OBVIOUS THINGS THAT WERE NOT OBVIOUS, BUT BROUGHT TO
17	OUR ATTENTION THAT WE MIGHT WANT TO DEAL WITH EITHER
18	IN-HOUSE AND TRY AND GET A RESOLUTION THAT WE THEN
19	ADVISE YOU ABOUT; OR IF IT'S A LETTER THAT'S COME TO
20	AN ICOC MEMBER, TO REASSURE THEM THAT IF THERE IS
21	SOME FACT HERE THAT NEEDS TO BE FURTHER EXPLORED OR
22	TEASED OUT OR AGREED TO AS A RE-REVIEW, THAT WE DO
23	THAT.
24	DR. PIZZO: MAY I FOLLOW? I THINK ALL OF
25	THOSE THINGS MAKE SENSE, BUT I STILL WANT TO PRESS
	200

1	MY POINT JUST A BIT, WHICH IS IT STILL SEEMS TO ME,
2	UNLESS IT'S IN VIOLATION OF
3	CHAIRMAN KLEIN: THAT'S THE PROBLEM.
4	DR. PIZZO: LET ME MAKE THE POINT, AND
5	THEN YOU CAN TELL ME WHERE THE VIOLATION IS. THAT
6	IT WOULD BE WHAT I WOULD PREFER IS FOR THESE TO
7	COME TO CIRM AND FOR CIRM TO DO THE EVALUATION AND
8	TO NOTIFY THE ICOC WHEN THERE IS AN EXCEPTIONAL CASE
9	THAT NEEDS TO BE REVIEWED.
10	CHAIRMAN KLEIN: THE KEY HERE IS THAT THEY
11	HAVE A LEGAL RIGHT TO WRITE TO THE CHAIRMAN, AND WE
12	WANT TO PUT THEM ON NOTICE THAT WHETHER THEY WRITE
13	TO THE CHAIRMAN OR THE PRESIDENT, THEY'RE ALL GOING
14	TO GO TO THE PRESIDENT AND THE STAFF.
15	DR. PIZZO: MAYBE THAT'S THE NUANCE THAT
16	WILL WORK.
17	CHAIRMAN KLEIN: SO THE KEY HERE IS THEY
18	NEED TO UNDERSTAND THAT BY WRITING TO THE CHAIRMAN,
19	WHICH IS THEIR LEGAL RIGHT, IT DOESN'T DO AN END
20	AROUND ON THE PRESIDENT.
21	DR. STEWARD: SO I THINK MAYBE THE
22	CLARIFICATION IS THAT THIS DOESN'T CHANGE THE RIGHT
23	OF ANYONE TO WRITE TO THIS BOARD AT ANY TIME. IT,
24	RATHER, SORT OF SETS THE STAGE OF WHAT WE WOULD BE
25	WILLING TO CONSIDER IN A FORMAL WAY AT THE MEETING.
	230

1	IS THAT REALLY THE WAY TO SAY THIS?
2	CHAIRMAN KLEIN: THEY STILL WILL HAVE THE
3	ABILITY TO MAKE A THREE-MINUTE PRESENTATION.
4	DR. STEWARD: OR TO WRITE.
5	CHAIRMAN KLEIN: BUT THE POINT IS FOR
6	SUBSTANTIVE CONSIDERATION BY THIS BOARD, THE BOARD'S
7	SAYING WE NEED TO HAVE A PROCESS HERE. TAMAR, WOULD
8	YOU LIKE TO COMMENT ON THIS, PLEASE?
9	MS. PACHTER: I JUST WANT TO TRY TO
10	CLARIFY FOR THE BOARD SOME OF THE DIFFERENT ISSUES
11	THAT WE DEAL WITH IN TERMS OF THE APPLICATION. WHAT
12	WE'RE DEALING WITH NOW IS HOW APPLICANTS COMMUNICATE
13	WITH THE BOARD PRIOR TO APPROVAL OR DISAPPROVAL, BUT
14	PRIOR TO YOUR FUNDING DETERMINATIONS. THERE'S A
15	SEPARATE PROCESS THAT EXITS IN THE GAP FOR APPEALS
16	WHICH MAY OCCUR AFTER THE FACT OF GRANTS WORKING
17	GROUP DETERMINATIONS. THOSE ARE STRICTLY LIMITED TO
18	CONFLICTS OF INTEREST.
19	SO WHAT WE'RE TALKING ABOUT HERE IN THIS
20	PARTICULAR AGENDA ITEM IS LIMITED TO TRYING TO
21	CREATE AN ORDERLY PROCESS FOR TAKING PUBLIC COMMENT
22	FROM APPLICANTS WHO COME TO MAKE A PLEA TO THE ICOC,
23	WHICH THEY'RE ENTITLED TO DO BECAUSE YOU'RE A PUBLIC
24	BODY, TO APPROVE THEIR GRANT IN ADDITION TO WHAT
25	WENT INTO THEIR APPLICATION, IN ADDITION TO WHAT
	221

YOU'VE READ IN THE SUMMARIES OF THE REVIEW OF THE
GRANTS WORKING GROUP.
SO THAT'S WHAT THIS IS ABOUT. IT'S NOT AN
ATTEMPT TO LIMIT THAT. IT IS AN ATTEMPT TO PUT IT
IN SOME ORDERLY PROCESS SO THAT YOU GET SOME READ ON
IT FROM STAFF IN ADVANCE OF THE MEETING. THEN YOU
MAKE YOUR OWN DETERMINATION.
DR. STEWARD: COULD I JUST FOLLOW UP? I
WANT ACTUALLY TO BUILD A LITTLE BIT ON DR. PIZZO'S
COMMENT OF THE CONCERN ABOUT FACT. AS A BOARD,
WE'RE RATHER POORLY SITUATED TO MAKE JUDGMENTS ABOUT
SCIENTIFIC FACT. THAT'S WHAT THE GRANTS REVIEW
COMMITTEE IS REALLY ALL ABOUT. AND SO IT CONCERNS
ME A BIT THAT WE WOULD BE GETTING THESE APPEALS WITH
SOMETHING ON THE ORDER OF FIVE DAYS FOR STAFF TO DO
ANYTHING WITH THEM IN A MEANINGFUL WAY. AND
MEANINGFUL MEANS, I THINK, THAT YOU WOULD REALLY
ALMOST HAVE TO GO BACK TO THE ORIGINAL REVIEWERS AND
DISCUSS THESE ISSUES WITH THEM BECAUSE THEY'RE
ISSUES OF SCIENTIFIC FACT MAINLY.
SO AS AN ALTERNATIVE POSSIBILITY, THE WAY
THAT WE MIGHT BE ABLE TO GET AROUND THIS IS TO HAVE
THIS AVAILABLE AS A REQUEST FOR DEFERRAL OF
CONSIDERATION. BY THAT I MEAN EVERYTHING ELSE IS IN
PLACE EXACTLY AS IT IS, BUT WHAT THE APPLICANT WOULD
232

1	DO IS REQUEST THAT THEIR APPLICATION NOT BE
2	CONSIDERED ALONG WITH THE REST OF THE APPLICATIONS
3	AND BE CARRIED OVER TO THE SUBSEQUENT ICOC MEETING
4	DURING WHICH TIME CIRM STAFF WOULD HAVE THE
5	OPPORTUNITY TO GO BACK TO THE GRANTS REVIEW GROUP
6	AND REVIEW THESE ISSUES OF FACT.
7	CHAIRMAN KLEIN: STEWARD, WHAT ABOUT THE
8	SCIENTIFIC STAFF? IN TERMS OF ECONOMY OF TIME,
9	THEY'VE DONE VERY THOROUGH REVIEWS OF THESE AT THE
10	TIME AND THEY'VE DONE WRITE-UPS OF THE REVIEWS, SO
11	THEY HAVE A LOT OF THIS. MANY OF THESE THEY CAN
12	HANDLE IMMEDIATELY.
13	WHAT WE MIGHT WANT TO DO, BASED ON YOUR
14	SUGGESTION, AND I'D LIKE TO ASK DR. TROUNSON, IS TO
15	GIVE THE STAFF THE OPTION, IF THEY THINK THEY NEED
16	ADDITIONAL TIME, OF DEFERRING A PARTICULAR ITEM THAT
17	REQUIRES MORE REVIEW.
18	DR. STEWARD: I WOULD DEFER TO STAFF'S
19	JUDGMENT ON THE TIMING ISSUE. I JUST HAVE A HARD
20	TIME BELIEVING THAT YOU COULD REALLY ESTABLISH ANY
21	CONTROVERSY OF FACT IN FIVE DAYS, ESPECIALLY
22	CHAIRMAN KLEIN: IF SOMEONE PRESENTS AN
23	ARTICLE AND THE PEER REVIEW WAS THAT THIS HAS NEVER
24	BEEN SHOWN TO BE EFFECTIVE, AND THE ARTICLE
25	SPECIFICALLY IS PUBLISHED IN A HIGHLY RECOGNIZED

1	JOURNAL, THAT MIGHT BE MATERIAL.
2	DR. STEWARD: I'M JUST ASKING ACTUALLY
3	I'M ASKING CIRM WHAT THEIR OPINION IS ON THIS.
4	DR. TROUNSON: I THINK, DR. STEWARD, MOST
5	OF THE ISSUES THAT ARE BROUGHT UP HAVE ACTUALLY BEEN
6	CANVASSED IN THE REVIEW AMONGST THE SCIENTISTS.
7	WHILE THE APPLICANT MAY HAVE A VIEW, THE REVIEW AS A
8	WHOLE, THE WHOLE GROUP PLUS THE PATIENT ADVOCATES,
9	HAD THE CHANCE OF BEING INVOLVED IN THE DISCUSSION
10	ABOUT WHATEVER THOSE ISSUES ARE. AND THEN A MARK IS
11	GENERATED BY 15 OF THEM.
12	I THINK IF IT'S BEEN DISCUSSED, AND
13	GENERALLY THOSE ISSUES ARE, YOU KNOW, I THINK WE
14	SHOULD ACCEPT THE REFEREE'S POINT OF VIEW, AND
15	THAT'S WHAT WE'D SAY. IT'S BEEN DISCUSSED. IT'S A
16	DIFFERENCE OF OPINION. AND THERE ARE PLENTY OF
17	THOSE IN SCIENCE. THERE MIGHT BE SOMETHING YOU
18	COULDN'T HAVE THOUGHT OF. SO UNDER CIRCUMSTANCES
19	WHERE A DEFERMENT FOR ADVICE FROM A SPECIALIST OF
20	SOME KIND OR THE SPECIALISTS THAT MIGHT HAVE BEEN
21	INVOLVED, FOR EXAMPLE, THAT IS NOT BASICALLY IN OUR
22	KNOWLEDGE FRAMEWORK COULD BE HELPFUL, AND THAT WE
23	WOULD APPRECIATE. AND WE WOULD HAVE PROBABLY PUT
24	THAT TO THE ICOC, THAT WE NEEDED MORE TIME TO LOOK
25	AT THIS.

1	SO WHILE I THINK WE CAN REALLY DEAL WITH
2	THE MAJORITY OF THEM, THERE MAY BE ON OCCASION
3	SOMETHING THAT WE HAVEN'T THOUGHT OF, OR IT'S IN A
4	SPECIALTY AREA THAT WE WOULD NEED TO TAKE SOME
5	FURTHER ADVICE TO REASSURE THE ICOC THAT IT'S BEEN A
6	FAIR PROCESS THAT'S BEEN UNDERGONE.
7	CHAIRMAN KLEIN: SO JOAN, AND THEN I'M
8	GOING TO GO TO DUANE AND JEFF.
9	MS. SAMUELSON: MY GUT INSTINCT IS IF WE
10	ESTABLISH ANY SORT OF PROCEDURE, WE'RE GOING TO
11	DROWN IN THE FLOOD OF LETTERS THAT WILL USE THIS
12	PROCEDURE TO GET ONE MORE SHOT BY SIMPLY WRITING A
13	LETTER.
14	HAVING SAID THAT, LET ME MAKE THIS POINT,
15	AND IT MAY SUGGEST AN ALTERNATIVE. THE GRANTS
16	WORKING GROUP, WHICH IS REALLY CALLED THE RESEARCH
17	FUNDING WORKING GROUP, ACTUALLY HAS SIX FUNCTIONS IN
18	PROP 71. ONE OF THEM IS PEER REVIEW, BUT THE OTHERS
19	ARE THE WHOLE SOUP-TO-NUTS PROCESS OF DEVELOPING
20	CRITERIA AND THEN APPLYING THEM TO A PEER REVIEW
21	PROCESS, AND THEN GRANTS MANAGEMENT, AND SO ON. SO
22	THEY'RE A SEAMLESS PART OF THIS PROCESS, AND WE USE
23	THE WISDOM THAT THEY'RE DEVELOPING IN THE SCIENTISTS
24	AND WITH THE PATIENT ADVOCATES IN THE PEER REVIEW
25	PROCESS AND RECOMMENDING AWARDS OF GRANTS TO THEN
	225

1	INFORM THE REST OF THAT SYSTEM.
2	AND THEY'RE THE ONES WHO ARE GOING TO KNOW
3	THE BEST, I THINK, WHETHER A LETTER THAT COMES IN IS
4	REALLY AN EXTRAORDINARY SITUATION, OR IS THE
5	COMPLAINT A STRUCTURAL COMPLAINT ABOUT A PROCESS
6	THAT REALLY COULD BE BETTER, BUT DOESN'T NECESSARILY
7	MEAN THAT THERE SHOULD BE A RE-REVIEW OF THAT
8	PARTICULAR SITUATION.
9	SO IF PEOPLE ARE SENDING IN LETTERS AND
10	IT'S GOING TO GO INTO THAT SYSTEM, NOW, HOW THEY
11	HAVE THE TIME TO DO THAT I'D PUT ASIDE FOR THE
12	MOMENT. I THINK WE HAVE TO CONSIDER THIS BECAUSE
13	THIS IS WHAT THE LAW SAYS. IF PEOPLE KNOW THAT
14	THEIR LETTER IS MAYBE IN VERY EXTREME SITUATIONS
15	GOING TO TRIGGER SOME KIND OF RELIEF, BUT MORE
16	LIKELY IT'S JUST GOING TO INFORM THE PROCESS, AND
17	MAYBE RESULT IN STRUCTURAL IMPROVEMENTS IN THE
18	FUTURE, BUT NOT NECESSARILY CHANGE THE OUTCOME, I
19	THINK IT WILL DRAMATICALLY REDUCE THE NUMBER OF
20	LETTERS THAT COME IN, FIRST OF ALL. SO IT WON'T BE
21	JUST LET'S TAKE A SHOT. WE WERE TURNED DOWN. AND
22	EVERY GRANT APPLICANT IS GOING TO THINK THAT THEIR
23	GRANT DESERVED FUNDING, RIGHT? THEY'RE GOING TO
24	HAVE SOME REASONS, SOME FACTUAL REASON.
25	SO MY HOPE IS THAT IF THERE IS SUCH A
	236

1	PROCESS, IT ENABLES THAT INFORMATION TO COME IN AND
2	INFORM OUR PROCESS, BUT NOT AS LIKELY CREATE THE
3	FLOOD.
4	CHAIRMAN KLEIN: OKAY. AND, JOAN, REALIZE
5	I THINK MR. HARRISON CREATED THIS PROCESS WITH THE
6	STATUTORY ISSUE IN MIND, THAT THIS BOARD, AS
7	INFORMED BY THE SCIENTIFIC STAFF, HAS TO BE THE
8	BOARD OF FINAL DECISION AS VERSUS THE PEER REVIEW
9	COMMITTEE. SO THIS IS A PROCESS THAT REINFORCES OUR
10	STATUTORY POINT, THAT WITH THE ADVICE OF THE
11	SCIENTIFIC STAFF, WE HAVE THIS IS THE BOARD OF
12	FINAL DECISION TO PROTECT THE CONFIDENTIALITY AND
13	ADVISORY ROLE OF THE PEER REVIEW SYSTEM.
14	MS. SAMUELSON: UNDERSTOOD. AND
15	PRESUMABLY THESE PROVISIONS HAVE SOME MEANING IN
16	THAT CONTEXT.
17	CHAIRMAN KLEIN: OKAY. WE HAD DUANE.
18	MR. ROTH: I THINK THIS IS A VERY
19	IMPORTANT POLICY. AND I'M REALLY PLEASED WITH THE
20	WAY IT'S BEEN LAID OUT. WE DON'T HAVE AN OPEN
21	SYSTEM SO THAT PEOPLE CAN REAPPLY FOR A GRANT. SO
22	IF YOU MISS AND YOU MAKE A MISTAKE, THAT'S IT. YOU
23	ARE GOING TO BE PROBABLY A COUPLE OF YEARS UNTIL YOU
24	CAN GET BACK INTO IT. SO I THINK HAVING A WAY TO
25	ADDRESS A MATERIAL DEFECT IN THE REVIEW IS PROBABLY
	007

1	VERY IMPORTANT.
2	A COUPLE OF SUGGESTIONS, AND YOU ALLUDED
3	TO THIS. IT WOULD BE I THINK FIVE PAGES IS AN
4	AWFUL LOT FOR MATERIALITY, AND IT COULD BE LIMITED
5	TO, I THINK, ONE TO TWO PAGES.
6	SECOND, I THINK IT WOULD BE VERY USEFUL
7	FOR US, WHEN WE'RE REVIEWING THESE GRANTS, LIKE THAT
8	GRAY AREA TODAY, TO HAVE A COPY OF WHAT WAS SENT BY
9	THE APPLICANT, BUT, BUT COMPLETELY BLIND. SO WE
10	KEEP THE BLIND INTEGRITY. I DON'T WANT TO KNOW WHO
11	THE APPLICANT IS OR WHAT INSTITUTION, BUT I'D LIKE
12	TO SEE WHAT THEY WROTE SO I CAN COMPARE THAT
13	DIRECTLY. SO THAT WOULD BE A FURTHER REQUEST THAT,
14	IN ADDITION TO STAFF GIVING US THEIR OPINION ABOUT
15	THAT, LET US LOOK, AND THAT TELLS THE APPLICANTS WE
16	ALL HAD A CHANCE TO READ WHAT YOU SAID VERBATIM.
17	DR. TROUNSON: YOU COULD DUANE, WE'RE
18	PROPOSING THAT YOU COULD ASK FOR THAT, AND WE WOULD
19	CERTAINLY GIVE IT TO YOU. WE WOULD SORT OF SAY THAT
20	IN OUR VIEW THAT THESE HAVE NO MERIT; BUT IF YOU
21	WISH TO LOOK AT THAT, THAT WOULD CERTAINLY BE
22	AVAILABLE. THAT IS WHAT WE PROPOSED, JAMES.
23	MR. ROTH: SO THAT WOULD BE MY REQUEST,
24	THAT IT BE INCLUDED RIGHT IN THE BOOK. WE CAN READ
25	IT IF WE WANT TO OR NOT, BUT NOT, YOU KNOW, IT'S THE

1	SALK INSTITUTE. AND THAT'S KIND OF WHERE THIS ALL
2	GOT STARTED, BUT JUST WHAT DID THE APPLICANT SAY IN
3	DEFENSE OF IT, AND WE CAN READ THEM BOTH SIDE BY
4	SIDE, AND HEAR FROM STAFF.
5	CHAIRMAN KLEIN: JEFF AND THEN DR. CSETE.
6	MR. SHEEHY: I THINK THERE'S A COUPLE OF
7	POINTS. FIRST, I REALLY WANT TO SUPPORT THE RIGOR
8	OF THE PEER REVIEW SYSTEM AND ACKNOWLEDGE THAT, LIKE
9	ANY SYSTEM, IT'S GOING TO BE IMPERFECT. AND SO I
10	WANT US TO BE VERY CAREFUL ABOUT SUGGESTING THAT
11	WE'RE GOING TO RE-REVIEW THE GRANTS AT THE BOARD,
12	WE'RE GOING TO DEFER THE GRANTS FOR RE-REVIEW. I
13	THINK THAT WILL DESTROY OUR PEER REVIEW SYSTEM.
14	AND ACTUALLY I WOULD I DO THINK, AND
15	JAMES AND TAMAR MAY HAVE AN OPINION ON THIS, BUT I
16	THINK DUANE IS CORRECT, THAT WE SHOULD GET THE
17	ACTUAL APPLICANT LETTER IF THEY WANT TO SEND IT TO
18	US. THAT'S THEIR RIGHT. WE SHOULD HAVE THE OPINION
19	FROM STAFF ABOUT THE MERITS, BUT THAT SHOULD COME TO
20	US.
21	HOWEVER, I DISAGREE ABOUT THE BLINDING
22	BECAUSE I THINK THAT ONCE SOMEONE COMES TO THE ICOC,
23	YOUR SCORE, YOUR NAME, YOUR INSTITUTION, PERSONALLY
24	I WOULD RELEASE WHATEVER STAFF FEELS APPROPRIATE
25	ABOUT THE FULL CRITIQUE SO THAT PEOPLE DON'T ABUSE
	ABOUT THE FOLE SKITTED SO THAT FED EE BOX F ABOUT

1	THE SYSTEM BECAUSE IT CAN JUST BE GAMED. WHY
2	WOULDN'T YOU SEND IN AN APPEAL? THE ODDS YOU
3	KNOW, WHY WOULDN'T YOU? AND SO I WOULD SAY, YOU
4	KNOW, SOMEBODY WROTE SOMETHING FAIRLY SCATHING ABOUT
5	YOU IN A CRITIQUE THAT HASN'T REALLY SEEN THE LIGHT
6	OF DAY. YOU GOT A TWENTY. YOU MAY NOT WANT YOUR
7	COLLEAGUES TO KNOW YOU GOT A 20. THAT'S THE COST OF
8	DOING AN APPEAL.
9	SO THERE SHOULD BE AND AGAIN, I'VE SEEN
10	THE SCIENTISTS IN THE PEER REVIEW. THEY ARE
11	INCREDIBLY DILIGENT, AND WE SHOULD PUT OURSELVES IN
12	THE POSITION OF RE-REVIEW. WE ARE THE FINAL
13	DECISION MAKERS, AND WE SHOULD HAVE ALL THE
14	INFORMATION THAT AN APPLICANT FEELS LIKE THEY HAVE
15	THE RIGHT TO PUT IN FRONT OF US. BUT THEY SHOULD
16	KNOW THAT IF THEY'RE GOING TO CONTEST WHAT IS A
17	WELL-REGARDED SYSTEM WITHIN THE WHOLE FIELD OF
18	SCIENTIFIC ENDEAVOR FOR EVALUATING SCIENCE, THAT
19	IT'S NOT A FREEBIE. YOU DON'T JUST THROW A LETTER
20	IN AND CROSS YOUR FINGERS.
21	SO I DO THINK THAT THE REVELATION OF THE
22	SCORE, THE NAME, WHATEVER CRITICAL INFORMATION FROM
23	THE FULL CRITIQUE THAT IS NECESSARY FOR US TO
24	EVALUATE THAT STAFF FEELS APPROPRIATE SHOULD BE
25	INCLUDED SHOULD GO IN THERE.
	0.40

1	BUT THE OTHER POINT I WANT TO MAKE IS THE
2	REAL STANDARD SETTING AND BULWARK FOR THIS WHOLE
3	PROCESS WILL BE EACH INDIVIDUAL MEMBER OF THIS
4	BOARD. IF WE FRIVOLOUSLY PULL APPLICATIONS UP
5	BECAUSE WE'LL SIT THERE THIS WILL BE IN OUR
6	BINDER. IT CAN SIT IN OUR BINDER AND HAVE NO IMPACT
7	AT ALL AND SHOULD HAVE NO IMPACT UNLESS AN
8	INDIVIDUAL MEMBER FEELS SO MOVED BY WHAT THEY HAVE
9	READ TO INTRODUCE THIS INFORMATION INTO THE PUBLIC
10	RECORD AND TO HAVE THIS DISCUSSION. BUT I WOULD
11	CAUTION US TO BE VERY, VERY CAREFUL ABOUT HOW WE DO
12	THAT BECAUSE THAT WILL ULTIMATELY UNDERMINE THE
13	INTEGRITY OF OUR PEER REVIEW PROCESS, AND WE SHOULD
14	SET OURSELVES PERSONALLY A VERY HIGH STANDARD BEFORE
15	WE START PICKING THESE UP.
16	CHAIRMAN KLEIN: JEFF, RECOGNIZING THAT
17	AND I'M GOING TO CALL ON DR. CSETE. BUT RECOGNIZING
18	THAT WE HAVE TO PROTECT PROPRIETARY INFORMATION,
19	JEFF, RECOGNIZING WE HAVE TO PROTECT PROPRIETARY
20	INFORMATION, TO THE EXTENT THERE'S A MATERIAL
21	MISTAKE AS TO PROPRIETARY INFORMATION, POTENTIALLY
22	THAT PROPRIETARY INFORMATION HAS ALWAYS BEEN TREATED
23	IN EXECUTIVE SESSION SO IT CAN BE PROTECTED. THE
24	PENALTY, IF YOU'RE TRYING TO CORRECT A MATERIAL
25	ERROR OF FACT, SHOULD NOT BE THAT YOUR PROPRIETARY

1	INFORMATION BECOMES PUBLIC.
2	THE OTHER ISSUE IS TO THE EXTENT THAT THEY
3	ARE CRITICIZING PEER REVIEWERS, WHICH IS SOMETIMES
4	COMMON, WE'RE GOING TO LOSE OUR PEER REVIEWERS TO
5	HAVE ALL OF THAT BE PUBLIC. SO THE ISSUE HERE IS IF
6	THEY'RE GOING TO CRITICIZE A PEER REVIEWER OVER
7	PROPRIETARY INFORMATION, I THINK THAT THAT'S A
8	DIFFERENT TYPE OF AN ISSUE. AND WE NEED TO BE
9	CAREFUL IN OUR CONSIDERATION OF HOW THAT WILL BE
10	TREATED BECAUSE WE DON'T WANT TO LOSE ALL OF OUR
11	PEER REVIEWERS, AND WE DON'T WANT TO VIOLATE
12	PROPRIETARY INFORMATION. PLEASE JUST CONSIDER THOSE
13	IN YOUR THOUGHTS.
14	MR. SHEEHY: I AGREE. I THINK REDACTING
15	APPROPRIATE INFORMATION RELATED TO PEOPLE INVOLVED
16	IN THE PROCESS. WHERE PROPRIETARY INFORMATION IS
17	INVOLVED, I'M A LITTLE BIT I DON'T WANT PEOPLE
18	YOU KNOW, I THINK PEOPLE NEED TO THINK CAREFULLY
19	BEFORE THEY APPEAL. SO THAT MAY BE A RISK THAT THE
20	APPLICANT MAY HAVE TO TAKE. WE HAVE TO TRUST OUR
21	PEER REVIEW SYSTEM. WE ARE NEVER GOING TO HAVE A
22	PERFECT PEER REVIEW SYSTEM. NOBODY DOES. AND, YOU
23	KNOW, SOMEONE WANTS TO HAVE THIS VERY INTENSE
24	PROPRIETARY INFORMATION DISCUSSION, NOBODY REALLY
24 25	PROPRIETARY INFORMATION DISCUSSION, NOBODY REALLY KNOWS IT EVER TOOK PLACE AND THEY'RE ABLE TO DO

1	THAT, I DON'T THINK I STILL THINK WE'RE
2	UNDERMINING OUR PEER REVIEW SESSION, BUT I DO
3	BELIEVE IN REDACTING THAT INFORMATION THAT MIGHT GO
4	TO THIRD PARTIES, INCLUDING REVIEWERS, NOT
5	APPROPRIATE. BUT I THINK THE APPLICANT SHOULD STAND
6	UP AND SAY I DON'T AGREE WITH THIS REVIEW. THEY
7	WANT TO DO IT, THEY SHOULD TAKE SOME HEAT.
8	CHAIRMAN KLEIN: I RECOGNIZE DR. CSETE, IF
9	I COULD PLEASE, AND THEN WE'LL RETURN TO THE BOARD.
10	DR. CSETE: THANK YOU. I JUST WANT TO
11	SPEAK FOR PEOPLE WHO DON'T HAVE A VOICE IN THIS
12	ROOM, AND THAT IS OUR REVIEW PANEL. AND I CAN SPEAK
13	TO THAT BECAUSE I WAS A REVIEW PANEL AS LONG AS
14	YOU'VE HAD I WAS ON THE REVIEW PANEL AS LONG AS
15	YOU'VE HAD REVIEW PANELS.
16	WHEN YOU SIGN ON TO BE A GRANTS WORKING
17	GROUP MEMBER, AND WE GO THROUGH AN ENORMOUS
18	INFORMATION PROCESS WITH THEM SO THEY KNOW WHAT
19	THEY'RE SIGNING ON FOR, IT'S A HUGE AMOUNT OF WORK.
20	AND ONE OF THE POSITIVE THINGS THAT'S WRITTEN INTO
21	THE PROCESS IS THE PROGRAMMATIC REVIEW WITH PATIENT
22	ADVOCATES AFTERWARDS. IT'S A REMINDER JUST AS THIS
23	MORNING WAS A REMINDER OF WHY THEY'RE DOING THIS
24	WORK. AND WE DON'T HAVE, AS PART OF OUR PROCESS, A
25	SYSTEM WHERE THERE'S FACTUAL RE-REVIEW. WE HAVE

1	PROGRAMMATIC REVIEW.
2	AND IF THERE BECOMES A SYSTEMATIC FACTUAL
3	RE-REVIEW, WE WILL COMPLETELY DEGRADE THIS SYSTEM.
4	AND THE DIFFICULTY WE HAVE GETTING HIGH QUALITY
5	REVIEWERS WILL BECOME AN IMPOSSIBILITY.
6	SO I THINK THE OPERANT WORD IN THIS IS
7	EXTRAORDINARY. AND ON AVERAGE I THINK WE GET
8	ABSOLUTELY SPECTACULAR BALANCED REVIEWS. EVERY
9	PROCESS ISN'T PERFECT, AS MENTIONED; BUT IF YOU
10	START DEALING ONE ON ONE WITH LEGITIMATE SCIENTIFIC
11	INTERESTS, YOU WILL COMPLETELY UNDERMINE THE GRANTS
12	WORKING GROUP PROCESS. AND THAT IS AN ENGINE THAT
13	FUELS THIS IN A VERY IMPORTANT WAY.
14	CHAIRMAN KLEIN: OKAY. I'D LIKE TO
15	DR. PRICE AND THEN STU HAD A POINT AND THEN DR.
16	PENHOET HAD A POINT. SO DR. PRICE.
17	DR. PRICE: WELL, I'D LIKE TO JUST RESPOND
18	AND ASK A QUESTION. HOW WOULD YOU OPERATIONALLY
19	DEFINE EXTRAORDINARY? I THINK YOUR POINT IS WELL
20	TAKEN. BUT SHORT OF SAYING WE HAVE NO APPEAL
21	PROCESS, HOW WOULD WE DIFFERENTIATE AN APPEAL OF
22	FACT FROM AN EXTRAORDINARY APPEAL OF FACT?
23	CHAIRMAN KLEIN: WELL, THERE'S TWO THINGS,
24	DR. PRICE. ONE IS YOU CAN HAVE A MISTAKE OF FACT IS
25	IN ISSUE, BUT MAKING IT CLEAR YOU HAVE AN EXTREMELY
	244

1	HIGH BURDEN OF PROOF ON THE APPLICANT BECAUSE IF
2	THEY UNDERSTAND COMING INTO THE SYSTEM THAT THE
3	COMPLETE BURDEN OF PROOF IS ON THEM AND IT'S A VERY
4	HIGH BURDEN OF PROOF, THEY'RE GOING TO UNDERSTAND
5	THAT THEY'RE GOING TO HAVE TO HAVE AN
6	EXTRAORDINARILY PERSUASIVE PIECE OF EVIDENCE TO MAKE
7	AN IMPACT HERE.
8	DR. CSETE, ANY ADDITIONAL?
9	DR. CSETE: YOU ARE LEAVING IT TO OUR
10	JUDGMENT. AND REMEMBER THAT WE'RE IN THE ROOM FOR
11	THE REVIEW PROCESS, ALAN AND I, PAT, THE WHOLE
12	SCIENCE STAFF IS IN THE ROOM. SO THERE ARE
13	OPPORTUNITIES FOR US WHEN WE HEAR THINGS THAT ARE
14	JUST NOT QUITE RIGHT OR AMBIGUOUS OR SEEM TO BE HUGE
15	DIFFERENCES OF OPINION IN THE ROOM FOR US TO
16	INTERVENE IN THAT CONVERSATION. SO I THINK THE
17	NUMBER OF TIMES WHERE WE HAVE, BASED ON THE KINDS OF
18	LETTERS THAT WE RECEIVE, AN EXTRAORDINARY DIFFERENCE
19	IN WHAT WAS IN THE REVIEW AND WHAT ACTUALLY SHOULD
20	HAVE BEEN THE OUTCOME OF THE REVIEW PROCESS IS VERY,
21	VERY SMALL.
22	DR. PRICE: I UNDERSTAND. I THOUGHT YOU
23	WERE ARGUING AGAINST ADOPTING THIS, SAYING IT WOULD
24	UNDERMINE THE WHOLE SYSTEM.
25	DR. CSETE: I AGREE THAT THE PROCESS HAS
	245

245

	BARRISTERS REPORTING SERVICE
1	TO BE MORE ORDERLY, BUT I THINK THAT THE RESPONSE
2	HAS TO BE THAT ONLY EXTRAORDINARY THINGS WILL MERIT
3	A RELOOK AT THE APPLICATION. AND EVERY APPLICANT IS
4	SO IMPASSIONED ABOUT WHAT THEY THINK IS AN IMPORTANT
5	FACT OR AN IMPORTANT MISSTATEMENT IN THE REVIEW,
6	THAT YOU WILL BE QUITE INFLUENCED TO TAKE ALL OF
7	THEM VERY SERIOUSLY. AND I WOULD REALLY ENCOURAGE
8	YOU TO THINK CAREFULLY ABOUT TAKING THEM ALL VERY
9	SERI OUSLY.
10	CHAIRMAN KLEIN: THANK YOU.
11	DR. PRICE: I WAS JUST RESPONDING. I HAVE
12	ONE COMMENT WHICH RELATES TO WHAT JEFF WAS TALKING
13	ABOUT IN A TERMS OF WHETHER THESE WHETHER THE
14	INDIVIDUAL PI MAKING THE APPEAL DOES THIS PUBLICLY
15	AND, THEREFORE, OPENS UP THE ENTIRE PROCESS TO US,
16	TO THE PUBLIC. THESE PEOPLE ARE ALLOWED BY LAW
17	ARE PERMITTED TO COME AND SPEAK TO US IN PUBLIC. SO
18	SHOULD WE PROVIDE A SECOND AVENUE TO DO SO WHERE
19	THEY DON'T HAVE TO SPEAK TO US IN PUBLIC, THEY CAN
20	DO IT SORT OF ON THE SIDE? I THINK NOT. IF THE
21	APPEAL PROCESS IS A PUBLIC PROCESS, THEN I THINK THE
22	APPEAL THEY MAKE TO US IS A PUBLIC PROCESS. AND
23	THAT IS AND THEY HAVE TO DEAL WITH WHETHER OR NOT
24	THEY WANT THE DOWNSIDE CONSEQUENCES OF MAKING ALL
25	THIS INFORMATION PUBLIC. IT'S A NICE DISINCENTIVE,

1	BY THE WAY, WHEN YOU SAY SO MUCH FRIVOLOUS OR
2	NONEXTRAORDINARY APPEALS BEING MADE.
3	CHAIRMAN KLEIN: OKAY.
4	DR. STEWARD: JUST TO BUILD ON THAT, AS I
5	UNDERSTAND IT, NO MATTER WHAT WE SAY HERE, THE
6	PUBLIC IS STILL PERMITTED TO WRITE US LETTERS OF ANY
7	SORT, RIGHT? WE HAVE TO KEEP THAT IN MIND. SO IN A
8	SENSE WE'RE ALMOST TALKING ABOUT APPLES AND ORANGES
9	HERE. WE CAN MAKE A POLICY FOR CIRM'S REVIEW. WE
10	CAN MAKE A POLICY THAT IS ADVISORY TO US ABOUT WHAT
11	WE WILL CONSIDER; BUT AT THE END OF THE DAY, ANYBODY
12	CAN SEND IN ANYTHING THEY WANT, LETTER OR STAND UP
13	HERE AND TALK. SO THAT'S ONE THING.
14	I JUST WANT TO BUILD ON JEFF'S POINT
15	THOUGH. I THINK THAT WHATEVER POLICY WE MAKE REALLY
16	SHOULD SET A VERY HIGH BAR AND MAKE IT A DIFFICULT
17	THING OR AT LEAST A CHALLENGING THING FOR AN
18	INVESTIGATOR TO DO. AND SO I THINK THAT THERE
19	SHOULD BE A SITUATION WHERE IF A PERSON WRITES TO
20	THE ICOC, THAT LETTER IS A PUBLIC DOCUMENT. THE
21	INSTITUTION HAS TO BE NAMED, THE PERSON HAS TO BE
22	NAMED. IT IS OUT OF THE BOUNDS OF CONFIDENTIALITY
23	ONCE THEY DO THAT. IT ALMOST HAS TO BE BECAUSE, IN
24	FACT, IT'S AN OPEN LETTER TO THE BOARD.
25	CHAIRMAN KLEIN: WELL, THE NAME AND THE
	247
	247

1	INSTITUTION IS ONE THING. THE INITIATIVE PROTECTS
2	PROPRIETARY INFORMATION. IT IS INTENDED TO PROTECT
3	IT. IT IS INTENDED TO PRESERVE THAT AS A RIGHT. SO
4	IN TERMS OF JEFF'S COMMENTS ABOUT REDACTING
5	PROPRIETARY INFORMATION, AND CRITICISM OF REVIEWERS
6	RELATED TO THAT PROPRIETARY INFORMATION BECAUSE
7	OTHERWISE WE'RE GOING TO LOSE OUR REVIEWERS.
8	DR. STEWARD: AGAIN, YOU CAN'T STOP PEOPLE
9	FROM WRITING ANYTHING THEY WANT IN AN OPEN LETTER TO
10	THE BOARD.
11	CHAIRMAN KLEIN: THEY CAN DO THAT. IT IS
12	IMPORTANT TO THE PRESERVATION OF THE ABILITY TO GET
13	REVIEWERS THAT WE TRY AND SET A STANDARD.
14	WE HAVE DR. PENHOET AND THEN SHERRY
15	LANSI NG.
16	DR. PENHOET: TWO POINTS. IN MY VIEW, THE
17	OPERATIVE TERM SHOULD BE SHOULD BE FACT AND NOT
18	
	EXTRAORDINARY. I THINK BY INVITING PEOPLE TO FILL
19	EXTRAORDINARY. I THINK BY INVITING PEOPLE TO FILL UP FIVE PAGES, IT'S HARD TO IMAGINE THERE ARE FIVE
19 20	
	UP FIVE PAGES, IT'S HARD TO IMAGINE THERE ARE FIVE
20	UP FIVE PAGES, IT'S HARD TO IMAGINE THERE ARE FIVE PAGES WORTH OF FACT. SO I THINK WE SHOULD DO
20 21	UP FIVE PAGES, IT'S HARD TO IMAGINE THERE ARE FIVE PAGES WORTH OF FACT. SO I THINK WE SHOULD DO EVERYTHING WE CAN TO DISCOURAGE ANY DISCOURSE ABOUT
20 21 22	UP FIVE PAGES, IT'S HARD TO IMAGINE THERE ARE FIVE PAGES WORTH OF FACT. SO I THINK WE SHOULD DO EVERYTHING WE CAN TO DISCOURAGE ANY DISCOURSE ABOUT THE DEBATE ON THE SCIENTIFIC MERITS OF A PROPOSAL.
20212223	UP FIVE PAGES, IT'S HARD TO IMAGINE THERE ARE FIVE PAGES WORTH OF FACT. SO I THINK WE SHOULD DO EVERYTHING WE CAN TO DISCOURAGE ANY DISCOURSE ABOUT THE DEBATE ON THE SCIENTIFIC MERITS OF A PROPOSAL. THAT'S WHAT OUR SCIENTIFIC REVIEW GROUP IS THERE TO

1	IF YOU ALLOW FIVE PAGES AND YOU SORT OF ALLOW A
2	DISCOURSE ON THE REVIEW ITSELF, THEN I THINK WE
3	REALLY DO OPEN OURSELVES UP TO EXACTLY JEFF'S POINT.
4	SO I PERSONALLY THINK WE SHOULD ONLY
5	ACCEPT OR WE SHOULD ONLY PROCESS LETTERS WHICH ARE
6	TRULY BASED ON FACT, DEMONSTRABLE FACT, AND NOT
7	ENCOURAGE THE DEBATE. BUT I THINK, AS OS POINTED
8	OUT, THE LETTERS ARE COMING IN NOW, SO I THINK WE DO
9	NEED SOME ORDERLY PROCESS.
10	I DO HAVE ONE SUGGESTION ABOUT THE WORDING
11	HERE, WHICH IS PERSONALLY I WOULD DROP UNDER NO. 3
12	EVERYTHING THAT FOLLOWS THE ICOC. YOU KNOW, I THINK
13	STAFF SHOULD GIVE US A PERSPECTIVE ON THIS. WHETHER
14	IT'S MERITORIOUS OR NOT IN THE END PROBABLY HAS TO
15	BE DECIDED BY US, SO I THINK THEY CAN SAY WE DON'T
16	THINK IT'S VERY GOOD OR HAVE A FACT BASIS OF WHAT IT
17	IS. AGAIN, I THINK IF WE STICK TO THE FACTS, IT
18	MAKES IT A LOT EASIER FOR YOU TO SAY THIS IS
19	FACTUALLY CORRECT OR IT'S FACTUALLY INCORRECT.
20	DR. TROUNSON: SOME OF THOSE CAN'T BE
21	PROVEN. WHAT SOMEBODY BELIEVES IS A WHOLE LOT OF
22	OTHER PEOPLE DON'T, SO THAT'S WHY THE REVIEW GOES
23	ON. SOME THINGS TENDERED AS FACT ARE, IN FACT,
24	DISAGREEMENTS OF FACT. THAT, YOU KNOW, THAT FACTS
25	ARE NOT ESTABLISHED, YOU KNOW, UNDER THE PREMISE OF

1	ABSOLUTE PROOF.
2	DR. PENHOET: IF THAT WERE THE CASE, I'D
3	LOVE TO HEAR FROM YOU GUYS ABOUT WHAT YOUR HOMEWORK
4	WAS TO DETERMINE THE BALANCE OF THE FACTS.
5	CHAIRMAN KLEIN: DR. PENHOET, BEFORE WE DO
6	THAT, SO THAT WE CONTINUE, SHERRY LANSING HAS A
7	POINT. BUT JAMES HARRISON HAS, I THINK, A LEGAL
8	POINT HE WANTS TO MAKE IN EXPLANATION OF AND IN
9	RESPONSE TO SOME OF THE POINTS ALREADY MADE BY THE
10	BOARD.
11	MR. HARRISON: I'D JUST LIKE TO CLARIFY
12	THREE POINTS. FIRST, THE POLICY AS WRITTEN REQUIRES
13	THAT LETTERS LIKE THIS THAT ARE SUBMITTED TO THE
14	PRESIDENT BE DISTRIBUTED TO THE BOARD.
15	SECONDLY, THE POINT ABOUT REDACTION WAS
16	INTENDED TO GO ONLY TO PROPRIETARY INFORMATION OR,
17	FOR EXAMPLE, ATTACKS ON REVIEWERS WHERE WE MAKE A
18	DETERMINATION THAT THE PUBLIC INTEREST AND
19	DISCLOSURE OF THAT INFORMATION IS OUTWEIGHED BY OUR
20	INTEREST IN REDACTING IT TO PROTECT THE REVIEWERS
21	PERSONALLY.
22	AND FINALLY, THE POLICY WAS NOT INTENDED
23	TO SUGGEST THAT EVERYONE WHO SUBMITS A LETTER TO THE
24	BOARD WILL HAVE THAT LETTER DISCUSSED AT A MEETING
25	LIKE THIS, BUT RATHER TO GIVE YOU DISCRETION TO SEE
	250

1	THE LETTERS. AND IF YOU THINK A LETTER RAISES AN
2	INTEREST THAT YOU'D LIKE TO DISCUSS, TO RAISE A
3	QUESTION ABOUT IT. IT'S NOT MEANT TO SUGGEST THAT
4	WE HAVE A ROUTINE REVIEW IN CONSIDERATION OF EACH
5	LETTER THAT'S SUBMITTED.
6	CHAIRMAN KLEIN: SHERRY HAS THE FLOOR.
7	MS. LANSING: I JUST WANT TO SAY THAT I
8	REALLY BELIEVE STRONGLY I'M ALL FOR THIS. I
9	REALLY BELIEVE STRONGLY THAT WE NEED A POLICY.
10	WHETHER YOU WANT TO USE THE WORD "FACTS," WHETHER
11	YOU WANT TO USE EXTRAORDINARY, HOW ABOUT JUST
12	EXCEPTIONS, DO YOU KNOW. WE HAVE A POLICY FOR
13	POSSIBLE EXCEPTIONS.
14	I GET THESE LETTERS, EVERYONE GETS THESE
15	LETTERS. I THINK REPRESENTING THE PUBLIC WE HAVE A
16	RESPONSIBILITY TO RESPOND. HOW THE SCIENTISTS
17	CHOOSE TO RESPOND, YOU'RE GOING TO ADVISE US. AND
18	IT'S A FINE LINE BECAUSE WE DO NOT WANT TO INTERFERE
19	WITH THE PROCESS THAT IS WORKING.
20	SO MY FEELING IS THAT WE JUST THIS IS
21	JUST A PROCESS FOR US TO RESPOND TO PEOPLE THAT ARE
22	LOOKING FOR EXCEPTIONS.
23	CHAIRMAN KLEIN: SO I THINK DR. PIZZO AND
24	THEN GO BACK TO IF I COULD, STU, GO TO DR.
25	POMEROY WHO HASN'T HAD A CHANCE TO SPEAK TO THIS
	251

1	AFTER DR. PI ZZO.
2	DR. PIZZO: SO I'M BACK TO WHERE I WAS AT
3	THE VERY BEGINNING, WHICH IS HOW WE'RE DEFINING FACT
4	AND THE ISSUE AROUND EXCEPTION. I THINK THAT PART
5	OF WHAT WE'RE DEALING WITH IS TWOFOLD. ONE IS THE
6	EXPECTATIONS OF INVESTIGATORS MAKING PROPOSALS WHO
7	GET A NONFUNDED REVIEW WHO HAVE SOME BASIS FOR
8	WANTING TO CONTEST THAT, FACT-BASED OR OTHERWISE.
9	AND I THINK PART OF WHAT WE NEED OR WHAT WE'RE
10	STRUGGLING WITH IS IS THERE A PROCESS FOR THAT TO
11	HAPPEN?
12	SO INDEPENDENT OF EXCEPTION, I THINK WE
13	MAY WANT TO COMMUNICATE THAT IF YOU HAVE SOME BASIS
14	FOR DISAGREEMENT, IT'S APPROPRIATE TO DIRECT YOUR
15	COMMENTS TO CIRM FOR A FACT-BASED CONTENTION, IF YOU
16	WILL, ABOUT THE PROCESS.
17	COUPLED WITH THAT COULD BE, THEN, IF YOU
18	FEEL THAT, ON THE BASIS OF THAT APPEAL, THAT YOU
19	WANT TO TAKE YOUR CASE TO THE ICOC, SO IT'S LIKE
20	GOING FROM STUDY SECTION TO COUNCIL, YOU KNOW, THAT
21	CAN HAPPEN, BUT IT WILL GO THROUGH A PROCESS THAT
22	IS, IN ESSENCE, CAPTURED IN THIS. SO I'M PUTTING
23	FORWARD A KIND OF TIERED APPROACH. ONE OF THEM IS
24	THE GENERAL INFORMATION IS THAT IF YOU HAVE A
25	FACT-BASED OR CONTENT DISAGREEMENT, YOU HAVE A RIGHT

1	TO BRING THAT TO CIRM.
2	IF YOU WANT TO FLAG THAT, BECAUSE OF THE
3	LACK OF RESPONSIVENESS THAT YOU FEEL STILL OBTAINS
4	FROM CIRM, YOU CAN MAKE YOUR APPEAL TO THE ICOC.
5	AND THAT WILL TAKE PLACE WITH, AGAIN, THE ICOC BEING
6	INFORMED OF THE FACT-BASED REVIEW. SO THAT WOULD
7	CREATE A GREATER ONUS. SO IT SORT OF TAKES ME BACK
8	TO WHERE I WAS AT THE BEGINNING, BUT MAYBE
9	ARTICULATES THIS A LITTLE BIT MORE CRISPLY IN TERMS
10	OF HOW IT MIGHT BE CAPTURED.
11	CHAIRMAN KLEIN: I THINK THAT THAT IS THE
12	INTENTION OF THIS PROCESS. AND SO NARRATIVELY, IT
13	COULD BE DESCRIBED BY THE PRESIDENT IN DESCRIBING
14	THE PROCESS, WHICH IS EVERYONE IS INTENDED TO DEAL
15	WITH SCIENTIFIC STAFF FIRST; AND, IN FACT, IF THE
16	SCIENTIFIC STAFF GIVES THEM A STRONG INDICATION THAT
17	THEY DON'T BELIEVE THERE IS A DIFFERENCE OF MATERIAL
18	FACT, THEN HOPEFULLY THEY WILL UNDERSTAND THAT THIS
19	EXTRAORDINARY PETITION IS NOT LIKELY TO HAVE A
20	YIELD. BECAUSE I THINK THE MOOD OF THIS BOARD, AS
21	EXPRESSED HERE, IS THAT IT WILL TAKE A MAJOR
22	PERSUASIVE SHOWING OF VERY HIGH BURDEN OF PROOF ON
23	THE APPLICANT'S PART BEFORE A BOARD MEMBER IS GOING
24	TO ASK FOR THIS TO BE BROUGHT INTO THE DEBATE.
25	DR. TROUNSON: I THINK, CHAIR, IT IS AS IT

1	IS, PHILIP, THAT THEY DO CONTACT US IN LARGE
2	NUMBERS. AND SO MAYBE WE OUGHT TO SORT OF RECOGNIZE
3	THAT IT STILL EXISTS THE TWO TIERS. IT'S MORE OUR
4	CONCERN THAT YOU ARE GOING TO BE INUNDATED AND BE
5	FORCED TO TRY AND MAKE DECISIONS ON A DAY'S NOTICE
6	YOURSELVES WITHOUT US BEING ABLE TO INFORM YOU.
7	DR. PIZZO: SO I'M SUGGESTING THAT WE, IN
8	ESSENCE, CODIFY THE PROCESS TO HAVE AN ORGANIZED
9	APPROACH SO THAT IF YOU HAVE A DISAGREEMENT ABOUT
10	YOUR GRANT, YOU HAVE A RIGHT TO MAKE AN APPEAL, IF
11	YOU WILL, TO CIRM. AND IF YOU FEEL THAT THE ANSWER
12	IS STILL UNSATISFACTORY, AND YOU WANT TO, FOR
13	EXCEPTIONAL REASONS, BRING THAT TO THE ATTENTION OF
14	THE ICOC, YOU HAVE A RIGHT TO DO THAT, BUT, YOU
15	KNOW, YOU NEED TO KNOW THAT IT'S GOING TO COME WITH
16	A FACT-BASED ASSESSMENT. SO THAT IN A SENSE WE'RE
17	REALLY TRYING TO SET EXPECTATIONS THAT WE'RE BROAD,
18	WE'RE TRANSPARENT, WE'RE BEING FAIR, BUT WE'RE ALSO
19	IN A SENSE HELPING TO DEFINE OR MOVE PEOPLE TOWARD A
20	DEFINITION OF WHAT REALLY IS THE WEIGHT OF
21	EXCEPTI ON.
22	CHAIRMAN KLEIN: SO, DR. PIZZO, NOT TO
23	OVERBURDEN STAFF WITH THE I'M THINKING THAT YOUR
24	USE OF THE WORD "APPEAL TO CIRM STAFF" IS YOU CAN
25	HAVE A DISCUSSION WITH THE STAFF ABOUT YOUR ISSUE AS

2 3 4 5 6 7
4 5 6 7
5 6 7
6
7
0
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
17 18 19 20 21 22 23

1	SCIENTIFIC REVIEW IS LIMITED TO INSTANCES WHERE A
2	DEMONSTRABLE FINANCIAL OR SCIENTIFIC CONFLICT OF
3	INTEREST HAD A NEGATIVE IMPACT ON THE REVIEW PROCESS
4	AND RESULTED IN A FLAWED REVIEW. I THINK THAT'S THE
5	ONLY REASON THAT THERE SHOULD BE AN APPEAL TO CIRM.
6	WE'RE TALKING HERE ABOUT SOMETHING ELSE.
7	WE'RE TALKING ABOUT THESE LETTERS THAT ARE COMING
8	INTO US AS THE ICOC. AND I THINK THAT WHAT YOU'RE
9	TALKING ABOUT REALLY THEN WOULD CAUSE US TO MODIFY
10	THAT FUNDAMENTAL GAP PROCESS.
11	SO I WOULD JUST LIKE TO RAISE THE POINT
12	THAT WE FOCUS ON THESE LETTERS THAT COME TO THE ICOC
13	ONLY AND TALK ABOUT THE ISSUES UNDER THE
14	CIRCUMSTANCES UNDER WHICH WE WOULD CONSIDER IT.
15	THAT'S REALLY WHAT WE'RE TALKING ABOUT. AND LIMIT
16	IT TO THAT.
17	DR. PIZZO: I TAKE YOUR POINT, BUT I DON'T
18	AGREE BECAUSE I DO THINK THAT THE DETERMINATION OF
19	WHETHER THERE'S A FUNDAMENTAL PROBLEM WITH THE
20	SCIENTIFIC REVIEW IS IN A SENSE IN THE EYES OF THE
21	BEHOLDER. WE'VE ALL BEEN ON BOTH ENDS OF THAT
22	EQUATION, RIGHT? AND SO I THINK THAT I'M NOT
23	SUGGESTING ANYTHING THAT WOULD CHANGE THE GAP. I
24	THINK THAT WHAT I'M SUGGESTING IS THAT WE'RE SIMPLY,
25	AS WE ANNOUNCE THIS, WE'RE CODIFYING THIS, THAT WE
	256

COULD REFER TO THE GAP AND SAY IF YOU HAVE A
CONCERN, THIS IS THE PROCESS YOU FOLLOW.
BUT WHAT I'M ALSO TRYING TO DO IS, AS
OTHERS HAVE DURING THE DISCUSSION, IS RAISE THE BAR
OF EXPECTATION AROUND WHAT SHOULD COME TO THE ICOC
BECAUSE THESE CAN ALSO BE, AS THEY HAVE BEEN, QUITE
HONESTLY, POLITICIZED VIEWS, SUBJECT TO INDIVIDUALS.
AND WE'LL WIND UP GETTING CAUGHT IN A QUAGMIRE OF
INTERNAL DEBATE.
CHAIRMAN KLEIN: IF I COULD TAKE PUBLIC
COMMENT BECAUSE I'VE ALREADY CALLED FOR THAT, JOAN,
IF WE CAN DO THAT. DR. POMEROY.
DR. POMEROY: YOU SAID I WAS NEXT.
CHAIRMAN KLEIN: THAT IS EXACTLY RIGHT.
MY APOLOGIES TO THE PUBLIC BECAUSE I HAD
SPECIFICALLY RECOGNIZED DR. POMEROY, WHO HAS NOT HAD
A CHANCE TO SPEAK.
DR. POMEROY: I JUST WANT TO URGE MY
COLLEAGUES ON THIS BOARD TO KEEP IN MIND WHAT OUR
ROLE IS VERSUS WHAT THE CIRM STAFF'S ROLE IS. AND I
THINK THAT SOME OF THE SEMANTICS THAT WE'VE USED ARE
UNFORTUNATE BECAUSE THIS SHOULD NOT BE ABOUT AN
APPEAL TO US ON THE SCIENTIFIC GROUNDS. WE ARE NOT
THE SCIENTIFIC REVIEWERS. WE HAVE A REVIEW PANEL
THAT DOES THAT. WE AS A BOARD, OUR ROLE IS ALL
257

1	OF US ARE SCIENTIFIC REVIEWERS IN OTHER LIVES. WE
2	HAVE TO LET THAT GO. AND OUR ROLE ON THIS BOARD IS
3	TO THINK ABOUT THE PROGRAMMATIC AND THE PUBLIC AND
4	ALL THOSE PERSPECTIVES. AND I THINK IT IS VERY
5	IMPORTANT THAT WHEN WE SEE THIS AGAIN IN SEPTEMBER,
6	IT IS MADE QUITE CLEAR WHAT THE APPROPRIATE THINGS
7	TO BRING TO THE ICOC WOULD BE.
8	I THINK THOSE ARE NOT APPEALS BECAUSE
9	THERE'S NOTHING TO APPEAL. THERE'S NOT BEEN A
10	DECISION YET. AND THEY'RE NOT SCIENTIFIC
11	EXCEPTIONS. THEY'RE ADDITIONAL INFORMATION THAT IS
12	PERTINENT TO OUR ROLE AS BOARD MEMBERS. AND THAT
13	PROBABLY IS MOSTLY ABOUT THE MIDDLE TIER OF
14	APPLICATIONS BECAUSE THOSE ARE THE ONES THE REVIEW
15	PANEL HAS ASKED US TO HAVE A SAY ABOUT AND TO
16	CONSI DER.
17	SO AS WRITTEN THIS IS BASICALLY AN APPEAL
18	PROCESS THAT COULD INCLUDE SCIENTIFIC MERIT AND ALL
19	SORTS OF THINGS, SO IT NEEDS TO BE MUCH MORE
20	SPECIFIC BEFORE I CAN SUPPORT IT.
21	CHAIRMAN KLEIN: OKAY. SO I'D LIKE TO
22	EMPHASIZE THAT ON A STATUTORY BASIS THE REASON FOR
23	EXECUTIVE SESSION FOR PROPRIETARY REVIEWS HERE AT
24	THIS BOARD AND FOR DISCUSSIONS THAT CAN COVER
25	SCIENCE HERE IS ON A STATUTORY BASIS, WE HAVE TO BE
	050

1	THE FINAL DECISION MAKER ON SCIENCE AS WELL AS
2	PROGRAMMATIC BASIS. WE RESPECT THE INPUT OF THE
3	PEER REVIEW PROCESS, AND WE HAVE A GREAT COMMITMENT
4	TO THE INTEGRITY OF THAT PROCESS. BUT, IN FACT, ON
5	THIS BOARD WE HAVE A GREAT DEAL OF SCIENTIFIC AND
6	CLINICAL KNOWLEDGE, AND THROUGH THE PATIENT
7	ADVOCATES EXPOSURE TO SCIENTIFIC KNOWLEDGE OR
8	THROUGH THE INDUSTRY REPRESENTATIVES EXPOSURE TO
9	SCIENTIFIC KNOWLEDGE THAT IS PERTINENT. SO IT'S A
10	BALANCE.
11	BUT I HEAR YOU. AND I WOULD LIKE TO SAY
12	THAT STATUTORILY WE HAVE TO BE THE FINAL DECISION
13	MAKER ON A SCIENTIFIC BASIS. WITH DUE RESPECT, WE
14	TAKE GREAT WEIGHT AND LISTEN CAREFULLY TO THE PEER
15	REVIEW SYSTEM AND THE ADVICE WE GET THROUGH IT AS
16	WELL AS GREAT WEIGHT FROM THE SCIENTIFIC STAFF WE
17	HAVE AS AN AGENCY AND THEIR POSITION.
18	DR. POMEROY: MY FINAL QUESTION IS
19	ACTUALLY A QUESTION FOR JAMES, WHICH IS, IS IT
20	LEGALLY ALLOWABLE FOR US TO SAY THAT IF YOU SUBMIT A
21	WRITTEN ADDITIONAL INFORMATION, THAT YOU WAIVE YOUR
22	RIGHT TO PUBLIC HEARING BECAUSE PART OF THIS IS TO
23	MOVE OUR PROCESS ALONG. WHAT PREVENTS EVERYONE FROM
24	BOTH SENDING US THE LETTER AND COMING TO READ THE
25	LETTER TO US?

MR. HARRISON: TO ANSWER YOUR FIRST
QUESTION, NO. WE CAN'T ASK SOMEONE TO WAIVE THEIR
RIGHT TO SPEAK PUBLICLY AT A MEETING. HOWEVER, THE
INTENT OF THE POLICY IS TO ADVISE APPLICANTS THAT IF
THEY DON'T SUBMIT SOMETHING IN WRITING FIVE DAYS IN
ADVANCE OF THE MEETING, WE'RE NOT GOING TO CONSIDER
THEIR COMMENTS OR TAKE ANY ACTION ON THEM AT THE
MEETI NG.
DR. POMEROY: SO WE'RE GOING TO LET THEM
SPEAK AND THEN IGNORE THEM. IS THAT WHAT THIS
PROPOSED POLICY SAYS?
MR. HARRISON: CORRECT.
MS. SAMUELSON: FOLLOW-UP QUESTION FOR
JAMES.
CHAIRMAN KLEIN: LET'S DO THIS. WE'VE HAD
A VERY GOOD AND VERY THOUGHTFUL INPUT FROM A NUMBER
OF PEOPLE, BUT THE PUBLIC NEEDS TO HAVE INPUT HERE.
MR. SIMPSON: JOHN SIMPSON FROM CONSUMER
WATCHDOG. IT SEEMS TO ME YOU'RE CONFUSING A COUPLE
OF ISSUES HERE. I UNDERSTOOD THIS. YOU HAVE, IN
FACT, AT SEVERAL MEETINGS RECEIVED LETTERS AND
RECEIVED PUBLIC COMMENT THAT I THINK ACTUALLY SWAYED
YOU. AT THE TIME THAT THOSE THINGS HAPPENED, PEOPLE
SAID, WAIT A MINUTE. WE NEED A LEVEL PLAYING FIELD.
I SEE THIS ESSENTIALLY AS A WAY NOT TO INSTITUTE AN
260

1	APPEAL PROCESS, BUT IT IS A WAY TO BRING ORDER TO
2	THE CHAOS OF PEOPLE WHO DECIDE TO, IN FACT, LOBBY
3	THE BOARD, WHICH AS PUBLIC OFFICIALS PEOPLE ARE
4	ENTITLED TO DO.
5	SO WHAT YOU'RE TRYING TO DO IS COME UP
6	WITH AN ORDERLY PROCESS TO DEAL WITH LOBBYING. AND
7	SO I THINK THIS GOES THAT WAY. AND I THINK IF YOU
8	LOBBY A BOARD, YOU HAVE TO UNDERSTAND THAT WHEN YOU
9	DO IT, ANYTHING YOU PUT IN WRITING IS PART OF THE
10	PUBLIC RECORD, AND IT THEN THEREFORE IT'S A
11	PUBLIC DOCUMENT. I CAN ASK FOR IT. I SOMETIMES
12	FILE REQUESTS FOR ALL THOSE KINDS OF THINGS.
13	SOMETIMES PEOPLE GET EMBARRASSED WHEN I ASK FOR
14	THEM. SO YOU FACILITATE THE PROCEDURE BY SIMPLY
15	POSTING THEM BEFORE THE MEETING, AND, YOU KNOW,
16	PROBABLY PEOPLE'S SCORES BECOME PUBLIC THEN TOO.
17	AND I SUSPECT THAT IT WON'T BE AS HORRIBLE AS SOME
18	OF YOU THINK. IT'S NOT AN APPEAL PROCESS. IT IS
19	A HOW WE'RE GOING TO HANDLE LOBBYING. AND THAT'S
20	PERFECTLY APPROPRIATE. THANK YOU.
21	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
22	SHERRY, IF I COULD JUST TAKE ONE MORE PUBLIC COMMENT
23	AND THEN
24	MS. LANSING: JOHN, I JUST WANT TO SAY
25	ONCE AGAIN THANK YOU. I THINK, AT LEAST FOR THOSE
	261

1	OF US THAT ARE SUPPORTING THIS, YOU WERE FAR MORE
2	ARTICULATE THAN I PERSONALLY WAS, AND IT'S ALWAYS
3	GREAT TO REALIZE WHAT A PARTNERSHIP IT IS WITH ALL
4	OF THE MEMBERS OF THE PUBLIC. AND ONCE AGAIN, THANK
5	YOU BECAUSE YOU WERE INCREDIBLY CLEAR. AT LEAST
6	FROM MY POINT OF VIEW, YOU SAID WHAT I WAS
7	STRUGGLING TO SAY, SO I THANK YOU.
8	MR. SIMPSON: I WAS ONLY ABLE TO SAY THAT
9	BECAUSE I LISTENED TO THE WHOLE DEBATE AND
10	SUMMARIZED IT AND ENCAPSULATED WHAT I THOUGHT
11	EVERYONE ONE WAS SAYING.
12	CHAIRMAN KLEIN: THANK YOU VERY MUCH,
13	JOHN.
14	MR. REED: I WONDER IF IT MIGHT NOT BE
15	USEFUL TO HAVE A PERSON, HAVE AN OMBUDSMAN TO WHERE
15 16	USEFUL TO HAVE A PERSON, HAVE AN OMBUDSMAN TO WHERE IF YOU GOT LETTERS, YOU COULD SEND THANK YOU FOR
16	IF YOU GOT LETTERS, YOU COULD SEND THANK YOU FOR
16 17	IF YOU GOT LETTERS, YOU COULD SEND THANK YOU FOR YOUR COMMENTS. I APPRECIATE YOUR CONCERNS. THEY'RE
16 17 18	IF YOU GOT LETTERS, YOU COULD SEND THANK YOU FOR YOUR COMMENTS. I APPRECIATE YOUR CONCERNS. THEY'RE BEING FORWARDED TO OUR OMBUDSMAN, WHO WILL BE
16 17 18 19	IF YOU GOT LETTERS, YOU COULD SEND THANK YOU FOR YOUR COMMENTS. I APPRECIATE YOUR CONCERNS. THEY'RE BEING FORWARDED TO OUR OMBUDSMAN, WHO WILL BE ADVISING YOU OF WHATEVER. THAT PERSON COULD HAVE
16 17 18 19 20	IF YOU GOT LETTERS, YOU COULD SEND THANK YOU FOR YOUR COMMENTS. I APPRECIATE YOUR CONCERNS. THEY'RE BEING FORWARDED TO OUR OMBUDSMAN, WHO WILL BE ADVISING YOU OF WHATEVER. THAT PERSON COULD HAVE WHATEVER POWERS YOU DECIDE HIM OR HER COULD BE, BUT
16 17 18 19 20 21	IF YOU GOT LETTERS, YOU COULD SEND THANK YOU FOR YOUR COMMENTS. I APPRECIATE YOUR CONCERNS. THEY'RE BEING FORWARDED TO OUR OMBUDSMAN, WHO WILL BE ADVISING YOU OF WHATEVER. THAT PERSON COULD HAVE WHATEVER POWERS YOU DECIDE HIM OR HER COULD BE, BUT IT WOULD BE A POLICY, IT WOULD BE A PUBLIC FORUM, IT
16 17 18 19 20 21	IF YOU GOT LETTERS, YOU COULD SEND THANK YOU FOR YOUR COMMENTS. I APPRECIATE YOUR CONCERNS. THEY'RE BEING FORWARDED TO OUR OMBUDSMAN, WHO WILL BE ADVISING YOU OF WHATEVER. THAT PERSON COULD HAVE WHATEVER POWERS YOU DECIDE HIM OR HER COULD BE, BUT IT WOULD BE A POLICY, IT WOULD BE A PUBLIC FORUM, IT WOULD BE A WAY TO TAKE PRESSURE OFF YOU. I JUST
16 17 18 19 20 21 22	IF YOU GOT LETTERS, YOU COULD SEND THANK YOU FOR YOUR COMMENTS. I APPRECIATE YOUR CONCERNS. THEY'RE BEING FORWARDED TO OUR OMBUDSMAN, WHO WILL BE ADVISING YOU OF WHATEVER. THAT PERSON COULD HAVE WHATEVER POWERS YOU DECIDE HIM OR HER COULD BE, BUT IT WOULD BE A POLICY, IT WOULD BE A PUBLIC FORUM, IT WOULD BE A WAY TO TAKE PRESSURE OFF YOU. I JUST THINK JUST HAVING AN OMBUDSMAN, HAVING A SPECIFIC

WHO HAS THE EXECUTIVE CAPACITY AND THE STAFF TO
SCIENTIFICALLY REVIEW THE SUBSTANCE AND MAKE
DETERMINATIONS ON THE VALUE OF THE CONTRIBUTION. SO
THAT'S WHAT WE'RE TRYING TO DO HERE.
MR. ADAMS: BILL ADAMS, INTERNATIONAL STEM
CELL. THERE WAS COMMENTS MADE ABOUT, LET'S CALL IT,
TICKING OFF REVIEWERS, BUT I WOULD ALSO SAY YOU NEED
TO THINK ABOUT APPLICANTS. I HAVE PERSONALLY HAD
EXPERIENCE WITH NIH WHERE WE'VE HAD REVIEWERS THAT
WERE EITHER OFF BASE OR HAD CONFLICTS THAT WE
FINALLY UNEARTHED AND DID GET OUR GRANT.
THE WHAT I'VE WRITTEN THREE LETTERS,
TWO TO DR. SAMBRANO AND ONE TO OUR PRESIDENT, AND
NEVER HAD A RESPONSE. SO I'M A LITTLE CONFUSED AS
TO WHAT THE POLICY IS. I DON'T KNOW WHETHER MY
LETTERS GOT, YOU KNOW, SENT ALONG WITH THE REST OF
YOU OR NOT.
BUT WHAT THE FOR-PROFIT COMPANIES, AND I
SAY I CAN SPEAK FOR AT LEAST THREE OF THEM, WOULD
STRONGLY RECOMMEND IS A VERY BRIEF, CONCISE POLICY.
AND I DON'T AGREE WITH JOHN ON THE LOBBYING SIDE,
AND I PROBABLY WON'T GET APPLAUSE FOR THIS, THAT WE
COULD COME IN AND SAY, PLEASE LOOK AT THIS, WHICH I
THINK IS WHAT I DID IN MY LETTERS, AND HAVE AN
OPPORTUNITY TO PRESENT IT. I'M NOT A BIG FAN OF
263

1	WRITING A LETTER OR A PETITION TO THE ICOC. I
2	WOULD, QUITE FRANKLY, RATHER SEE THINGS RESOLVED
3	HERE AT THIS LEVEL FROM OUR PERSPECTIVE. THANK YOU.
4	CHAIRMAN KLEIN: THANK YOU.
5	DR. TROUNSON: MR. CHAIR, JUST TO CORRECT
6	THE RECORD. THERE HAS BEEN LENGTHY PHONE
7	CONVERSATIONS WITH THE GROUP, SO WE HAVE RESPONDED.
8	CHAIRMAN KLEIN: WHAT DR. TROUNSON JUST
9	SAID IS THEY HAD PHONE RESPONSES TO THESE LETTERS,
10	AT LEAST TO THE BEST OF HIS KNOWLEDGE, BUT THANK
11	YOU.
12	MR. KESSLER: MY NAME IS STEVEN KESSLER.
13	I'M WITH ANOTHER FOR-PROFIT ORGANIZATION, ADVANCE
14	CELL TECHNOLOGY. WE PUT IN A NUMBER OF GRANT
15	PROPOSALS WHEN WE WERE FINALLY ALLOWED TO SUBMIT
16	PROPOSALS. AND, OF COURSE, THEY WERE NOT
17	RECOMMENDED FOR FUNDING.
18	I'D LIKE TO POINT OUT TO THE BOARD THAT
19	IT'S MY UNDERSTANDING THAT FOR THE NEW CELL LINES
20	AWARDS, THAT THERE WERE 58 PROPOSALS OVERALL, THAT
21	12 CAME FROM FOR-PROFIT ORGANIZATIONS, NONE OF THOSE
22	WERE RECOMMENDED FOR FUNDING, COMPARED TO PRESUMABLY
23	18 OF 38 FROM NOT-FOR-PROFIT ORGANIZATIONS. TO ME,
24	THAT'S CLEAR EVIDENCE OF BLAS. I'VE HAD WE
25	FORMALLY APPEALED THIS ON JUNE 26TH. THE APPEAL, I
	264

1	WAS THE PI ON ONE OF THEM, WAS TWO AND A HALF PAGES
2	DESCRIBING FOR CIRM WHAT A CONFLICT OF INTEREST IS
3	FROM A BUSINESS PERSPECTIVE, AND ANOTHER SEVEN AND A
4	HALF PAGES SPECIFICALLY REBUTTING POINT BY POINT ALL
5	THE REVIEWERS' CRITICISMS.
6	I DON'T SEE HOW WE CAN DO THIS. WE CAN
7	CERTAINLY CONDENSE THE LETTER, BUT WHAT WE DID WAS
8	CITE THE REVIEWERS' COMMENTS AND WHAT OUR PROPOSAL
9	ACTUALLY STATED THAT FACTUALLY CONTRADICTED THAT.
10	YOU KNOW, IT WOULD BE MORE DIFFICULT, I THINK, FOR
11	THE BOARD TO UNDERSTAND WHAT ACTUALLY TOOK PLACE IF
12	WE DIDN'T DO IT IN THAT TYPE OF A SEQUENCE.
13	BUT JUST TO COME BACK TO THE CONFLICT OF
14	INTEREST ISSUES, I'VE HAD DISCUSSIONS WITH CIRM
15	STAFF JUST THIS WEEK FOLLOWING UP CITING CIRM'S OWN
16	CONFLICT OF INTEREST POLICY TO THEM ON SPECIFIC
17	ISSUES. ONE ISSUE WAS, YOU KNOW, IF A GRANT
18	REVIEWER HAS A FINANCIAL RELATIONSHIP WITH COMPANY
19	X, YOU KNOW, THAT IS, HE'S RECEIVING FUNDING FROM
20	THAT ORGANIZATION OR HE'S EXPECTING ROYALTY INCOME
21	FROM SOME COMPANY BY VIRTUE OF HAVING LICENSED
22	TECHNOLOGY TO THAT COMPANY. AND THAT REVIEWER IS
23	SITTING IN ON REVIEWS FROM OTHER FOR-PROFIT
24	ORGANIZATIONS, COMPANIES A, B, OR C, AND DOESN'T
25	RECOMMEND THOSE FOR FUNDING. TO US, FROM A BUSINESS

1	PERSPECTIVE, THAT'S A CONFLICT OF INTEREST.
2	THIS IS A BIT DIFFERENT FROM THE SITUATION
3	IN ACADEMIA WHERE PEOPLE QUIBBLE ABOUT
4	TECHNICALITIES ON PAPERS. YOU KNOW, FOR-PROFIT
5	ORGANIZATIONS, THEY INVEST MILLIONS OF DOLLARS
6	BUILDING UP THEIR PATENT ESTATE BECAUSE THEY WON'T
7	PROCEED DOWN THE DEVELOPMENT PATH, WHICH INCURS, YOU
8	KNOW, TENS OF MILLIONS OF DOLLARS IN EXPENSES,
9	UNLESS THEY HAVE A CLEAR PATENT PATH.
10	SO IT IS REALLY A SERIOUS ISSUE IF, YOU
11	KNOW, SOMEBODY, SOME REVIEWER WITH CONFLICTS, AND WE
12	CITED NUMEROUS INSTANCES, IN OUR VIEW THERE'S NO
13	REASON TO RECITE THOSE RIGHT NOW, WHERE, YOU KNOW, A
14	REVIEWER WOULD HAVE EVERY INCENTIVE TO HELP IMPEDE
15	THE COMPETITION FOR THE COMPANY THAT HE HAS A
16	RELATIONSHIP WITH.
17	CHAIRMAN KLEIN: WELL, I VERY MUCH
18	APPRECIATE THOSE COMMENTS. WE DO HAVE AN EXISTING
19	SEPARATE POLICY FOR CONFLICTS. WE TREAT THEM VERY
20	SERIOUSLY. WE HAVE A SEPARATE POLICY IN PLACE FOR
21	RE-REVIEW IN THE EVENT OF CONFLICTS. AND THE STAFF
22	DOES A THOUGHTFUL ANALYSIS. THEY HAVE GONE THROUGH
23	AND FOUND A CONFLICT IN A PARTICULAR POTENTIAL
24	EVEN IF THEY FIND A POTENTIAL FOR A CONFLICT, THEY
25	LOOK AT POTENTIALLY RE-REVIEWING IT. THEY'RE TRYING

1	TO ERR ON THE SIDE OF EQUITY AND JUSTICE HERE.
2	MR. KESSLER: I REALIZE THAT. AND I WAS
3	TOLD THAT THE WAY CIRM INTERPRETS ITS OWN CONFLICT
4	OF INTEREST POLICY, THE EXAMPLE I GAVE YOU WAS NOT A
5	CONFLICT OF INTEREST. SO
6	CHAIRMAN KLEIN: OKAY. SO WE'LL HAVE THE
7	OPPORTUNITY BETWEEN NOW AND THE NEXT SESSION TO LOOK
8	AT THAT AS WELL, BUT WE APPRECIATE YOUR COMMENTS.
9	THANK YOU VERY MUCH.
10	I'D LIKE TO, WITH THE BENEFIT OF VERY
11	THOUGHTFUL DISCUSSION HERE, TO MOVE TO THE NEXT
12	ITEM, IF WE COULD. AND WE'RE GOING TO GO TO LUNCH
13	IN JUST A MINUTE, BUT THERE'S AN ITEM THAT I'D LIKE
14	TO TOUCH ON VERY QUICKLY, ITEM 15. AND I'M HANDLING
15	THESE IN THE HIERARCHY OF PRIORITIES RELATED TO
16	TIMING OF DIFFERENT EXTERNAL EVENTS. IN THIS CASE,
17	THERE'S GOING TO BE SOME GROUNDBREAKINGS POTENTIALLY
18	OCCURRING BEFORE THE NEXT BOARD MEETING, AND THEY'D
19	LIKE SOME SENSE OF THIS BOARD AS TO THE NAMES
20	THEY' RE USING.
21	ON ITEM 15 I BELIEVE THAT DON GIBBONS IS
22	GOING TO MAKE A PRESENTATION ON THE NAMES OF THE
23	FACILITIES BEING SUGGESTED.
24	MR. GIBBONS: THANK YOU, MR. CHAIRMAN,
25	MEMBERS OF THE BOARD. WE'VE BEEN IN CONTACT WITH
	247

1	THE VARIOUS INSTITUTIONS WHO RECEIVED MAJOR
2	FACILITIES GRANTS BECAUSE THOSE GRANTS COME WITH A
3	STIPULATION THAT THE ICOC NEEDS TO APPROVE THOSE
4	NAMES, AND THE NAMES NEED TO IN SOME FASHION
5	ACKNOWLEDGE CIRM AND ITS CONTRIBUTION.
6	THERE ARE TWO INSTITUTIONS GOING TO
7	GROUNDBREAKING NEXT MONTH PRIOR TO YOUR NEXT
8	MEETING. SO WE WOULD LIKE SOME SENSE OF THE BOARD
9	WHETHER OR NOT THEY CAN START TO TALK ABOUT THAT
10	NAME AT THAT EVENT. OBVIOUSLY IT CAN'T BE LOCKED IN
11	STONE UNTIL YOU'VE OFFICIALLY VOTED ON IT WITH A
12	QUORUM IN SEPTEMBER.
13	THERE ARE TWO DIFFERENT STYLES OF NAMES
14	THAT HAVE BEEN PROPOSED. I WANT TO READ THEM TO
15	YOU. THEY'RE IN YOUR BINDERS. FROM THE UNIVERSITY
16	OF CALIFORNIA AT DAVIS, THEY ARE PROPOSING THE UC
17	DAVIS INSTITUTE FOR REGENERATIVE CURES WITH A
18	SMALLER TYPED TAG LINE THAT SAYS A FACILITY
19	SUPPORTED BY THE CALIFORNIA INSTITUTE FOR
20	REGENERATIVE MEDICINE. IT'S A CONFIGURATION THAT
21	ALLOWS OUR ENTIRE NAME TO BE SPELLED OUT FOR THE
22	VAST QUANTITY OF THE COMMUNITY WHO DOESN'T
23	UNDERSTAND WHAT OUR ACRONYM IS.
24	THE UNIVERSITY OF SOUTHERN CALIFORNIA HAS
25	CHOSEN A DIFFERENT CONFIGURATION, WHICH IS THE ELI
	268

1	AND EDYTHE BROAD CIRM CENTER FOR REGENERATIVE
2	MEDICINE AND STEM CELL RESEARCH AT USC. WE BROUGHT
3	BOTH THESE CONFIGURATIONS TO OUR EXECUTIVE COMMITTEE
4	INTERNALLY. WE WOULD LIKE TO PROPOSE THAT BOTH ARE
5	ACCEPTABLE, THAT WE WOULD LET THEM BOTH GO FORWARD
6	AS NAMES FOR THE BUILDING, EXTERIOR OF THE BUILDING.
7	WE WOULD LIKE TO GO FURTHER AND ADVISE AND
8	REQUEST THAT USC FIND SOME SPOT WITHIN THE BUILDING
9	ON A DONOR NAMING WALL OR SOMEWHERE WHERE THE CIRM
10	ACRONYM IS SPELLED OUT SO THAT GOING FORWARD IN THE
11	YEARS IN THE FUTURE, THAT THERE BE SOMEPLACE WHERE
12	THE ACRONYM WOULD HAVE ITS FULL WEIGHT.
13	CHAIRMAN KLEIN: SO IN USE OF THE TERM
14	"SPELLED OUT," I THINK YOU ARE REFERRING TO A FULL
15	STATEMENT OF THE NAME.
16	DR. GIBBONS: THE CALIFORNIA INSTITUTE FOR
17	REGENERATIVE MEDICINE, CORRECT.
18	CHAIRMAN KLEIN: SO IN A COMMUNICATIONS
19	ROLE, YOUR ADVICE, AS I UNDERSTAND IT, IS ON GOING
20	FORWARD, IF INSTITUTIONS WILL FIND SOMEPLACE,
21	HOPEFULLY CLOSE TO THE NAME, AS DAVIS DID, TO HAVE A
22	SUBSCRIPT SO PEOPLE CAN UNDERSTAND THAT THE
23	CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IS
24	THE INSTITUTION BECAUSE CIRM DOESN'T EXACTLY ROLL
25	OFF THE TONGUE. IT IS NOT IN COMMON USAGE.
	240

MR. GIBBONS: FOR THOSE OF US INSIDE THE
GAME, I WOULD LIKE TO THINK CIRM IS A VERY GOOD
BRAND, BUT FOR THOSE OUTSIDE OF THE GAME A LITTLE
BIT, IT'S NOT SUCH A GOOD BRAND.
CHAIRMAN KLEIN: DO WE HAVE A COMMENT?
DR. PIZZO: IT'S A COMMENT/QUESTION, I
GUESS, DON. NEEDLESS TO SAY, WE DON'T WANT TO DO
MICROMANAGING OF INDIVIDUAL INSTITUTIONS' WORDS THAT
THEY USE TO NAME THEIR BUILDINGS. BUT IT WOULD BE
HELPFUL TO HAVE SOME PRINCIPLES. I THINK PRINCIPLE
A IS THAT BY ALREADY STATUTE, WE KNOW THAT THE NAME
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE NEEDS
TO BE ON THE BUILDING.
IN OUR INSTITUTION THERE ARE GUIDELINES
DEFINING NAMING OF BUILDINGS. SO WE WILL HAVE A
NAMED DONOR. THAT USUALLY NEEDS TO BE CLOSE TO 50
PERCENT OF THE OVERALL COST OF THE BUILDING. AND
THAT, IN A SENSE, TAKES ACTUALLY IT WILL TURN OUT
TO BE ALMOST TWICE THE AMOUNT THAT IS COMING FROM
CIRM. SO IT WILL TAKE MORE DOMINANCE, IF YOU WILL,
IN THE ACTUAL NAME. AND I THINK WE CAN
MR. GIBBONS: THAT'S IN THE GAP ALREADY,
THAT THAT EXTRA DOMINANCE IS ABSOLUTELY ACKNOWLEDGED
IN THE GAP.
DR. PIZZO: SO WHAT I'M GETTING AT IS THAT
270

1	I DON'T KNOW IN THE CASE OF DAVIS WHETHER THERE'S
2	ANOTHER NAMING DONOR. CLAIRE COULD SPEAK TO THAT.
3	NOR DO I KNOW WHERE THE BROAD NAME FITS IN TERMS OF
4	THE AMOUNT OF FUNDS THAT ARE GIVEN IN COMPARISON TO
5	THE AMOUNT RECEIVED FROM CIRM. I CAN ENVISION THAT
6	IF THEY'RE ABOUT THE SAME, THAT CREATES AN
7	INTERESTING QUESTION IN TERMS OF WHAT, IF YOU WILL,
8	THE DOMINANCE IS. SO I'M SUGGESTING THAT YOU COME
9	BACK TO US, NOT WITH JUST AN APPROVAL, BUT MAYBE
10	SOME GENERAL GUIDELINES THAT WE SHOULD THINK ABOUT.
11	CHAIRMAN KLEIN: IN THIS PARTICULAR CASE,
12	SINCE BOTH OF THESE ARE FAR DOWNSTREAM, WOULD IT BE
13	ACCEPTABLE TO YOU FOR US TO HAVE JUST A SENSE OF THE
14	COMMITTEE SO THEY CAN PROCEED?
15	DR. PIZZO: SURE. ABSOLUTELY. I HAVE NO
16	INTENTION OF WANTING TO MICROMANAGE THOSE NAMES. I
17	JUST WANTED TO WE'RE THINKING ABOUT THIS VERY
18	ACTIVELY RIGHT NOW OURSELVES, AND IT WOULD BE
19	INTERESTING TO KNOW WHAT THE BOUNDARY CONDITIONS
20	ARE.
21	MR. ROTH: I LIKE THE TAG LINE APPROACH
22	THAT IS BEING USED, BUT YOU MIGHT CONSIDER SOMETHING
23	CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
24	CENTER OF EXCELLENCE, SO IT CAN BE THE ELI BROAD OR
25	THE UC DAVIS, AND THEN UNDER IT.

1	CHAIRMAN KLEIN: OR INSTITUTE AS
2	APPROPRI ATE.
3	MR. ROTH: AS APPROPRIATE BASED ON WHAT
4	THEY ARE. AND THEN THEY CAN USE IT AS A TAG LINE,
5	BUT DON'T HAVE TO USE ALL.
6	MS. SAMUELSON: COUPLE QUICK COMMENTS.
7	I'VE BEEN WAITING TO SAY THIS A LONG TIME. I HATE
8	THE BRAND CIRM. IN THE CAMPAIGN WE CALLED OURSELVES
9	CALIFORNIANS FOR CURES. AND NOW IT'S A WORD THAT
10	MEANS ABSOLUTELY NOTHING TO THE PUBLIC WHO ARE OUR
11	PARTNERS. IT SOUNDS LIKE SPERM. AND IT'S IN AN ERA
12	IN WHICH THE DIVISION OF FORESTRY HAS BECOME CAL
13	FIRE. MY LAW SCHOOL HAS GONE TO CAL-LAW. AND
14	THAT'S THE TREND, AND THAT'S THE PUBLIC THAT WE'RE
15	CONNECTED TO. CIRM JUST DOESN'T MEAN ANYTHING.
16	THE OTHER POINT IS I HAD AN IDEA THIS
17	MORNING, AND I DON'T KNOW IF THERE'S ANY OPPORTUNITY
18	FOR THIS. BUT IT WOULD BE LOVELY TO START NAMING
19	BUILDINGS THAT ARE GOING TRY TO GET CURES FOR PEOPLE
20	AFTER THE PEOPLE WHO ARE SUFFERING, LIKE THAT MAN
21	WHO JUST DIED OF ALS.
22	CHAIRMAN KLEIN: THANK YOU VERY MUCH. SO
23	COULD I HAVE A SHOW OF HANDS AS A SENSE OF THE
24	COMMITTEE TO SUPPORT THE TWO NAMES THAT HAVE BEEN
25	SUBMITTED? ALL IN FAVOR. THIS IS NOT A VOTE. THIS
	272

1	IS A SHOW OF SENSE OF SUPPORT. RAISE YOUR RIGHT
2	HAND IF YOU SUPPORT THE NAMES THAT HAVE BEEN
3	SUGGESTED. IT APPEARS TO ME THAT A SENSE OF THE
4	COMMITTEE IS STRONG SUPPORT FOR THESE TWO NAMES, SO
5	THEY CAN GO AHEAD IN CONFIDENCE WITH THIS.
6	I'D LIKE TO SEE IS THAT SUFFICIENT,
7	DON?
8	DR. GIBBONS: YES, IT IS.
9	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
10	AND, MELISSA, SHOULD WE ADJOURN FOR LUNCH? AND THIS
11	LUNCH, HOPEFULLY WE CAN KEEP SHORT. WE NEED TO COME
12	BACK. THE TRANSLATIONAL RFA, WE HAVE A POINT TO
13	DISCUSS JUST AS A REPORTING ISSUE AND DISCUSSION ON
14	THE CRITERIA THEY'RE GOING FORWARD WITH, RECONCILED
15	TO THE CRITERIA THAT HAVE BEEN PUT FORTH IN THE TASK
16	FORCE GUIDELINE APPLICATIONS THAT'S BEEN APPROVED.
17	AND WE HAVE THE LOAN POLICY. THE LOAN POLICY WILL
18	BE OUR HEADLINER RETURNING FROM LUNCH. IT'S A VERY
19	IMPORTANT PART OF OUR PROGRAM. AND DOES THE
20	COMMITTEE THINK WE COULD DO THIS IN 35 OR 40
21	MINUTES? 35 OR 40 MINUTES IS OUR GOAL. AND WE LOOK
22	FORWARD TO SEEING YOU SHORTLY. WE'RE ADJOURNED FOR
23	LUNCH.
24	(A RECESS WAS TAKEN.)
25	CHAIRMAN KLEIN: IF WE CAN RECONVENE,
	273
	210

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	PLEASE. WE'RE GOING TO TRY AND MOVE EXPEDITIOUSLY.
2	WE HAVE TWO ITEMS OF SIGNIFICANT IMPORTANCE HERE
3	THAT WE'RE GOING TO COVER, LOAN POLICIES AND THEN
4	THE REPORT ON THE CRITERIA FOR THE UPCOMING
5	TRANSLATIONAL RFA. WE'RE ALSO GOING TO THEN FOLLOW
6	THAT BY A QUICK ITEM ON ASSEMBLYMAN MULLIN'S BILL ON
7	CONTROLLING TERRORISM RELATED TO ANIMAL RESEARCH.
8	AND THEN WE WILL HAVE A COUPLE OF REPORTS AT THE END
9	OF THE DAY, BUT THE HIERARCHY OF PRESENTATION IS, IN
10	FACT, SIGNIFICANT SO THAT WE MAKE SURE WE RETAIN AS
11	MANY BOARD MEMBERS AS POSSIBLE FOR THESE NEXT TWO
12	I TEMS.
13	FIRST ITEM, DUANE ROTH WILL LEAD TO THE
14	LOAN POLICY. AND DUANE HAS DONE A FABULOUS JOB ON
15	LEADING THAT LOAN TASK FORCE.
16	MR. ROTH: THANK YOU. SO LET ME JUST
17	QUICKLY MENTION THE NAMES OF THE TASK FORCE, ED
18	PENHOET, TED LOVE, JEFF SHEEHY, OSWALD STEWARD,
19	FLOYD BLOOM, BOB KLEIN, MARCY FEIT, MICHAEL
20	GOLDBERG.
21	THE LOAN TASK FORCE SET OUT TO DEVELOP A
22	POLICY THAT WOULD GOVERN OUR LOANS ONCE THEY ARE PUT
23	INTO EFFECT AND CAN, IN FACT, BE APPLIED FOR. LYNN
24	HARWELL STAFFED OUR COMMITTEE AND DID A FANTASTIC
25	JOB OF HELPING US ORGANIZE AND PULL TOGETHER ALL THE

1	COMMENTS FROM THE VARIOUS STAKEHOLDERS THAT WE MET
2	WI TH.
3	THERE WERE THREE MAJOR MEETINGS THAT WE
4	HELD. THE FIRST WITH THE FINANCIAL COMMUNITY TO
5	TALK ABOUT HOW THE LOAN PROGRAM SHOULD BE
6	STRUCTURED. THE SECOND WAS AN INDUSTRY MEETING TO
7	MEET WITH INDUSTRY AND TALK ABOUT ANY ISSUES OR
8	SUGGESTIONS THAT THEY MAY HAVE IN THE LOAN POLICY.
9	AND THEN BOB AND I SPENT A DAY WITH KEY LEGISLATORS
10	IN SACRAMENTO TRYING TO MAKE SURE THEY UNDERSTOOD
11	THE RATIONALE BEHIND THIS PARTICULAR LOAN POLICY.
12	SO IF YOU LOOK AT THE POLICY, AND IT'S IN
13	YOUR BOOKS. I THINK IT'S TAB 15 OR 16. I DON'T
14	REMEMBER. 14.
15	THE ONE THING I WANT TO MENTION IN THE
16	BACKGROUND ON THE FIRST PAGE THAT'S VERY IMPORTANT
17	IS THESE LOANS ARE GOING TO BE TARGETED WHERE THERE
18	ARE FUNDING GAPS, WHICH MEANS THAT FOR THESE
19	TRANSLATIONAL PRODUCTS TO MOVE FORWARD, WE WANT TO
20	IDENTIFY WHERE THERE'S VIRTUALLY NO ALTERNATIVE
21	CAPITAL AVAILABLE TO INVEST OR LIMITED CAPITAL
22	AVAILABLE. AND THAT WILL BE THE JOB OF THE CIRM
23	STAFF AND OTHERS TO IDENTIFY THOSE GAPS AND TO BRING
24	THOSE TO OUR ATTENTION.
25	THE SECOND PART OF THE BACKGROUND IS AN
	275

1	ADDITIONAL COMMENT SECTION ABOUT HOW WE WENT ABOUT
2	IDENTIFYING WHAT A PORTFOLIO MIGHT LOOK LIKE. AND I
3	ONLY BRING THAT TO YOUR ATTENTION BECAUSE THE
4	DECISIONS REGARDING HOW LARGE A PORTFOLIO THE LOAN
5	PROGRAM WILL ENCOMPASS WILL BE UP TO THE FINANCE
6	COMMITTEE AND TO MICHAEL GOLDBERG TO HELP DEFINE
7	THAT. AND THEN WHEN WE GET TO THE SPECIFIC RFA'S,
8	THE RANGE OF HOW MUCH AN INDIVIDUAL LOAN MIGHT BE
9	WOULD BE DEALT WITH.
10	SO WE DIDN'T, OTHER THAN FOR MODELING
11	PURPOSES, WHICH WE HIRED PRICEWATERHOUSECOOPERS TO
12	DO, WE DID NOT TRY TO DEAL WITH THE SCOPE OR THE
13	SIZE OF THE INDIVIDUAL RFA'S.
14	SO WITH THAT AS BACKGROUND, WHAT I WOULD
15	LIKE TO DO IS JUST BRIEFLY RUN THROUGH THE TERM
16	SHEET THAT IS ENCLOSED. SO IN TERMS OF
17	DISBURSEMENT, IT WILL BE MILESTONE DRIVEN. IN OTHER
18	WORDS, THERE CAN BE A CERTAIN TOTAL LOAN, BUT IT
19	WILL BE MILESTONE DRIVEN. NOT UNLIKE THE
20	CONVERSATION WE HAD EARLIER TODAY ABOUT PROGRESS,
21	THESE WILL BE MORE DEFINED IN GENERAL.
22	THE TERM OF THE LOAN WAS AN ISSUE THAT WE
23	ADDRESSED BY HAVING TWO OPTIONS, A SIX- OR TEN-YEAR
24	TERM. AND WITH THE SIX-YEAR TERM, THERE WOULD BE NO
25	EARLY PAYBACK. BUT WITH A TEN-YEAR TERM, IF THE

1	APPLICANT SELECTED A TEN-YEAR TERM, THERE ARE
2	CERTAIN TRIGGERS THAT WOULD COME INTO PLAY WHERE
3	THEY WOULD BE REQUIRED TO REPAY, AND WE CAN GO
4	THROUGH THOSE IN JUST A MOMENT.
5	CHAIRMAN KLEIN: DUANE, WHEN YOU SAY IN
6	THE SIX-YEAR TERM, I THINK YOU SAID THERE'S LIMITED
7	EARLY TRIGGERS.
8	MR. ROTH: I SHOULD HAVE SAID LIMITED
9	BECAUSE THERE IS ONE. WE'LL GET TO THOSE. THEY'RE
10	ACTUALLY IN ACCELERATED TRIGGERS DOWN BELOW, THE SIX
11	AND THE TEN.
12	BUT ANOTHER VERY IMPORTANT ADDITION WE
13	MADE AFTER THESE STAKEHOLDER INPUTS WAS THAT WE HAVE
14	BOTH A RECOURSE LOAN AND NONRECOURSE LOAN. AND THE
15	RECOURSE LOAN WOULD SAY THAT THE ENTITY THAT MAKES
16	OR BORROWS THE MONEY IS OBLIGATED TO PAY IT BACK
17	REGARDLESS OF WHAT HAPPENS TO THE PRODUCT. SO IT'S
18	MORE OF A COMPANY OR INSTITUTIONAL LOAN, NOT A
19	PRODUCT LOAN. THE NONRECOURSE MEANS THAT THE LOAN
20	IS ON THE PRODUCT, AND IF THE PRODUCT FAILS, GOES
21	AWAY, THEN THE LOAN IS TERMINATED. IT'S NOT DUE.
22	NOW, TO COMPENSATE FOR THOSE TWO
23	DIFFERENCES, WE HAVE A DIFFERENT WARRANT COVERAGE
24	POLICY. SO ON THE RECOURSE LOAN, THE WARRANT
25	COVERAGE ON THE AMOUNT OF THE LOAN IS 10 PERCENT.
	077

1	SO 10 PERCENT OF A MILLION DOLLARS, IF THAT'S THE
2	CASE, WOULD BE THE WARRANT COVERAGE. AND IF IT'S A
3	NONRECOURSE LOAN, THEN THERE WOULD BE A MILLION
4	DOLLARS WORTH OF WARRANT COVERAGE. SO THAT'S HOW
5	THE FINANCIAL INTERACTIONS BETWEEN THESE TWO
6	RECOURSE AND NONRECOURSE AND HOW WE DEALT WITH RISK.
7	THE NEXT PART IS THE PART THAT WE STARTED
8	TO TALK ABOUT. THE SIX-YEAR LOAN HAS TWO CONDITIONS
9	FOR EARLY REPAYMENT. ONE IS CHANGE OF CONTROL,
10	WHICH WOULD INCLUDE A MERGER WITH A PUBLIC OR
11	PRIVATE COMPANY. IF THE COMBINED ENTERPRISE EXCEEDS
12	100 MILLION, THAT WOULD TRIGGER A REPAYMENT OF THE
13	LOAN IN THE SIX-YEAR CASE AND A SECOND ONE IF
14	THERE'S INITIAL PUBLIC OFFERING; IN OTHER WORDS, THE
15	COMPANY GOES PUBLIC, AND THERE'S IN EXCESS OF \$20
16	MILLION RAISED, THEN THE LOAN WOULD BECOME DUE.
17	IN THE TEN-YEAR THERE ARE BOTH OF THOSE,
18	AND THEN THERE ARE THREE OTHERS THAT ARE INCLUDED.
19	A 20-FOLD FINANCING; IN OTHER WORDS, IF YOU BORROWED
20	A MILLION AND YOUR FOLLOW-ON FUNDING EXCEEDS 20
21	MILLION, THEN THE LOAN BECOMES DUE.
22	NO. 4, IS IF THERE IS PROGRESS IN THE
23	CLINIC AND A COMPANY MOVES TO FILE WITH THE FOOD AND
24	DRUG ADMINISTRATION EITHER AN INVESTIGATIONAL DEVICE
25	APPLICATION, WITHIN 90 DAYS OF FILING THAT WITH THE

1	FDA, THE LOAN WOULD BECOME DUE. IF IT'S A
2	THERAPEUTIC, WE ASK THAT THAT LOAN BE REPAID WITHIN
3	SIX MONTHS OF STARTING A PIVOTAL PHASE 3 OR EVEN IF
4	IT'S A PHASE 2. YOU HEARD THIS MORNING ABOUT A
5	PIVOTAL STUDY THAT MIGHT BE, IN FACT, VERY EARLY AND
6	INVOLVE VERY FEW PATIENTS, BUT WITHIN SIX MONTHS OF
7	THAT, THEN THE LOAN WOULD BECOME DUE ON THE TEN-YEAR
8	PROGRAM.
9	THERE ARE SOME OTHER THINGS THAT ARE JUST
10	FOR CLARITY. PREPAYMENT IS ALLOWED. THE LOAN IS
11	SUBORDINATED TO OTHER LOANS THAT THE COMPANY MAY
12	TAKE. SO WE WILL ALWAYS BE BEHIND ADDITIONAL LOANS
13	THAT ARE THERE. WE'D BE ON PAR WITH THE EQUITY.
14	THE MATCHING FUNDS REQUIREMENT IS AN INDIRECT
15	REQUIREMENT, AND SOMETHING THAT WILL NEED ADDITIONAL
16	DISCUSSION BECAUSE MATCHING FUNDS CAN MEAN MANY
17	THINGS. MATCHING FUNDS COULD BE WHAT ARE THE
18	FOLLOW-ON FINANCINGS THAT OUR LOAN ENABLED TO
19	HAPPEN. AND SO WE MAY LOAN SOMEBODY A MILLION
20	DOLLARS, THEY MAKE PROGRESS ON THAT MILLION, THEY
21	RAISE A \$10-MILLION ROUND TO FURTHER FUND IT, THOSE,
22	IN MY OPINION, WOULD BE MATCHING FUNDS AND CREATE
23	LEVERAGE.
24	CHAIRMAN KLEIN: SO, DUANE, UNDER MATCHING
25	FUNDS, WHEN THE FINANCE COMMITTEE ADDRESSES THE SIZE

1	OF LOANS IN TERMS OF PORTFOLIO RISK, IT'S POSSIBLE
2	THAT THE FINANCE COMMITTEE MIGHT SAY FOR LOANS OVER
3	A CERTAIN DOLLAR AMOUNT, A SIGNIFICANT MATCH IS
4	NECESSARY BECAUSE OF THE RISK BECAUSE OF PORTFOLIO
5	CONCENTRATION. DO YOU EXPECT THOSE KINDS OF
6	TRADE-OFFS TO OCCUR?
7	MR. ROTH: I THINK THOSE KIND OF
8	TRADE-OFFS, I THINK WE WANT TO BE, ESPECIALLY IF
9	IT'S MILESTONE DRIVEN, BOB, WE MAY WANT TO BE IN A
10	POSITION WHERE WE DON'T REQUIRE THE TRADITIONAL
11	MATCHING FUNDS, WHICH MEANS WE'LL PUT UP A MILLION
12	IF YOU PUT UP A MILLION. BUT IT MAY BE THE PROGRAM
13	COSTS THREE MILLION. WE'LL PUT UP OUR MILLION. YOU
14	OBVIOUSLY HAVE TO RAISE TWO MILLION TO MAKE THIS
15	THING WORK. SO IT REALLY DEPENDS ON HOW WE CHOOSE
16	TO ADMINISTER THAT, BUT I THINK WE NEED TO HAVE A
17	FLEXIBLE DEFINITION THERE ABOUT MATCHING FUNDS.
18	CHAIRMAN KLEIN: FOR EXAMPLE, IF ANOTHER
19	APPROACH TO THAT IS IF THERE'S NO MONEY FOR A PHASE
20	2A TRIAL AND IT'S \$15 MILLION, WE MAY SAY, LOOK, TO
21	PUT UP SEVEN AND A HALF MILLION AS A CONCENTRATION
22	ISSUE, WE'RE GOING TO REQUIRE YOU TO HAVE ANOTHER
23	SEVEN AND A HALF MILLION BECAUSE THIS IS A LARGE
24	CONCENTRATION OF RISK IN A SINGLE COMMITMENT.
25	MR. ROTH: THAT WOULD BE MY BELIEF, THAT
	280
	1 ZUU

1	THAT'S HOW IT WOULD BE STRUCTURED. IT COULD BE THE
2	FACT THAT THERE'S A MULTIMILESTONE, AND THE THIRD
3	MILESTONE REQUIRES WHAT YOU'RE TALKING ABOUT. SO WE
4	NEED TO SEE WE WANT THE COMPANY TO USE THAT AS
5	LEVERAGE TO BRING IN THE REST OF THE MONEY AND MAKE
6	SURE THE MONEY IS SITTING. SO THERE IS A MATCHING
7	FUND REQUIREMENT, BUT I JUST WANT TO SPECIFY THAT
8	THAT'S A PRETTY LOOSE DEFINITION RIGHT NOW, AND
9	WE'LL HAVE TO DEAL WITH THAT DOWN THE ROAD.
10	DEFAULT, IN THE EVENT THAT WE DO HAVE
11	DEFAULTS AND THERE'S INTELLECTUAL PROPERTY, THERE'S
12	A REQUIREMENT ON THE COMPANY OR THE INSTITUTION THAT
13	RECEIVES THE LOAN TO TRY TO DISPOSE OF THE
14	INTELLECTUAL PROPERTY WORKING WITH US. BUT WE
15	REVIEWED THIS INTERNALLY. NANCY HELPED US DETERMINE
16	THAT WE REALLY SHOULDN'T OWN IP AT CIRM. SO WE'VE
17	DEALT WITH THAT IN THE WAY WE WORDED THE DEFAULT
18	PROVISION HERE.
19	THE LAST THING, BEFORE WE OPEN IT UP, ARE
20	THE COVENANTS. AND I WANT TO JUST STRESS THAT WE
21	WENT THROUGH THESE COVENANTS IN EACH OF THOSE
22	STAKEHOLDER MEETINGS PRETTY CAREFULLY. START WITH
23	THE PREMISE THAT THE MONEY WE'RE LOANING CANNOT BE
24	GOTTEN ANY OTHER PLACE. IN OTHER WORDS NO. 2,
25	THERE'S NO COLLATERAL. WE'RE NOT COLLATERALIZING.

1	NO. 3, WE OFFER THEM THE OPPORTUNITY OF A
2	NONRECOURSE LOAN. IN OTHER WORDS, THE PRODUCT
3	FAILS, YOU DON'T HAVE TO REPAY US IF YOU CHOOSE THAT
4	OPTION. SO KEEP IN MIND THESE ARE VERY, VERY OPEN
5	TERMS THAT NO BANK OR NO VENTURE CAPITALIST WOULD
6	OFFER TO THAT. BUT THAT'S PART OF FULFILLING OUR
7	MISSION, TO FUND THOSE THINGS THAT ARE VERY
8	DIFFICULT AND MAKE IT EASY.
9	SO IN EXCHANGE, WE ASK FOR THE FOLLOWING
10	COVENANTS: THAT AT THE TIME OF COMMERCIALIZATION,
11	THE COMPANY WILL ABIDE BY WHATEVER THE GOING LAWS
12	ARE AROUND CALIFORNIA RX, MEDICARE, MEDICAID, ANY OF
13	THE OTHER GOVERNING POLICIES THAT ARE IN PLACE. AND
14	NO. 2, THAT THEY'LL PROVIDE AT THE TIME OF LAUNCH AN
15	INDUSTRY STANDARD ACCESS PROGRAM FOR ALL THOSE
16	PATIENTS THAT NEED THIS THERAPY, BUT HAVE ABSOLUTELY
17	NO OTHER WAY TO PAY FOR IT OR TO GET IT.
18	SO IF I DESCRIBE TODAY'S INDUSTRY
19	STANDARD, IT IS THAT MOST COMPANIES MAKE THIS
20	AVAILABLE AS A LAST RESORT. AND, IN FACT, IF YOU GO
21	TO THE CALIFORNIA RX WEBSITE, YOU WILL FIND THAT
22	THERE'S WAYS FOR PATIENTS TO UNDERSTAND THAT. YOU
23	SEE IT ADVERTISED ON TELEVISION AND SO ON. THAT
24	HAPPENS TO BE WHAT'S TODAY. I DON'T KNOW WHAT IT
25	WILL BE OR WE DON'T KNOW WHAT IT WILL BE TEN YEARS

1	FROM NOW, BUT WE'RE ASKING THE COMPANIES AT THAT
2	POINT IN TIME, WHATEVER IS THE STANDARD POLICY FOR A
3	COMPANY OF YOUR SIZE, SO WE DON'T ASK NECESSARILY
4	FOR A PFIZER PATIENT ACCESS PROGRAM, BUT ONE FOR
5	YOUR SIZE AND FOR THE SCOPE OF YOUR PRODUCT. IF
6	IT'S YOUR FIRST PRODUCT AND YOU DON'T HAVE ENOUGH
7	RESOURCES TO PROVIDE FREE, MAYBE IT'S PROVIDED AT
8	SOME ADDITIONAL DISCOUNT. BUT THOSE ARE THE THINGS
9	THAT WILL HAVE TO BE DEALT WITH AT THAT TIME.
10	AND THERE'S ONE OTHER VERY IMPORTANT POINT
11	I WANT TO MAKE HERE, THAT THIS HAS TO BE AT THE TIME
12	OF COMMERCIALIZATION, MEANING THE COMPANY IS NOW FDA
13	APPROVED AND READY TO LAUNCH THE PRODUCT. TO ASK
14	THE COMPANIES TO DO THIS IN ADVANCE OF THAT COULD,
15	A, IN SOME WAY JEOPARDIZE THEIR APPROVAL; B, COULD
16	INTERFERE WITH THEIR ABILITY TO COMPETE IN THE
17	MARKETPLACE BY MAKING THAT WIDELY AVAILABLE TO
18	THEIR, QUOTE, COMPETITORS OR OTHER ISSUES THAT I
19	THINK WOULD COME IN IN TERMS OF CONFIDENTIALITY,
20	WHAT THE COMPANY IS TRYING TO DO. SO I THINK THAT
21	HAS TO BE HANDLED VERY CAREFULLY AND SHOULD COME
22	PRIOR TO SALES, BUT NOT IN SOME FORM PRIOR TO THE
23	APPROVALS THAT THEY WOULD GO THROUGH.
24	DR. PENHOET: JUST TO EXPAND ON THAT A
25	LITTLE BIT. FOLLOWING UP ON THE PRESENTATION WE HAD
	202

1	THIS MORNING, WE HAVE CLARIFIED IN THE IP POLICIES
2	GENERALLY ON THIS ISSUE THAT THE COMPANIES ARE ONLY
3	RESPONSIBLE FOR THE THERAPEUTIC ENTITY THAT THEY
4	PRODUCE. SO IF YOU GO BACK TO THIS MORNING'S
5	PRESENTATION, YOU SAW A SUBSTANTIAL NEUROSURGERY
6	PROCEDURE TAKING PLACE ON THESE PATIENTS. WE WOULD
7	NOT EXPECT THE COMPANY TO PAY FOR THE NEUROSURGERY
8	AND PAY FOR WHAT THEY PRODUCE.
9	SO WE DON'T KNOW WHAT THAT WILL BE IN ALL
10	CASES, BUT THE SURGERY WOULD BE A SEPARATE ITEM THAT
11	HAS TO BE DEALT WITH. BUT THAT WOULD BE AN
12	OUT-OF-POCKET EXPENSE FOR THE COMPANY, SO WE DIDN'T
13	ANTICIPATE THE COMPANIES TAKING RESPONSIBILITY FOR
14	THE WHOLE THERAPY, BUT TAKING RESPONSIBILITY FOR THE
15	PLECE OF THE THERAPY THAT THEY PRODUCED.
16	SECOND ISSUE IS THERE'S BEEN SOME
17	CONTROVERSY AROUND THIS FINAL ISSUE THAT DUANE
18	MENTIONED, WHICH IS WHEN SHOULD THE PROGRAM BE
19	PROSCRIBED FOR THE ACCESS PROGRAM. SHOULD IT BE NOW
20	OR SHOULD IT BE AT THE TIME OF COMMERCIALIZATION?
21	STEM CELLS, INC. HAS A POINT OF VIEW, WHICH IS IT
22	SHOULD BE NOW. BUT AT LEAST TEN COMPANIES HAVE
23	RESPONDED THAT THE RIGHT ANSWER IS AT THE TIME OF
24	COMMERCIALIZATION. SO THERE'S A PREPONDERANCE OF
25	COMPANY FEEDBACK SAYING IT SHOULD BE AT THE TIME OF

1	COMMERCIALIZATION, BUT THERE ARE COMPANIES WHO
2	BELIEVE WE SHOULD DEFINE IT TODAY. I JUST WANTED TO
3	MAKE SURE PEOPLE KNEW.
4	CHAIRMAN KLEIN: ED, I THINK WOULD SAY,
5	DUANE, THAT MY DISCUSSIONS ARE IF WE DO OUR WORDING
6	NOT LATER THAN THE COMMERCIALIZATION AFTER FDA
7	APPROVAL, THEN IT HANDLES BOTH. COMPANY GROUPS CAN
8	BE SATISFIED AND YET WE CAN ACHIEVE OUR ULTIMATE
9	MI SSI ON.
10	DR. PENHOET: THAT'S CORRECT.
11	MR. ROTH: SO, AGAIN, I THINK THIS IS VERY
12	IMPORTANT. IF THIS IS WE HAD SO MUCH INPUT
13	BEGINNING WITH THE INTELLECTUAL PROPERTY POLICY,
14	WHICH WE ADAPTED THIS FROM, THAT THIS IS THE ONE
15	THAT INDUSTRY WOULD, I THINK, PULL IN AND SAY WE'RE
16	NOT SURE WHAT THAT MEANS. THE ONE WE HAVE NOW, THIS
17	DEFINITION, I THINK, IS UNDERSTANDABLE. INDUSTRY
18	STANDARD AT THE TIME YOU LAUNCH THE PRODUCT. AND
19	THAT'S WHY IT'S WORDED THAT WAY.
20	WE DID NOT CONTEMPLATE A PUBLIC HEARING.
21	I THINK THAT WOULD BE HAVE TO BE CAREFULLY
22	ORCHESTRATED BECAUSE THERE WOULD BE PROPRIETARY
23	QUESTIONS COMING OUT THAT I THINK MAY DISADVANTAGE
24	THE COMPANIES FROM DOING THAT. I THINK SENDING IT
25	TO US AND HAVING US AN OPPORTUNITY TO REVIEW THAT

1	THAT IT IS, IN FACT, MEETING INDUSTRY STANDARD IS
2	PROBABLY APPROPRIATE, BUT WE CAN DISCUSS THAT LATER.
3	THE FINAL THREE, JUST QUICKLY.
4	PUBLICATION-RELATED BIOMEDICAL MATERIAL SHARING,
5	THAT'S A REQUIREMENT IN THE IP POLICY. IT SAYS IF
6	YOU PUBLISH, YOU HAVE TO DECIDE FIRST YOU WANT TO
7	PUBLISH THE INFORMATION. SECOND, IF IT'S NOT
8	COMMERCIALLY AVAILABLE, SOME OF THE REAGENTS OR
9	THINGS YOU'RE USING IN YOUR STUDIES, THEN YOU WOULD
10	AGREE TO MAKE THOSE AVAILABLE TO OTHER ORGANIZATIONS
11	AS A RESEARCH TOOL.
12	AND THEN THE NEXT ONE IS PRESS RELEASE.
13	WE WOULD LIKE YOU TO NOTIFY US IF YOU ARE GOING TO
14	MAKE A PRESS RELEASE REFERRING TO CIRM-FUNDED
15	RESEARCH. AND FUNDING FOR CALIFORNIA OPERATIONS,
16	THE FAMOUS CALIFORNIA SUPPLIER DEFINITION WOULD
17	APPLY.
18	SO WITH THAT, THOSE ARE MY COMMENTS.
19	MICHAEL OR SOME OF THE OTHERS THAT WERE ON THE TASK
20	FORCE MAY HAVE ADDITIONAL COMMENTS. ED, BOB.
21	CHAIRMAN KLEIN: AND ON THE PRESS RELEASE
22	REQUIREMENTS, YOU NOTICE NOTIFICATION TO CIRM. I
23	THINK THAT CONJUNCTIVELY WE HAD REFERENCED THERE
24	WOULD BE CREDIT TO CIRM, BUT SUBJECT TO CIRM
25	APPROVAL. SO OUR COMMUNICATIONS DEPARTMENT WOULDN'T
	286

1	GET SOME ATTRIBUTION FOR A PRODUCT THAT THEY DIDN'T
2	THINK HAD BEEN PROPERLY SIGNED OFF ON BY FDA OR
3	THERE WERE PROBLEMS, REAL PROBLEMS WITH. AT LEAST
4	WE HAVE SOME NOTIFICATION AND ABILITY TO HAVE INPUT
5	ON WHAT WE'RE GETTING CREDITED WITH.
6	MR. ROTH: SCOTT TOCHER ALSO HAS SPENT A
7	LOT OF TIME WORKING ON THIS AND THE IP POLICY. SO
8	IF YOU HAVE QUESTIONS ABOUT THE ACTUAL WORDING OF
9	THOSE COVENANTS.
10	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
11	IT'S AN EXCELLENT REPORT. BOARD COMMENTS HERE?
12	DR. POMEROY: SO, DUANE, I'M TRYING TO
13	UNDERSTAND WHEN A COMPANY WOULD GET A LOAN VERSUS
14	WHEN A COMPANY WOULD GET A GRANT FROM CIRM. SO CAN
15	YOU BRIEFLY ADDRESS THAT, SORT OF THE MISSION OF THE
16	LOAN PROGRAM. AND THEN ALSO WHAT ARE THE
17	DIFFERENCES IN BOTH THE IP AND THE ACCESS BRIEFLY
18	BECAUSE I KNOW IT'S A COMPLEX QUESTION IF YOU HAVE A
19	LOAN VERSUS A GRANT FROM THE CIRM.
20	MR. ROTH: ON THE FIRST ONE, WHETHER IT'S
21	A GRANT OR A LOAN, WE AGAIN DECIDED THAT SHOULD BE
22	RFA DRIVEN. BUT IN GENERAL, THE THINKING IS THAT
23	MOST OF THE TRANSLATIONAL PROGRAMS THAT WE PUT OUT
24	WOULD BE THE LOAN PROGRAM PRIMARILY. THERE CAN BE
25	TIMES WHEN IT BECOMES BOTH LOANS AND GRANTS. AND

1	ADDITIONALLY, WE FELT THAT INSTITUTIONS SHOULD BE
2	ABLE TO FORM CORPORATIONS AND APPLY FOR THE LOANS IF
3	THEY WANT TO DO MORE TRANSLATIONAL WORK WITHIN THE
4	INSTITUTION, WHICH IS BECOMING MORE AND MORE
5	NECESSARY BECAUSE FUNDING FOR VERY EARLY STAGES IS
6	BECOMING MORE DIFFICULT.
7	IT WOULD REALLY BE UP TO STAFF TO
8	RECOMMEND, WORKING WITH MICHAEL ON THE ALLOCATION,
9	ABOUT WHETHER A GIVEN RFA WOULD BE LOANS ONLY, LOAN
10	OR GRANT, OR A COMBINATION OF THE TWO.
11	IN TERMS OF THE ACCESS PROGRAM, THEY'RE
12	IDENTICAL, AND THAT'S BY DEFINITION. SO WE JUST
13	PICKED IT, SAID WE'D DONE THE WORK THERE. AND,
14	AGAIN, FROM THE COMPANY SIDE, GIVEN ALL THE
15	ADVANTAGES WE GIVE THEM IN THIS FINANCING PACKAGE, I
16	THINK THE FACT THAT THEY WOULD ACCEPT AN ACCESS
17	PROGRAM IS REASONABLE.
18	CHAIRMAN KLEIN: AND, CLAIRE, THERE MAY BE
19	IN THE FINANCE COMMITTEE'S HEARINGS AND THE BOARD
20	HEARINGS RELATED TO THIS, THERE MIGHT BE, FOR
21	EXAMPLE, A SIZE THRESHOLD, THAT AT \$25 MILLION, FOR
22	EXAMPLE, A LOAN MAY BE SOMETHING THAT GIVES US THE
23	CAPACITY TO SERVICE MORE PROGRAMMATIC OBJECTIVES.
24	PRICEWATERHOUSECOOPERS DID A STUDY THAT SHOWED EVEN
25	WITH A 40-PERCENT OR A 50-PERCENT DEFAULT RATE IN
	200

1	CERTAIN CATEGORIES OF THESE LOANS, THAT WITH THE
2	WARRANTS ATTACHED, WE COULD HAVE BETTER THAN CAPITAL
3	PRESERVATION AS AN OUTCOME ON A SIX- OR SEVEN-YEAR
4	TURN POTENTIALLY OR A TEN-YEAR TURN DEPENDING UPON
5	THE PORTFOLIO LENGTH.
6	SO THAT THE LOAN PROGRAM HAS THE
7	POTENTIAL, NOT ONLY TO GIVE US THE ABILITY TO REACH
8	TO HIGHER LEVELS OF SUPPORT, AND GIVEN THE DEARTH OF
9	CAPITAL IN THE CLINICAL TRIAL PHASE OF DEVELOPMENT,
10	IT APPEARS WE MAY HAVE TO CONTEMPLATE DEALING WITH
11	SOME LARGER SIZE LOANS OR FINANCIAL SUPPORT OF SOME
12	KIND TO REALLY MOVE THINGS DOWNSTREAM TO THE CLINIC
13	AND COMMERCIALIZATION. BUT, AGAIN, THIS IS GOING TO
14	BE A SEPARATE POLICY DISCUSSION THAT WILL COME
15	BEFORE THE BOARD.
16	MR. ROTH: I DIDN'T MENTION INTEREST RATES
17	AT ALL, SO IT WOULD BE SET ON A PER RFA BASIS. THAT
18	WAY WE CAN STAY RELEVANT. ANYTHING THE POLICY
19	THAT'S IN FRONT OF US IS REALLY DESIGNED TO STAND
20	ALONE AND STAND LONG TERM, AND THEN THE FLEXIBILITY
21	COMES IN FROM LOOKING AT THE TOTAL PORTFOLIO,
22	LOOKING AT THE INDIVIDUAL RFA'S, AND, AS BOB JUST
23	TALKED ABOUT, THE SIZE. AND THAT ALL NEEDS SEPARATE
24	DISCUSSION PROBABLY ON A CASE-BY-CASE BASIS OF RFA.
25	CHAIRMAN KLEIN: OKAY.
	200

1	DR. TROUNSON: JUST FOR YOU. I'M STILL
2	NOT QUITE CLEAR WHAT'S THE INDUCEMENT TO TAKE A LOAN
3	RATHER THAN A GRANT IF THE IP IS THE SAME.
4	MR. ROTH: THE IP POLICY IS THE SAME ONLY
5	IN TERMS OF THE REQUIREMENTS, THE COVENANTS. IT'S
6	NOT THE SAME. THERE'S AN INTEREST, THERE'S ROYALTY,
7	AND OTHER THINGS INVOLVED IN IP.
8	DR. TROUNSON: SO NOW I BETTER UNDERSTAND
9	IT.
10	DR. POMEROY: SO THE ACCESS PROGRAM IS THE
11	SAME.
12	MR. ROTH: THE ACCESS IS THE SAME.
13	DR. POMEROY: BUT IF YOU GET BLOCKBUSTER,
14	THE RETURN TO THE STATE IS DIFFERENT DEPENDING UPON
15	WHETHER IT'S A LOAN OR A GRANT.
16	MR. ROTH: THAT'S CORRECT. THE IP POLICY
17	COMES WITH ITS OWN SET OF REQUIREMENTS FOR ROYALTY
18	RATES AND PAYBACK TO THE STATE, ETC.
19	CHAIRMAN KLEIN: SO AS AN ILLUSTRATION,
20	BESIDES THE ROYALTIES DIFFERENCE, IN TERMS OF OUR
21	MISSION, WHICH IS IN THE GREATEST BENEFIT TO THE
22	STATE, WHICH IS TO DRIVE THERAPIES, WE HAVE MORE
23	RECOVERY OF MONEY TO FUND MORE THERAPIES. SO THE
24	STATE IS BEING SERVED IN THAT MANNER AS VERSUS
25	ROYALTIES, WHICH ARE LIKE 5 PERCENT OF THE TOTAL
	290

1	RETURN TO THE STATE. AND IN TERMS OF THE LOAN SIZE,
2	IT VERY AS A POLICY MATTER, WE MAY DECIDE NOT TO
3	FUND A \$30-MILLION GRANT. THAT AT THOSE SCALES,
4	THAT WE REALLY HAVE TO DEAL WITH IT ON A LOAN BASIS,
5	SO WE CAN HAVE A CAPITAL RECOVERY PROGRAM AND BE
6	ABLE TO DO LARGE LOANS, BUT BE ABLE TO HAVE THE
7	PROGRAM BREADTH THAT WE NEED AS WELL.
8	OKAY. ADDITIONAL MEMBER COMMENT?
9	MR. SHEEHY: SO MY INTEREST IS REALLY IN
10	THE COVENANTS. THE FINANCIAL STUFF IS GOING TO GO
11	BY ME A LOT. I'M GLAD WE CALLED THEM COVENANTS
12	BECAUSE I REALLY THINK THE ORIGIN OF THESE
13	PROVISIONS, I SPECIFICALLY SPEAK TO THE FIRST TWO,
14	REALLY CAME OUT OF A COMMITMENT THAT ED LED IN THE
15	IP TASK FORCE TO THE PEOPLE OF CALIFORNIA FOR GIVING
16	US THIS MONEY. WE'RE JUST GOING TO SET A CERTAIN
17	BASELINE STANDARD IN TERMS OF PRICING FOR CALIFORNIA
18	PUBLIC ENTITIES AND ALSO ACCESS FOR CALIFORNIANS WHO
19	DON'T HAVE INSURANCE OR THE WORKING POOR, SO TO
20	SPEAK.
21	MY CONCERN IS THE STICKINESS OF THESE
22	COVENANTS GIVEN WE HAVE REALLY TWO DIFFERENT
23	POSTURES PUBLICLY ON THESE VERY ITEMS. SO IF YOU
24	LOOK AT THE LOAN TASK FORCE, WE'VE GONE THROUGH, AND
25	THE IP TASK FORCE, WE'VE GONE THROUGH VERY ELABORATE

1	PUBLIC PROCESSES, TAKEN TESTIMONY, HEARD OBJECTIONS
2	TO THIS, BUT REALLY KIND OF SET A LINE IN THE SAND
3	AND SAID WE'RE GOING TO DO THIS. THIS IS IMPORTANT.
4	THIS IS A PROMISE WE'RE MAKING TO THE PEOPLE WHO ARE
5	GIVING US THE MONEY TO DO THIS RESEARCH.
6	1565, AS OFFERED BY SENATOR KUEHL, WHICH
7	WE CONTINUE TO OPPOSE, AT THIS POINT HAS WHAT AND
8	I THINK THERE HAVE BEEN SOME PROBLEMS UP TO THIS
9	POINT, BUT IF YOU LOOK SIMPLY AT THE IP PROVISIONS,
10	THEY ARE SOLELY THESE TWO ITEMS, AND THEY'RE REALLY
11	MUCH WEAKER THAN WHAT WE HAVE HERE. AND I WONDER
12	ABOUT THE DURABILITY OF THE COMMITMENT TO THESE
13	PROVISIONS, WHICH MATTER MORE TO ME. I WON'T SPEAK
14	FOR THE OTHER MEMBERS OF THE BOARD, BUT IT MATTERS
15	VERY MUCH TO ME PERSONALLY AS SOMEONE WHO WAS
16	UNINSURED, WHO ACCESSED MY THERAPIES FIRST THROUGH A
17	STATE-FUNDED PROGRAM, WHO WENT TO A PUBLIC CLINIC.
18	IF I LIVED IN A DIFFERENT STATE, I MIGHT NOT EVEN BE
19	HERE.
20	WHEN WE COME TO 1565, AND I DON'T KNOW
21	WHAT WE WILL DO, BUT IF WE CONTINUE TO REITERATE OUR
22	OPPOSITION TO MOSTLY THESE SAME PROVISIONS, I WONDER
23	HOW I CAN COUNT ON US FULFILLING OUR COVENANTS WITH
24	THE PEOPLE OF CALIFORNIA IF WE HAVE A MAJORITY OF
25	THE BOARD THAT DOESN'T WANT TO SUPPORT THESE BEING

1	STATUTORY. YOU KNOW, IT MEANS THAT THEY'RE NOT
2	REALLY SET VERY STRONG, AND I'M NOT COMFORTABLE,
3	ESPECIALLY IN THE NUMBERS OF THE MILLIONS OF
4	DOLLARS WE'RE TALKING ABOUT GIVING MONEY AWAY AND
5	THE TERMS, WHICH I THINK DUANE HAS RIGHTLY SAID
6	THEY'RE VERY GENEROUS, BUT THIS IS OUR ROLE. SO I'M
7	COMFORTABLE WITH US DOING ALL OF THIS, BUT THESE
8	COVENANTS HAVE TO REALLY BE COVENANTS.
9	AND FOR ME, AT LEAST PERSONALLY, TO FEEL
10	COMFORTABLE GOING FORWARD, I HAVE TO FEEL LIKE WE
11	ARE GOING TO MAKE THIS PART OF EVERY LOAN THAT WE
12	DO. AND SO, YOU KNOW, THERE'S A CIRCLE THAT'S NOT
13	SQUARED HERE, AND I DON'T REALLY KNOW HOW TO RESOLVE
14	IT. MAYBE IT WILL HAPPEN WHEN WE GET INTO A
15	DISCUSSION OF 1565, BUT IT'S HARD FOR ME TO BE
16	OPPOSED TO 1565 AND TO BE FOR THIS.
17	CHAIRMAN KLEIN: JEFF, LET ME ASK YOU THIS
18	QUESTION. FIRST OF ALL, AS TO TAKING AWAY THE
19	PRIORITY FOR EMBRYONIC STEM CELL RESEARCH IN THE
20	VOTING STRUCTURE OF 1565, THAT'S A SEPARATE ISSUE.
21	AND BUT AS TO THE APPLICATION HERE, HOW WOULD YOU
22	DEAL WITH THE SITUATION, WHICH BY REGULATION WE CAN
23	DEAL WITH, BUT NOT IF IT'S STATUTORY AND UNDER 1565
24	SAYS THERE'S A SINGLE PRICE THAT YOU CAN ASSIGN. AS
25	LONG AS THERE IS A COMMERCIAL PRICE, YOU CAN ONLY

1	HAVE A SINGLE PRICE FOR STATE ENTITIES WHEN YOU KNOW
2	THAT WITH ALZHEIMER'S, YOU HAVE A MAJORITY OF THE
3	PERSONS HAVE LATE ONSET, AND THEY'LL BE COVERED BY
4	MEDICARE OR SOME RELATED PROGRAM.
5	WHEREAS, YOU HAVE A SUBSET, WHICH IS AN
6	EARLY ONSET GROUP, AND FOR THAT EARLY ONSET GROUP,
7	WE MIGHT LOOK AT IT AND SAY TO REALLY REACH OUR
8	PUBLIC PURPOSE, WE MAY WANT TO SAY WE'RE GOING TO
9	SET A HIGHER PRICE FOR THOSE COVERED BY MEDICARE
10	THAT ARE WORKING THOSE COVERED BY MEDICARE, AND
11	WE WANT TO SET A LOWER PRICE. ESSENTIALLY WE WANT
12	THE COMPANY TO TAKE THAT HIGHER PRICE AND
13	CONTRACTUALLY AGREE THAT THEY'LL TAKE THAT SUBSIDY
14	AND SUBSIDIZE DOWN THAT EARLY ONSET GROUP WHO MAY
15	GET ALZHEIMER'S IN THEIR 40S OR 50S AND NEED
16	IMMEDIATE ATTENTION TO STOP THAT FROM BECOMING
17	PROGRESSIVELY WORSE. AND YET THERE'S TWO YEARS
18	BEFORE THEY CAN QUALIFY FOR MEDICARE EVEN UNDER AN
19	EXCEPTI ON.
20	SO THE POINT IS HERE, IN ORDER TO SERVE
21	THE PUBLIC PURPOSE, THE 1565 DOESN'T ALLOW US THE
22	ABILITY TO DIFFERENTIATE THOSE PRICES EVEN THOUGH
23	THEY'RE FACTUALLY DIFFERENT CONSTRAINTS WE HAVE.
24	AND WE REALLY WANT TO MAKE SURE THAT WE GET TO THAT
25	GROUP THAT HAS THE GREATEST PUBLIC DISTRESS AND
	204
	294

1	NEEDS THE GREATEST ASSISTANCE. HOW UNDER 1565 WOULD
2	YOU REACH THAT SUBSET?
3	MR. SHEEHY: I THINK MY POINT WOULD BE,
4	AND WE TALKED ABOUT THIS IN THE IP TASK FORCE, I
5	DON'T THINK WE'RE GOING TO BE SETTING PRICES. THAT
6	WAS NOT MY UNDERSTANDING, THAT THAT WAS GOING TO BE
7	CIRM'S ROLE.
8	CHAIRMAN KLEIN: THAT'S PART OF 1565.
9	MR. SHEEHY: 1565 STIPULATES FOR THESE
10	CALIFORNIA PUBLIC PURCHASERS, AND THIS IS ALL WITHIN
11	THE CONTEXT OF CALRX, WHICH I DON'T THINK IS A
12	COMMUNIST PROGRAM. I MEAN THE GOVERNOR PUT THIS
13	TOGETHER. SO CALRX IS A BENCHMARK. AND I JUST
14	I'M NOT ACCEPTING THIS EXCEPTIONAL SEE, THIS IS
15	EXACTLY WHY I START GETTING CONCERNED ABOUT GOING
16	FORWARD WITH THIS PROGRAM IF THE COVENANTS ARE GOING
17	TO BE ARE ON SHAKY GROUND BECAUSE OF
18	HYPOTHETICALS IN AREAS IN WHICH WE DECIDED WE
19	WEREN'T GOING TO DELVE IN. WE WEREN'T GOING TO
20	PRICE PRODUCTS. GOVERNMENTS GET SPECIAL PRICING
21	ANYWAY, YOU KNOW. AND I DON'T THINK IT'S OUTRAGEOUS
22	TO SUGGEST THAT THERE BE A SPECIAL PRICE FOR
23	CALIFORNIA PUBLIC ENTITIES PURCHASING THESE
24	THERAPIES BECAUSE WE'VE GIVEN THE MONEY FOR THOSE.
25	SO I DON'T SEE 1565 I MEAN I JUST I
	205

295

GOT TO SAY I NEITHER UNDERSTAND NOR ACCEPT YOUR
ARGUMENT. AND I THINK
CHAIRMAN KLEIN: JEFF, I'M TRYING TO SAY
THE PURPOSE WOULD BE TO GIVE A LOWER PRICE TO STATE
AND LOCAL GOVERNMENT FOR THE EARLY ONSET GROUP. SO
WE'RE TRYING TO SET TWO DIFFERENT PRICES, BUT A
LOWER PRICE FOR STATE AND LOCAL GOVERNMENT FOR THAT
GROUP THAT HAS GOT GREATER ECONOMIC DISTRESS AND NO
MEDICARE SUPPORT.
MR. SHEEHY: HOW WOULD 1565 KEEP US FROM
DOING THAT? THAT I DON'T UNDERSTAND.
MR. GOLDBERG: MIGHT I SUGGEST, WITH
PERMISSION OF MY FELLOW BOARD MEMBERS, THAT WE DEFER
THE DISCUSSION OF 1565 TO
MR. SHEEHY: WE'RE NOT GOING TO TAKE
ACTION ON THIS. I WAS JUST EXPRESSING MY BASIC
I'VE BEEN VERY SUPPORTIVE OF THIS PROCESS, AND I
THINK DUANE HAS DONE A PHENOMENAL JOB. AND I HAVE
BEEN PUSHING THIS FORWARD, BUT I REALLY DO HAVE
YOU KNOW, THIS IS WHERE THIS IS MY MAIN CONCERN.
THE FINANCIAL ARRANGEMENTS ON THIS ARE BRILLIANT,
AND I APPLAUD STAFF, I APPLAUD PRICEWATERHOUSE, BUT
I WANT TO BE CLEAR THAT IF I START TO FLOAT AWAY, I
DON'T WANT MY COLLEAGUES TO THINK THAT I'M DOING THE
BIG DOUBLE CROSS. JUST THIS INCONSISTENCY IS
206

1	BOTHERING ME, AND I REALLY THINK THAT THESE ARE
2	REASONABLE THINGS TO ASK FROM INDUSTRY IF THEY'RE
3	GOING TO GET OUR MONEY. I JUST DO. I WANT TO FEEL
4	LIKE THAT WE'RE DIGGING IN ON THIS AS KIND OF IT'S
5	BEEN UP TO THIS POINT. IT'S JUST THIS REALLY KIND
6	OF WIGGLY ROOM WE'RE SEEKING IN THE CONTEXT OF 1565
7	THAT'S ALARMING ME.
8	CHAIRMAN KLEIN: DR. PENHOET.
9	DR. PENHOET: IF I COULD MAKE A POINT. I
10	BELIEVE THAT THESE COVENANTS ARE REAL. MAYBE AS
11	SOMEONE ONCE SAID ABOUT THE POPE, MOVES FROM ONE
12	STATE OF CERTAINTY TO ANOTHER STATE OF CERTAINTY. I
13	BELIEVE WE WOULD ONLY MOVE AWAY FROM THIS STATE OF
14	CERTAINTY IF WE HAD A COMPELLING SET OF REASONS TO
15	DO SOMETHING DIFFERENT.
16	SO I'VE INTERPRETED THESE COVENANTS IN THE
17	LOAN PROGRAM AND THE IP POLICY AS OUR POLICIES AS
18	THEY EXIST TODAY. WE HAVE NO EVIDENCE IN FRONT OF
19	US, IN MY VIEW, TO SAY THAT WE SHOULD CHANGE THEM
20	TODAY. I THINK THE QUESTION THAT BOB BRINGS UP IS
21	COULD THERE BE CIRCUMSTANCES IN THE FUTURE WHERE WE
22	WOULD WISH TO CHANGE SOME OF THESE THINGS BASED ON
23	NEW KNOWLEDGE, BASED ON FACTS WE DON'T HAVE TODAY,
24	ETC. SO I THINK I CERTAINLY DON'T TAKE WHAT'S IN
25	FRONT OF US HERE IN THE LOAN POLICY AS WE'RE SOFT ON

1	THESE THINGS. IT SAYS IN PLAIN ENGLISH WHAT WE
2	INTEND TO DO HERE. I THINK THIS IS OUR POLICY IF WE
3	ADOPT THIS. AND IF WE CHOOSE TO MAKE CHANGES IN THE
4	FUTURE FOR SOME GOOD REASON, I THINK WE COULD HAVE
5	THE FLEXIBILITY TO DO THAT UNDER REGULATIONS. I
6	DON'T WANT TO GET INTO 1565, BUT I NEVER VIEWED
7	THESE AS TENTATIVE MYSELF. I DON'T KNOW HOW THE
8	REST OF YOU FEEL ABOUT THIS. I THINK THIS IS THE
9	CERTAINTY THAT WE HAVE IN FRONT OF US TODAY.
10	CHAIRMAN KLEIN: AND I WOULD REITERATE DR.
11	PENHOET'S POSITION. I THINK THIS IS ABSOLUTELY OUR
12	POLICY. AND THE MODIFICATION THAT I'M SUGGESTING WE
13	WANT FLEXIBILITY FOR IS TO ACHIEVE OUR POLICY
14	OBJECTIVELY. BUT THERE'S FACT PATTERNS THAT WOULD
15	MEAN THAT YOU WANT TO HAVE TWO PRICES FOR THE STATE
16	TO GET TO THE PEOPLE IN GREATEST NEED, NOT A SINGLE
17	PRICE AS DICTATED BY 1565.
18	SO IT'S ONLY TO ACHIEVE OUR REAL POLICY TO
19	GET TO THE PEOPLE WITH GREATEST NEED THAT WE NEED
20	THE FLEXIBILITY.
21	MR. ROTH: MAYBE I CAN JUST CLARIFY AGAIN
22	THE GOAL. AND THIS REALLY CAME OUT OF ED'S TASK
23	FORCE ON IP AND CARRIED OVER. THE GOAL THAT WE
24	FINALLY SETTLED ON IS THAT NO CALIFORNIAN SHOULD GO
25	WITHOUT ACCESS TO THESE THERAPIES, AND TO THE BEST

1	OF OUR ABILITY COLLECTIVELY, INSURANCE COMPANIES,
2	STATE OF CALIFORNIA, PATIENT ADVOCACY GROUPS, AND,
3	FINALLY, THE COMPANIES THAT PRODUCE THEM, LET'S BE
4	SURE EVERYBODY GETS THE PRODUCT. AND THAT'S WHAT
5	THAT'S WHAT'S EMBEDDED HERE. I, FOR ONE, WILL STAY
6	WITH THAT BECAUSE I THINK THAT IS THE ABSOLUTE
7	FUNDAMENTAL KEY TO WHAT WE'RE TRYING TO ACCOMPLISH.
8	CHAIRMAN KLEIN: OKAY. SO I THINK WE'RE
9	IN HEATED AGREEMENT ON OUR GOALS AND OUR POLICIES.
10	LET'S ASK FOR PUBLIC COMMENT, PLEASE.
11	MR. SIMPSON: JOHN SIMPSON, CONSUMER
12	WATCHDOG. I JUST WANTED TO REITERATE WHAT JEFF
13	SAID. I THINK THAT THE IP ACCESS POLICIES AND THE
14	COVENANTS HERE ARE MINIMAL POLICIES THAT ABSOLUTELY
15	MUST BE REQUIRED OF ANY COMPANY THAT WANTS TO TAKE
16	THE STATE OF CALIFORNIA'S MONEY. THERE HAVE BEEN
17	RUMBLINGS THAT SOME COMPANIES DON'T LIKE IT. AND I
18	SEE PUSHBACK COMING FROM THE COMPANIES, AND I'M
19	CONCERNED THAT I'VE SEEN, READING BETWEEN THE LINES
20	OF SOME OF THE LETTERS THAT HAVE BEEN WRITTEN TO
21	SENATOR KUEHL, SORT OF A NOTION WE NEED FLEXIBILITY,
22	WE NEED TO LISTEN TO THESE COMPANIES, OR THEY'RE NOT
23	GOING TO BE WILLING TO TAKE LOANS FROM US. AND MY
24	ANSWER TO THOSE COMPANIES IS THEN FINE. DON'T TAKE
25	IT.

1	AND I THINK THAT THIS IS THE BOTTOM LINE.
2	I'M DELIGHTED TO HAVE HEARD WHAT I WAS HEARING NOW
3	IS STRONG COMMITMENTS TO THE COVENANTS AND TO THE IP
4	POLICY, BUT I WOULD ENCOURAGE ALL THE BOARD MEMBERS
5	TO READ VERY CLOSELY THE LETTERS THAT HAVE COME FROM
6	CIRM MANAGEMENT TEAM TO THE SENATOR'S OFFICE IN THE
7	1665 CONTEXT. AND TO SOMEONE WHO FOLLOWS THIS, BUT
8	WHO'S NOT BEEN PRIVY TO THE CONVERSATIONS, THE PLEA
9	FOR FLEXIBILITY COMES ACROSS TO ME AS, WELL, WHEN
10	PUSH COMES TO SHOVE, WE'RE GOING TO CAVE AND GIVE IN
11	TO BIOTECH. THANK YOU.
12	MR. REED: I'VE ALWAYS LOVED THE ICOC'S
13	ABILITY TO THINK CREATIVELY AND COME UP WITH WAYS TO
14	GET MORE BANG FOR THE BUCK. THE FACILITIES WHERE
15	\$271 MILLION WAS LEVERAGED TO 1.5 BILLION WAS
16	MAGNI FI CENT.
17	I WONDER IF THERE MIGHT BE A WAY TO DO
18	SOMETHING LIKE THAT WITH THE LOAN REQUESTS. FOR
19	INSTANCE, SOME OF THE EQUIPMENT USED IS SO
20	EXPENSIVE. A MICROSCOPE CAN COST \$250,000. I
21	WONDER IF THERE'S A WAY WE CAN ASK PEOPLE THAT ARE
22	ASKING LOANS FROM US TO SAY, ALL RIGHT, IS THERE ANY
23	PART OF YOUR EQUIPMENT THAT YOU'D BE WILLING TO LET
24	OTHER CIRM GRANTEES USE, HAVE ACCESS TO? AND THEY
25	COULD LIST THIS, AND IT MIGHT GIVE THEM LEVERAGE FOR
	200

1	PREFERENCE FOR POSSIBLE LOANS. OR THEY MIGHT SAY,
2	WELL, WE'VE GOT EXPERTISE MANY YEARS IN THIS FIELD,
3	AND WE WOULD BE WILLING TO DO TRAINING SESSIONS TO
4	HELP SHARE OUR EXPERTISE. SO THEY WOULD BRING MORE
5	THINGS TO THE TABLE AS TO HELP THEM GET A BETTER
6	CHANCE FOR THEIR LOANS.
7	CHAIRMAN KLEIN: OKAY. THANK YOU. ALL
8	RI GHT.
9	MR. ADAMS: I WAS ON THE PANEL FOR THE
10	PROFIT COMPANIES DUANE AND YOU ALL PUT TOGETHER.
11	AND I MUST SAY THAT THIS THING HAS EVOLVED VERY
12	NICELY. A YEAR AGO I WAS SHAKING MY HEAD TO THINK
13	HOW YOU WERE EVER GOING TO GET TO THIS POINT. I
14	THINK IT ABSOLUTELY IS TERRIFIC.
15	I REALLY DISAGREE WITH MY COLLEAGUE JOHN.
16	IT'S NOT A QUESTION OF IN MY MIND IT'S A QUESTION
17	FOR US FOR-PROFITS OF HOW DO WE APPLY FOR A LOAN?
18	HOW DO WE GET THROUGH THE PROCESS AND GET APPROVED?
19	AND AT THIS MOMENT IN TIME, I DON'T SEE IT. AND I
20	KNOW YOU'RE WORKING ON NEW PROCEDURES AND NEW
21	PROCESSES TO HELP US WITH THAT, BUT I THINK YOU GUYS
22	HAVE DONE A GREAT JOB.
23	CHAIRMAN KLEIN: THANK YOU. ADDITIONAL
24	PUBLIC COMMENT? ALL RIGHT. ON THE POLICY AS
25	PRESENTED, CAN I HAVE A SENSE OF THE COMMITTEE IN
	204

1	TERMS OF JUST A SHOW OF HANDS WHO WOULD BE
2	SUPPORTIVE. THANK YOU VERY MUCH.
3	LIKE TO MOVE FORWARD. AND, MR. HARRISON,
4	IN TERMS OF THE DISCUSSION WE NEED RELATED TO
5	CRITERIA FOR THE TRANSLATIONAL GRANT RFA THAT WILL
6	COME OUT SOON, COULD YOU GIVE US THE CONTEXT IN
7	WHICH THAT SHOULD BE BROUGHT BEFORE US?
8	MR. HARRISON: YES. AT THE LAST MEETING
9	STAFF PRESENTED THE CONCEPT PLAN FOR THE
10	TRANSLATIONAL I RFA FOR APPROVAL, AND THE BOARD
11	APPROVED THE CONCEPT PLAN WITH THE UNDERSTANDING
12	THAT IT WOULD BE RECONCILED BY STAFF TO THE RFA
13	REQUIREMENTS WHICH YOU ADOPTED YESTERDAY.
14	SO NO BOARD ACTION IS REQUIRED ON THE RFA,
15	ALTHOUGH I DON'T KNOW WHETHER STAFF WANTS TO MAKE
16	ANY PRESENTATION. I WOULD DEFER TO
17	CHAIRMAN KLEIN: I THINK WE HAVE A STAFF
18	PRESENTATION AS A DISCUSSION LITEM. AND, DR.
19	TROUNSON, WOULD YOU LIKE TO DIRECT THAT.
20	DR. TROUNSON: I UNDERSTAND ROSA IS GOING
21	TO PRESENT THAT TO YOU.
22	DR. CANET-AVILES: SO, MR. CHAIRMAN,
23	MEMBERS OF THE BOARD AND GUESTS, AS MR. HARRISON
24	MENTIONED, AT OUR PREVIOUS ICOC MEETING, THE BOARD
25	ASKED US TO COME BACK TO ADDRESS THE ELIGIBILITY
	302

1	PROVISIONS FOR THE TRANSLATIONAL RFA AND RECONCILE
2	WITH THE TASK FORCE RECOMMENDATIONS. YOU APPROVED
3	THOSE RECOMMENDATIONS LAST NIGHT. AND JUST AS A
4	REMINDER, THIS ITEM DOES NOT REQUIRE A VOTE AND IS
5	JUST POINT OF INFORMATION.
6	WITH THIS DIAGRAM, WHICH YOU'VE ALL SEEN
7	SEVERAL TIMES, WE WOULD LIKE TO REMIND YOU THAT CIRM
8	HAS A SET OF INITIATIVES DESIGNED TO MOVE STEM CELL
9	RESEARCH INTO THE CLINIC. TRANSLATIONAL I IS THE
10	EARLIEST OF THE INITIATIVES AND SHARES SOME OVERLAP
11	IN SCOPE WITH THE DISEASE TEAMS.
12	IN A COUPLE OF SLIDES, THIS DIAGRAM WILL
13	BE REFERRED WHEN TALKING ABOUT THE RATIONALE THAT
14	CIRM HAS ADOPTED FOR THE NUMBER OF APPLICATIONS PER
15	I NSTI TUTI ON.
16	SO IN TERMS OF ELIGIBILITY FOR THE
17	PRINCIPAL INVESTIGATOR, ALTHOUGH NOT ALL IS LISTED
18	HERE, IT IS, IN FACT, THE DEFINITION OF THE
19	ELIGIBILITY CRITERIA THAT WAS DISCUSSED BY THE TASK
20	FORCE AND AGREED TO BY THE ICOC BOARD YESTERDAY. IN
21	ESSENCE, THE PRINCIPAL INVESTIGATOR MUST HOLD AN
22	M.D. OR A PH.D. OR EQUIVALENT DEGREE AND BE
23	AUTHORIZED BY THE APPLICANT INSTITUTION TO CONDUCT
24	THE PROPOSED RESEARCH IN THE STATE OF CALIFORNIA.
25	CIRM HAS ALSO AGREED THAT A MINIMUM OF A

303

,	10 DEDOCNT EFFORT COMMITMENT FOR THE PRIMALENT
1	10-PERCENT EFFORT COMMITMENT FOR THE PRINCIPAL
2	INVESTIGATOR IS REQUIRED IN THIS PRESENT RFA.
3	HOWEVER, AS RECOMMENDED BY THE TASK FORCE, WE ARE
4	ALLOWING THE EXCEPTION THAT EXTRAORDINARY
5	CIRCUMSTANCES MAY BE APPLIED BY CIRM AT THE
6	DISCRETION OF THE PRESIDENT TO ALLOW SENIOR RESEARCH
7	SCIENTISTS TO HAVE REDUCED PERCENT EFFORT
8	COMMITMENT. AGAIN, THIS WAS AGREED BY THE TASK
9	FORCE YESTERDAY.
10	WE ALSO WANTED TO BRING TO YOUR ATTENTION
11	THE PRESENT ADDITIONAL CONSIDERATION. IN ORDER TO
12	BROADEN THE POOL OF APPLICANTS AND ENCOURAGE A WIDE
13	GROUP OF INVESTIGATORS IN OUR OVERALL TRANSLATIONAL
14	RESEARCH PROGRAM, NOT THE SAME PEOPLE ARE APPLYING
15	FOR BOTH RFA'S, CIRM WILL INCLUDE IN THE
16	TRANSLATIONAL I RFA THE ADDITIONAL CONSIDERATION
17	THAT THE PRINCIPAL INVESTIGATORS MAY APPLY FOR
18	EITHER A TRANSLATIONAL I AWARD OR A DISEASE TEAM
19	RESEARCH AWARD.
20	THIS HAS BEEN ALSO DETERMINED AS THERE IS
21	OVERLAP IN SCOPE BETWEEN BOTH RFA'S. FOR EXAMPLE, A
22	DEVELOPMENT CANDIDATE IS A GOAL IN BOTH PROGRAMS,
23	ALBEIT AN INTERIM GOAL FOR THIS ESTEEMED RESEARCH
24	AWARD.
25	CHAIRMAN KLEIN: AND ON THAT POINT IS A
	304

1	QUESTION, DR. TROUNSON. IF SOMEONE'S A CO-PI ON A
2	DISEASE TEAM GRANT, COULD THEY ALSO BE A CO-PI ON A
3	TRANSLATIONAL GRANT? I'M TRYING TO UNDERSTAND
4	BECAUSE THE SIZE OF THESE TEAMS AND THE
5	INCORPORATION OF EXPERTISE HOW THAT WOULD APPLY.
6	DR. TROUNSON: I HAVEN'T THOUGHT
7	SPECIFICALLY ABOUT THAT, BUT IT IS A POSSIBILITY.
8	THE ISSUE IS THAT I THINK WE'RE ONLY THINKING ABOUT
9	TEN TRANSLATIONAL GRANTS AND, OF COURSE, ABOUT SIX
10	DISEASE TEAMS WITH WHAT WE'RE BRINGING FORWARD, SO
11	THAT'S NOT VERY MANY. I WOULD HAVE THOUGHT, IF THIS
12	FOCUSED REALLY ON THE PRIMARY PI, RATHER, TO SORT OF
13	TRY AND MAINTAIN SOME DIVERSITY IN A VERY TIGHT
14	SELECTION PROCESS HERE WITHOUT TRYING TO SEEK ALL OF
15	THE INPUTS LEFT AND RIGHT HERE.
16	CHAIRMAN KLEIN: SO A CO-PI WHO IS NOT THE
17	PRIMARY MIGHT NOT BE DISQUALIFIED BY THIS PROCESS?
18	DR. CANET-AVILES: CAN I JUST SAY
19	SOMETHING? IN TERMS OF THE TRANSLATIONAL I RFA, DUE
20	TO IMPLEMENTATION ISSUES, WE DO NOT ALLOW CO-PI'S.
21	CHAIRMAN KLEIN: BUT THE PRINCIPAL ON A
22	TRANSLATIONAL GRANT COULD BECOME A COOPERATING CO-PI
23	ON A DISEASE TEAM GRANT.
24	DR. OLSON: YES, THAT'S CORRECT. I THINK
25	PART OF THE GOAL HERE TOO IS WE REALLY DON'T WANT
	205

305

1	THE SAME PROGRAM PRINCIPAL INVESTIGATOR COMING WITH
2	THE SAME GRANT TO BOTH BECAUSE THERE IS OVERLAPPING
3	IN THE TIMEFRAME. AND NO DECISIONS WILL BE MADE ON
4	THE ONE BEFORE THE OTHER. SO I THINK WE'D LIKE TO
5	ENCOURAGE PEOPLE JUST SO WE CAN HAVE A BROADER SCOPE
6	OF APPLICATIONS.
7	DR. STEWARD: I'M SORRY. COULD YOU
8	CLARIFY WHY YOU'RE NOT ALLOWING CO-PI'S ON THIS
9	AGAI N?
10	DR. OLSON: IT'S SIMPLY AN IMPLEMENTATION
11	ISSUE. WE CANNOT HAVE THAT READY FOR TRANSLATIONAL.
12	WE CAN HAVE COLLABORATORS THAT WE HAD BEFORE. WE
13	SIMPLY CANNOT DO THE IMPLEMENTATION FOR CO-PI'S ON
14	THE TRANSLATIONAL I.
15	DR. PRICE: BECAUSE OF YOUR SOFTWARE?
16	DR. OLSON: BECAUSE OF THE WAY YES.
17	BECAUSE OF BASICALLY WHAT THE INSTITUTE'S ABLE TO DO
18	RIGHT NOW. I THINK, AS I INDICATED, WE ARE TRYING
19	IMPLEMENT OUR GRANTIUM PROGRAM. WE ARE HOPING TO
20	HAVE CO-PI'S BY THE TIME OF DISEASE TEAMS. THAT'S
21	OUR GOAL.
22	DR. STEWARD: I WOULD JUST SAY THAT I
23	THINK THAT IS VERY UNFORTUNATE BECAUSE ONE COULD
24	EASILY IMAGINE THAT CO-PI'S WOULD BE A CRITICAL PART
25	OF THE TRANSLATIONAL AWARD IN THE SAME WAY THAT IT
	306

1	IS CRITICAL FOR THE DISEASE TEAM.
2	DR. OLSON: THIS IS AN EARLY TRANSLATIONAL
3	AWARD. I DON'T DISAGREE WITH YOU ON THAT. I THINK
4	WE ARE JUST DEALING WITH THE REALITY OF WHAT WE ARE
5	ABLE TO DO AND THE STAFF THAT WE HAVE WHO COULD
6	HANDLE THAT.
7	CHAIRMAN KLEIN: DR. PIZZO HAS A COMMENT.
8	DR. PIZZO: THE COMMENT IS I CERTAINLY
9	AGREE WITH THE TWO POINTS THAT ARE HERE, BUT I WANT
10	TO MAKE A SUGGESTION. SO I THINK OF THE TWO.
11	BROADEN THE POOL OF APPLICANTS TO ME IS A STRONG
12	ONE. HAVING BEEN INVOLVED MYSELF AT LEAST IN EARLY
13	TRANSLATIONAL AND THEN SORT OF DISEASE-BASED
14	RESEARCH AT ONE PART OF MY CAREER AND HAVING RUN
15	BOTH OF THOSE WITHIN MY OWN LAB GROUP, I CAN
16	ENVISION SCENARIOS WHERE THERE IS SYNERGISTIC
17	OVERLAP RATHER THAN ANTAGONISTIC OVERLAP.
18	SO MY SUGGESTION IS JUST AS IN THE PRIOR
19	SLIDE WHERE YOU HAD AN EXCEPTION BASED UPON THE
20	PRESIDENT OF CIRM, SORT OF THE SAME EXTRAORDINARY
21	CIRCUMSTANCES MAY BE APPLIED, I WONDER IF YOU WOULD
22	BE WILLING TO ENTERTAIN THAT SO THAT WE DON'T
23	PRECLUDE SOMETHING THAT MIGHT BE REALLY EXCEPTIONAL.
24	DR. TROUNSON: ABSOLUTELY. ABSOLUTELY.
25	WITHIN THE SPIRIT OF THINGS. I CAN SEE THAT MAKES
	307

1	SENSE.
2	DR. OLSON: I CAN SEE WHERE THAT MIGHT
3	SHOW UP IN THE GOALS OF EACH PROJECT. WE'RE
4	STRIVING FOR IN THESE EARLY TRANSLATIONAL I AWARDS
5	TO GET DEVELOPMENT CANDIDATES; WHEREAS
6	DR. PIZZO: THINKING ABOUT IT, AGAIN, WHEN
7	I WAS INVOLVED IN A DIFFERENT PART OF MY LIFE, THERE
8	WAS ACTUAL SYNERGY RATHER THAN ANTAGONISM BETWEEN
9	THOSE TWO FACETS OF THE SPECTRUM. SO WE WERE ALWAYS
10	THINKING ABOUT HOW TO BE INVOLVED IN MULTIPLE PARTS
11	OF THAT. IF YOU CAN JUST BE OPEN TO THAT, THAT
12	WOULD BE GREAT.
13	CHAIRMAN KLEIN: DR. PIZZO, AS I
14	UNDERSTAND IT, WHAT THEY WERE TRYING TO AVOID IS
15	HAVING THE PRINCIPAL PI ON BOTH OF THEM BE THE SAME.
16	AND REALLY I THINK THAT WHAT YOU'RE ADDRESSING IS
17	WHAT I WAS ADDRESSING WHERE YOU MIGHT HAVE A
18	PRINCIPAL PI ON THE TRANSLATIONAL WHO'S A CO-PI ON
19	THE DISEASE TEAM; IS THAT CORRECT?
20	DR. PIZZO: I WASN'T ACTUALLY. I WAS OPEN
21	TO THE POSSIBILITY THAT IT MIGHT BE PI-PI. CO-PIS
22	ARE ANOTHER WAY OF LOOKING AT IT. BUT I'M JUST
23	SAYING WITHIN DEPENDS ON THE SIZE AND SCOPE OF
24	THE RESEARCH GROUP AND THE DIMENSIONS THAT ARE GOING
25	ON THERE. I THINK I'M JUST THIS MAY NOT COME UP,
	200

SO IT MAY BE A MINOR ISSUE. BUT ON THE OTHER HAND,
IF SOMEONE DOES COME UP WITH SOMETHING THAT REALLY
IS QUITE EXCITING AND COMPELLING, I WOULD HATE TO
SEE US MISS THAT SYNERGY BETWEEN EARLY TRANSLATION
AND DISEASE BASED.
CHAIRMAN KLEIN: SO YOU'RE ASKING THAT
THERE BE AN EXCEPTION THAT THE PRESIDENT
DR. PIZZO: CARRY THAT SAME ASTERISK OVER.
DR. TROUNSON: IN THE SAME PRINCIPAL, YES.
CHAIRMAN KLEIN: ALL RIGHT. ANY
ADDITIONAL BOARD COMMENTS? ANY ADDITIONAL
DR. CANET-AVILES: YES.
CHAIRMAN KLEIN: I THINK YOU MAY HAVE SOME
MORE TO PRESENT.
DR. PENHOET: CAN I ASK A PRACTICAL
QUESTION? HOW DO YOU WRITE THE RFA TO INCLUDE DR.
PIZZO'S? PUT AN ASTERISK IN?
CHAIRMAN KLEIN: THIS ONE RIGHT HERE,
THAT'S WHAT DR. PIZZO IS SUGGESTING.
DR. OLSON: IT DOES OFFER SOME CHALLENGES,
I THINK, BECAUSE BASICALLY AT THE LEVEL OF THE LOI,
I THINK THERE'D HAVE TO BE A DETERMINATION MADE.
AND, YOU KNOW, IF SO ONE WILL HAVE TO THINK ABOUT
THAT A BIT.
CHAIRMAN KLEIN: SO, ROSA, YOU HAD MORE TO
309

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	PRESENT?
2	DR. CANET-AVILES: SO IN TERMS OF NUMBER
3	OF APPLICATIONS, CIRM ADHERES TO THE PRINCIPLES THAT
4	THE NUMBER OF APPLICATIONS CAN BE LIMITED, AND THIS
5	WAS AGREED BY THE TASK FORCE YESTERDAY AND APPROVED.
6	SO THIS IS MY LAST SLIDE. AND CIRM HAS
7	DETERMINED THAT NONPROFIT INSTITUTIONS WITH
8	ACCREDITED MEDICAL SCHOOLS WILL BE ELIGIBLE TO
9	SUBMIT UP TO THREE APPLICATIONS PER INSTITUTION.
10	NONPROFIT INSTITUTIONS, FOR-PROFIT INSTITUTIONS WITH
11	MORE THAN OR EQUAL TO 250 EMPLOYEES MAY SUBMIT UP TO
12	TWO APPLICATIONS PER INSTITUTION. AND THE REST,
13	NONPROFIT AND FOR-PROFIT INSTITUTIONS, WITH LESS
14	THAN 250 EMPLOYEE MAY SUBMIT UP TO ONE APPLICATION.
15	IN THIS CONTEXT, I WOULD LIKE TO REMIND
16	YOU THAT THE PI'S INSTITUTION IS DETERMINANT OF
17	WHICH CATEGORY THEY WILL FALL INTO. THIS FACT DOES
18	NOT PRECLUDE COLLABORATION AMONG INVESTIGATORS AT
19	DIFFERENT INSTITUTIONS, INCLUDING PUBLIC AND PRIVATE
20	PARTNERSHIPS. AND, IN FACT, CIRM STRONGLY
21	ENCOURAGES THEM. ALL THESE CRITERIA HAVE BEEN
22	DETERMINED BASED ON A SERIES OF CRUCIAL FACTORS THAT
23	DIFFERENTIATE THE PRESENT RFA'S FROM PREVIOUS RFA'S,
24	AND ALSO THE FACT THAT THE TASK FORCE RECOGNIZE THE
25	NEED TO SET LIMITS ON THE WORKLOAD FOR THE GRANTS

1	WORKING GROUP MEMBERS.
2	SO IF YOU HAVE ANY QUESTIONS, I WILL BE
3	HAPPY TO ANSWER THEM.
4	CHAIRMAN KLEIN: THANK YOU, DOCTOR. I
5	DON'T SEE ANY ADDITIONAL COMMENTS. BUT PUBLIC
6	COMMENTS ON THIS ITEM?
7	MR. ROTH: VERY QUICKLY, I'M A LITTLE
8	CONCERNED ABOUT THAT LAST ONE IN TERMS OF THE
9	FOR-PROFIT COMPANIES. THERE AREN'T A LOT OF STEM
10	CELL COMPANIES WITH GREATER THAN 250 EMPLOYEES.
11	CHAIRMAN KLEIN: OKAY.
12	MR. ROTH: SO I WOULD LIKE TO SEE THAT
13	BUMPED AND NOT BE A RESTRICTION ON THE COMPANIES.
14	DR. CANET-AVILES: YOU WANT TO RAISE THE
15	NUMBER?
16	MR. ROTH: I WOULD LIKE TO SEE IT BE TWO
17	BECAUSE I THINK YOU GREATLY RESTRICT. IN FACT,
18	ALMOST ALL THE STEM CELL COMPANIES I'M FAMILIAR WITH
19	ARE FAR UNDER 250 EMPLOYEES. IT WOULD BE NICE IF
20	THEY COULD SUBMIT TWO.
21	DR. OLSON: I JUST WANTED YOU TO KNOW A
22	LITTLE BIT HOW WE GOT TO THIS. FIRST, LET ME REMIND
23	YOU THAT THERE WILL ONLY BE TEN OF THESE AWARDED, AT
24	LEAST THAT IS AT LEAST WHAT THE BOARD APPROVED AT
25	OUR PREVIOUS MEETING ON THE CONCEPT. WE HAVE TAKEN

1	THE INSTITUTIONS THAT HAVE APPLIED TO US IN THE
2	PAST, ONES THAT WE THOUGHT MIGHT BE INTERESTED IN
3	THIS. WE HAVE ACTUALLY MODELED THIS AS TO WHAT WE
4	THINK. WE COULD HAVE AS MANY AS A HUNDRED. SHOULD
5	WE HAVE A HUNDRED APPLICATIONS, WE ARE RIGHT OFF THE
6	BAT IN A DOUBLE REVIEW AGAIN. WE ARE HOPING THAT
7	PEOPLE WOULD BE MORE CONSERVATIVE.
8	I AGREE WITH DUANE. IT IS LIKELY THAT
9	MOST OF THE STEM CELL COMPANIES ARE SMALLER THAN 250
10	EMPLOYEES. WE WOULD POINT OUT THAT THIS IS A
11	SUBSTANTIAL GRANT THAT WE'RE TALKING ABOUT, AND WE
12	WOULD SUGGEST THAT PERHAPS HAVING ONE OF THEM IS
13	PERHAPS NOT INAPPROPRIATE. AND EVERYBODY GETS TO
14	GET THE BEST SHOT. WE HAVE BEEN CONSISTENT IN AT
15	LEAST ALLOWING BOTH THE FOR-PROFIT AND THE NONPROFIT
16	TO HAVE THE SAME NUMBER ON THAT. SO THAT AT LEAST
17	WAS OUR THINKING THERE.
18	IF WE WERE TO RAISE THAT NUMBER TO TWO,
19	THAT WOULD SUBSTANTIALLY INCREASE THE NUMBER OF
20	POTENTIAL APPLICATIONS WE COULD RECEIVE. AND THESE
21	ARE LIKELY TO BE SOMEWHAT BIG APPLICATIONS TOO
22	BECAUSE, AS YOU RECALL, ONE OF THE PRIMARY GOALS
23	HERE IS A DEVELOPMENT CANDIDATE. SO, AGAIN, WHEN
24	YOU HAVE LARGER APPLICATIONS, IT'S MORE OF A
25	WORKLOAD ON YOUR GRANTS WORKING GROUP. SO THESE ARE

1	THE KINDS OF THINGS WE TOOK INTO CONSIDERATION, AND
2	I APPRECIATE DUANE'S COMMENT, BUT THAT WAS THE
3	RATI ONALE.
4	MR. ROTH: JUST THIS IS ABOUT
5	TRANSLATIONAL, AND YOU WANT THE COMPANIES.
6	CHAIRMAN KLEIN: JEFF.
7	MR. SHEEHY: I AGREE WITH DUANE. I MEAN
8	IT'S ABOUT COMPANIES, AND I DO THINK THERE'S AN
9	EQUITY ISSUE. YOU KNOW, WHY AND WE WEREN'T
10	OVERWHELMED BY COMPANIES IN THE TOOLS AND
11	TECHNOLOGY. WE WERE OVERWHELMED BY THE ACADEMIC
12	RESEARCH INSTITUTIONS. SO, YOU KNOW, IF WE
13	EFFECTIVELY SAY THAT FOR COMPANIES IN THIS FIELD,
14	YOU GET ONE APPLICATION, THAT'S IT, BUT IF YOU'RE A
15	NONPROFIT ACADEMIC RESEARCH INSTITUTION, YOU GET
16	THREE, THAT DOESN'T SEEM FAIR. IT JUST DOESN'T.
17	DR. PIZZO: IT DOESN'T SEEM FAIR IN THE
18	OTHER DIRECTION EITHER, TO BE HONEST WITH YOU,
19	BECAUSE THE SIZE OF THE ACADEMIC INSTITUTIONS COULD
20	HAVE LOTS OF PI'S. AND LIMITING THEM TO THREE MAY
21	WELL PRECLUDE SOME OF THE BEST IDEAS COMING FORWARD
22	FOR EARLY TRANSLATION.
23	CHAIRMAN KLEIN: SO A LIVELY DIFFERENCE OF
24	OPINION. WHAT WOULD THE OTHER BOARD MEMBERS THINK
25	OF THESE COMPETING IDEAS? HOW SHOULD WE BALANCE
	212

1	THEM?
2	DR. POMEROY: I THINK THAT MY PRINCIPLE
3	HERE IS THAT THE STAFF HAS PUT A LOT OF EFFORT INTO
4	THINKING ABOUT THESE RECOMMENDATIONS, AND THAT THERE
5	ARE ARGUMENTS ON ALL SIDES. AND SO I THINK I WOULD
6	BE SUPPORTIVE OF ACCEPTING THE STAFF'S
7	RECOMMENDATIONS.
8	CHAIRMAN KLEIN: OKAY. ADDITIONAL
9	COMMENTS FROM THE BOARD MEMBERS?
10	DR. PENHOET: AS A PRACTICAL MATTER, MOST
11	TRANSLATION GOES ON IN COMPANIES, NOT IN ACADEMIA.
12	AND I THINK TO FACE THE REALITY THAT THERE MAY NOT
13	BE ANY STEM CELL COMPANIES IN CALIFORNIA THAT HAVE
14	MORE THAN 250 EMPLOYEES, I'M NOT SURE THERE ARE ANY
15	STEM CELL COMPANIES IN CALIFORNIA THAT HAVE MORE
16	THAN 250 EMPLOYEES, WELL, MAYBE ONE OR TWO AT THE
17	MOST.
18	SO I DO THINK I AGREE WITH DUANE. I
19	THINK IT'S AN ARTIFICIAL CONSTRAINT AGAINST THE VERY
20	GROUP THAT WE'RE HOPING TO ENLIST IN TRANSLATIONAL
21	WORK. SO I WOULD MOVE TO WIPE OUT THE BOTTOM
22	CATEGORY AND SIMPLY HAVE TWO CATEGORIES.
23	CHAIRMAN KLEIN: LET ME ASK THIS QUESTION.
24	I KNOW THAT THERE'S BEEN A DISCUSSION THAT THERE ARE
25	START-UP FOR-PROFIT COMPANIES THAT MAY HAVE TEN

1	EMPLOYEES. DO YOU WANT TO TREAT THEM THE SAME AS
2	SOMEONE THAT HAS A HUNDRED EMPLOYEES? DO YOU WANT
3	TO PAINT THIS WITH A LITTLE FINER BRUSH? WOULD YOU
4	LIKE TO SAY IF THEY HAVE OVER 75 EMPLOYEES, THAT
5	THEY GET TWO?
6	THE ISSUE HERE IS DO WE WANT TO REALLY
7	TREAT A TRUE START-UP WITH FIVE OR TEN EMPLOYEES THE
8	SAME AS A NONPROFIT ENTITY THAT HAS, YOU KNOW, 150
9	PEOPLE WITH 50 PI'S AMONG THEM? THE ISSUE HERE IS
10	BALANCE. MAYBE AN ALL OR NONE IS NOT NECESSARILY
11	THE ONLY OPTION WE HAVE BEFORE US.
12	DR. PENHOET: I'M JUST ARGUING FOR TWO.
13	I'M NOT ARGUING ALL OR NONE.
14	CHAIRMAN KLEIN: YOU'RE ARGUING FOR TWO IS
15	FOR THE 10-PERSON COMPANY AS WELL AS THE
16	HUNDRED-PERSON COMPANY.
17	DR. PENHOET: I WOULDN'T DISTINGUISH ON
18	THE BASIS OF SIZE.
19	DR. OLSON: I JUST WANT TO RAISE THIS
20	CONCERN, AND DUANE AND MAYBE ED COULD ADDRESS IT
21	BECAUSE THEY HAVE SOME EXPERIENCE WITH IT AS WELL.
22	IT'S OUR I AM CONCERNED THAT YOU HAVE A COMPANY
23	WHO MAYBE HAS A PI, BUT DOESN'T HAVE EVERYBODY IN
24	PLACE TO DO THIS, AND THEY DON'T HAVE THE FINANCIAL
25	CONCERNS AND EVERYTHING. HOW ARE THEY GOING TO

1	START OFF, AND YOU'RE GOING TO GIVE THEM \$2 MILLION
2	A YEAR OR UP TO \$2 MILLION A YEAR TO MOVE FORWARD.
3	AGAIN, WITH RESPONSE TO YOUR POINT OF TWO,
4	DO YOU WANT OUR PROJECTS TO BE THEIR ONLY PROJECTS,
5	TO BE ESSENTIALLY THE BULK OF THEIR WORK? I GUESS
6	THAT WAS ALSO PART OF THE ISSUE ABOUT THE ONE. THIS
7	WOULD BE A MAJOR COMPONENT OF THEIR WORK, BUT DO YOU
8	WANT IT TO BE THE SOLE FOCUS? IS THAT WHAT THEY'RE
9	DOING? ARE WE THE REASON ARE WE IN THE WORDS
10	OF A VENTURE CAPITALIST, ARE WE A HUNDRED PERCENT OF
11	THEIR FUNDING? ARE WE THE SOLE PROVIDER? THESE ARE
12	CONSI DERATI ONS.
13	DR. PENHOET: YOU'RE MAKING THAT DECISION
14	BEFORE YOU SEE WHAT THEY PROPOSE.
15	DR. OLSON: I GUESS I'M ALSO TRYING TO
16	ADDRESS HOW MUCH WILL THE REVIEWERS HAVE TO LOOK AT.
17	MR. ROTH: I THINK THE ANSWER, PAT, TO
18	YOUR QUESTION IS THEY SELF-SELECT. I DON'T THINK
19	ALL RIGHT. YOU KNOW BETTER.
20	CHAIRMAN KLEIN: WE HAVE DR. POMEROY AND
21	THEN JEFF.
22	DR. POMEROY: I JUST WANT TO REMIND
23	EVERYONE THAT THESE ARE FOR WHO THE PI IS. AND SO A
24	SMALL COMPANY COULD BE INVOLVED WITH THREE
25	APPLICATIONS. AND THIS IS A LOT OF WORK TO PUT ONE

316

1	OF THESE HUGE GRANTS, AND HOW REALISTIC IS IT FOR A
2	SMALL TEN-PERSON COMPANY TO PUT TOGETHER TWO MAJOR
3	GRANTS IN THIS TIME PERIOD AS THE PI'S? IT'S
4	DIFFERENT THAN ENCOURAGING THEM TO BE INVOLVED IN
5	OTHER APPLICATIONS THROUGH PARTNERSHIPS.
6	DR. TROUNSON: MR. CHAIRMAN, I TAKE THE
7	TENOR OF THE DISCUSSIONS. WE THINK THAT WE'RE ONLY
8	GOING TO GIVE TEN OF THESE AWARDS. WE BETTER BE
9	CAREFUL THAT WE DON'T INVOLVE 60 OR 80 PEOPLE IN
10	WRITING GRANTS. I THINK THEY OUGHT TO PUT THEIR
11	BEST FOOT FORWARD. I'D BE REALLY SURPRISED IF MANY
12	OF THESE COMPANIES WILL REALLY HAVE A HIGHLY ARGUED
13	CASE FOR MORE THAN ONE. IF THEY DO, THEY'LL BE
14	ASTONISHINGLY IT WILL BE SURPRISING.
15	THIS IS NOT THE ONLY TIME WE'RE GOING TO
16	DO IT, AND I THINK WE DON'T A, WE DON'T WANT TO
17	OVERWHELM THE REVIEWERS; BUT, B, WE DON'T WANT TO
18	TAKE ALL THE TIME FROM ALL THESE PEOPLE TO WRITE
19	NUMEROUS NUMBERS OF VERY COMPLEX GRANTS. AND SO I
20	THINK IT'S TIME ON BOTH SIDES.
21	I LISTENED TO THE DISCUSSIONS OF THE STAFF
22	ON THIS MATTER. I FELT IT WAS FAIR AND REASONABLE
23	THIS TIME. I THINK THERE'S SOME TOE-IN-THE-WATER
24	FEELINGS THAT WE'VE GOT TO GET FROM INDUSTRY. AND I
25	THINK WE'VE ALSO GOT TO BE FAIR TO THE GREAT MEDICAL

1	INSTITUTES THAT ARE HERE AND WE'VE DRAWN INTO MAJOR
2	FACILITIES. THEY OFFER A VERY WIDE COMPENDIUM OF
3	OPPORTUNITY. I THINK MAKING THEM THREE IN MANY
4	INSTANCES IS A VERY HARD TASK FOR THOSE
5	I NSTI TUTI ONS.
6	CHAIRMAN KLEIN: WE ALSO WOULD EXPECT, I
7	WOULD THINK, IN THE TRANSLATIONAL AREA TO HAVE SOME
8	OF THE COMPANIES COLLABORATING WITH THE ACADEMIC
9	INSTITUTIONS ON SOME OF THESE GRANTS. SO THERE'S
10	MORE THAN ONE DOOR FOR PRIVATE PARTICIPATION, BUT
11	MR. ROTH: JUST TO BE CLEAR, IT SAYS
12	MAXIMUM NUMBER OF APPLICATIONS PER INSTITUTION.
13	DOESN'T SAY PER PI. THAT'S MAYBE PART OF THE
14	CONFUSION HERE. CAN THEY APPLY THROUGH MULTIPLE
15	SOURCES HERE?
16	CHAIRMAN KLEIN: MY UNDERSTANDING, PLEASE
17	CORRECT ME, DR. TROUNSON, IF I'M INCORRECT ON THIS,
18	IS THAT A FOR-PROFIT ENTITY COULD BE COLLABORATING
19	WITH A MEDICAL SCHOOL IN AN APPLICATION. THEY COULD
20	BE ONE OF THE COLLABORATING PARTIES.
21	DR. TROUNSON: IN THIS OCCASION, THE PI
22	AND THE INSTITUTE ARE ESSENTIALLY THE SAME BECAUSE
23	THERE'S ONLY ONE PI. SO LET'S TAKE IT THAT'S
24	WHAT THE INTENTION OF THIS WAS. SO THAT BUT THE
25	PI COULD BE AN ASSOCIATE IN OTHER GRANTS BECAUSE

1	WE'RE ONLY HAVING ONE PI THIS TIME.
2	BY THE TIME WE GET TO DISEASE TEAMS AND
3	THEREAFTER, WE'LL HAVE MULTIPLE PI'S, IMPORTANT, I
4	THINK, IMPORTANT TRANSITIONS TO TEAM PROCESSES FOR
5	WHICH, YEAH, I THINK FURTHER CONSIDERATION WOULD BE
6	NECESSARY. BUT FOR THIS PARTICULAR ONE, WE'RE
7	TALKING ABOUT ONE PI, ONE INSTITUTE LEADER.
8	CHAIRMAN KLEIN: ONE INSTITUTE LEADER, BUT
9	DOESN'T RULE OUT COLLABORATIONS BETWEEN THE
10	FOR-PROFIT SECTOR AND THE NONPROFIT SECTOR.
11	MR. ROTH: IF THAT'S CLEAR, THEN IT'S
12	PROBABLY OKAY.
13	DR. OLSON: PI IS DETERMINATIVE OF WHAT
14	CATEGORY THEY FALL IN.
15	CHAIRMAN KLEIN: JEFF SHEEHY.
16	MR. SHEEHY: I JUST WANT TO GO BACK TO THE
17	PRINCIPLE, AND THE PRINCIPLE IS TO LIMIT THE NUMBER
18	OF APPLICATIONS. IT SEEMS TO ME IF WE WERE STILL TO
19	MAINTAIN OUR THREE CATEGORIES BECAUSE I DO THINK
20	NONPROFIT INSTITUTIONS UNDER 250 WOULD SEND IN AN
21	APPLICATION. BUT IT'S NOT I'M NOT CONVINCED THAT
22	IF WE ALLOWED JUST HAD ONE FOR-PROFIT CATEGORY
23	AND ALLOWED THEM TWO THAT THE SMALL COMPANIES WOULD
24	TAKE ADVANTAGE OF THAT AND ABUSE THAT, AND THAT THEY
25	WOULD SEND IN I THINK AS PEOPLE HAVE DESCRIBED,
	210

1	FOR THE SMALL COMPANIES, IT WILL BE ENOUGH WORK JUST
2	TO GET ONE IN. BUT RATHER THAN BUT I ALSO THINK
3	FOR ONES ON THE LARGER SIDE, THEY MAY HAVE THIS
4	IS WHAT THEY DO. THEY MAY HAVE TWO PROJECTS THAT
5	ARE WORTHY OF OUR CONSIDERATION. AND I DON'T THINK
6	THAT THEY'RE GOING TO OVERWHELM I'M NOT SURE THAT
7	THEY'RE GOING TO OVERWHELM US. WE HAVEN'T BEEN
8	OVERWHELMED BY INDUSTRY SO FAR. I MAY BE WRONG.
9	MAYBE IF WE TELL COMPANIES THEY CAN HAVE TWO,
10	EVERYBODY IS GOING TO SEND IN TWO, BUT IT'S NOT
11	GOING TO HELP THEM.
12	CHAIRMAN KLEIN: THE PRIOR GRANTS HAVE NOT
13	BEEN OF THIS SCALE.
14	DR. OLSON: WE HAVE HAD 40 OVER 40
15	FOR-PROFIT COMPANIES SUBMITTING TO US. 40, OVER 40,
16	AND MOST OF THEM ARE PROBABLY SMALLER.
17	CHAIRMAN KLEIN: WHAT PERCENTAGE OF THOSE
18	WERE IN THE TOOLS?
19	DR. OLSON: MANY.
20	CHAIRMAN KLEIN: WITH \$6 MILLION AT PLAY,
21	YOU COULD HAVE
22	DR. OLSON: MORE INTEREST.
23	DR. TROUNSON: I THINK IT'S A PRETTY BIG
24	INDUCEMENT TO BE AN APPLICANT.
25	CHAIRMAN KLEIN: SO
	320
	JZU

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	DR. PIZZO: SO THE BOTTOM LINE IS, I THINK
2	CLAIRE STATED IT, THIS IS A RECOMMENDATION. WE CAN
3	MODIFY THESE THINGS GOING FORWARD. I WOULD PREFER
4	THERE NOT TO BE A LIMIT ON THE NUMBER OF
5	APPLICATIONS AT ALL. I'VE STATED THAT BEFORE. I
6	WOULD PREFER TO HAVE MORE PER NONPROFIT MEDICAL
7	SCHOOL-BASED INSTITUTION. I THINK THAT WOULD BE A
8	GOOD THING, BUT I UNDERSTAND WHY YOU'VE DONE IT THIS
9	WAY. SO I WOULD ADVISE THAT WE TRY THIS AND SEE
10	WHAT HAPPENS. WE CAN COME BACK AND REVISE IT
11	OBVIOUSLY FOR SUBSEQUENT AWARDS.
12	CHAIRMAN KLEIN: ALL RIGHT. IS THERE
13	PUBLIC COMMENT ON THIS ITEM? SEEING NO PUBLIC
14	COMMENT, WE HAVE A NUMBER
15	DR. PIZZO: I HAVE TO SAY, JOHN, WHAT'S
16	HAPPENED? THIS IS THE FIRST TIME.
17	CHAIRMAN KLEIN: THANK YOU VERY MUCH. AT
18	THIS POINT I WOULD SAY I'M JUST GOING TO CARRY OVER
19	TO THE NEXT MEETING ANY ADDITIONAL ITEMS. WE'VE
20	LOST SO MUCH OF OUR BOARD, WE'LL NO LONGER BE
21	REPRESENTATIVE IN OUR DISCUSSIONS.
22	THERE'S A LIVER PATIENT HERE FROM UC DAVIS
23	WHO CAME TO MAKE A PUBLIC COMMENT, AND LET'S TRY AND
24	RESPECT THE FACT THEY'VE COME THIS FAR. IF YOU
25	WOULD PLEASE COME FORWARD. THANK YOU VERY MUCH,
	204

1	MELISSA KING.
2	AGAIN, THANK YOU FOR THE STAFF FOR THEIR
3	TREMENDOUS DEDICATION. THANK YOU FOR THE BOARD
4	MEMBERS. IT'S SUCH AN EXTRAORDINARY EVENT TO HAVE
5	ILLNESS AND EXIGENT CIRCUMSTANCES AFFECT SO MANY OF
6	OUR BOARD MEMBERS AT ONE TIME. BUT, AGAIN, IT
7	RAISES A GREAT CHALLENGE THAT I'M SURE THAT CHAIR OF
8	OUR GOVERNANCE COMMITTEE IS UP TO.
9	MS. LANSING: I'M INTO THIS.
10	CHAIRMAN KLEIN: SO THANK YOU ALL OF YOU
11	FOR YOUR UNDERSTANDING AS WE'VE HAD IN REAL-TIME TO
12	ADJUST, BUT IT'S BEEN A VERY PRODUCTIVE SESSION, A
13	LOT OF GOOD SUBSTANTIVE DECISIONS, AND THE FACULTY
14	PROGRAM HAS MOVED FACULTY II PROGRAM IS MOVING
15	FORWARD WITH SOME MAJOR APPROVALS WE'VE ALREADY
16	MADE, AND, OF COURSE, WE HAVE SOME DEFERRED
17	DISCUSSIONS FOR THE NEXT SESSION ON THE REMAINING
18	OUTSTANDING APPLICANTS.
19	JENNA, COULD YOU GIVE ME A READ FROM
20	MELISSA IF THERE'S GOING TO BE ANY DELAY IN HELPING
21	THE LIVER PATIENT TO COME IN, PLEASE? CERTAINLY WE
22	SHOULD PROBABLY TAKE THIS MOMENT TO GIVE A ROUND OF
23	APPLAUSE TO THE MANAGEMENT AND STAFF WHO ALWAYS PUT
24	TOGETHER THIS REMARKABLE EFFORT. AND TO MELISSA

KING AND JENNA FOR PULLING THIS TOGETHER WITH HELP

25

1	FROM EVERYONE, BUT COULD WE GIVE A GREAT ROUND OF
2	APPLAUSE TO THE MANAGEMENT AND STAFF.
3	(APPLAUSE.)
4	MS. TAKAHASHI: GOOD AFTERNOON. MY NAME
5	IS JODY TAKAHASHI. ABOUT 14 MONTHS AGO I HAD A
6	LIVER TRANSPLANT. IT WAS FULMINANT LIVER FAILURE.
7	THEY DON'T KNOW WHAT HAPPENED TO ME, WHY MY LIVER
8	FAILED. I CAME VERY CLOSE TO DYING, ABOUT SIX HOURS
9	BEFORE THEY FOUND AN ORGAN FOR ME.
10	I GOT A CALL NOT TOO LONG AGO STATING THAT
11	THERE WAS SOME RESEARCH THAT WAS ONGOING ON STEM
12	CELL RESEARCH FOR REGENERATION OF LIVERS. AND WOULD
13	I COME UP SPEAK WITH YOU FOLKS AND KIND OF GIVE MY
14	STORY. AND EXCUSE ME. I'M REALLY, REALLY NERVOUS.
15	IT'S KIND OF HARD TO TALK ABOUT AS FAR AS WHAT
16	HAPPENED. BUT I WAS VERY HEALTHY. I WAS PROBABLY
17	THE HEALTHIEST I HAD EVER BEEN IN MY WHOLE LIFE, AND
18	I GOT JAUNDICED ONE DAY. AND IT KIND OF WENT
19	DOWNHILL FROM THERE. I ENDED UP IN THE HOSPITAL AND
20	TWO DAYS LATER I WAS IN A COMA. IT CAME VERY CLOSE,
21	LIKE I SAID, ABOUT SIX TO 12 HOURS THAT THEY WERE
22	MAKING THE DECISION WHETHER OR NOT I SHOULD BE
23	TRANSPLANTED. THEY WEREN'T SURE IF THE DAMAGE TO MY
24	BRAIN WAS TOO SIGNIFICANT AND THEY WERE JUST GOING
25	TO LET ME DIE OR NOT.
	323

1	AND THE REASON I'M UP HERE IS I THINK, IN
2	ESSENCE, IF STEM CELL RESEARCH CAN HELP TO PROLONG
3	SOMEONE'S LIFE WHO HAS LIVER DISEASE, WHETHER IT'S
4	FULMINANT OR HEPATITIS C OR CIRRHOSIS OF THE LIVER,
5	IT CAN GIVE US THREE MONTHS, A MONTH IN ORDER TO TRY
6	AND HELP OUR LIVERS REGENERATE AND GET HEALTHY AGAIN
7	OR FIND A DONOR BECAUSE THERE ARE SO FEW, I THINK
8	IT'S SOMETHING THAT WE NEED TO CONTINUE RESEARCHING.
9	IT PROBABLY WOULDN'T HAVE HELPED ME
10	BECAUSE I GOT SICK SO QUICKLY, BUT IT COULD HELP
11	THOSE WHO KNOW THAT THEY'RE SICK AND CAN HAVE THAT
12	TIME TO GET ANOTHER MONTH FOR A DONOR TO BE FOUND OR
13	A LIVER TO BE GROWN, I GUESS. IT'S AMAZING
14	TECHNOLOGY.
15	SO THAT'S ABOUT IT. THANK YOU SO MUCH. I
16	APPRECIATE YOUR TIME.
17	CHAIRMAN KLEIN: THANK YOU.
18	(APPLAUSE.)
19	CHAIRMAN KLEIN: AND JUST TO DOUBLE
20	UNDERLINE MY REFERENCE TO THE STAFF AND THE
21	MANAGEMENT WAS VERY FUNDAMENTALLY FOCUSED ON THE
22	TREMENDOUS CONTRIBUTIONS AND EFFORTS OF THE
23	SCIENTIFIC STAFF PUTS TOGETHER TO MAKE EVERY ONE OF
24	THESE REVIEW SESSIONS WORK BECAUSE REGARDLESS OF
25	WHATEVER INDIVIDUAL DIFFERENCES AND PERSPECTIVE, THE
	324

1	SCIENTIFIC STAFF JUST DOES A REMARKABLE JOB.
2	AND MELISSA KING, WHILE YOU WERE OUT, I
3	ALSO THANKED YOU AND JENNA FOR THE LOGISTICS AND THE
4	HEROIC EFFORTS TO TRY AND MAINTAIN, AGAINST ALL
5	ODDS, A FUNCTIONAL QUORUM. BUT HOPEFULLY YOUR JOB
6	WILL BECOME EASIER WITH THE LEADERSHIP OF SHERRY
7	LANSI NG.
8	MS. LANDING: WE CAN'T FAIL, MELISSA.
9	CHAIRMAN KLEIN: AGAIN, THANK THE
10	SCIENTIFIC STAFF, THANK THE PUBLIC, THANK THE BOARD,
11	THANK YOU FOR A PRODUCTIVE SESSION. WE ARE
12	ADJOURNED.
13	(THE MEETING WAS THEN ADJOURNED AT
14	02: 47 P. M.)
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
	325

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

STANFORD UNIVERSITY
ARRILLAGA ALUMNI CENTER
MC GAW HALL, 326 GALVEZ STREET
STANFORD, CALIFORNIA
ON
AUGUST 13, 2008

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

Beek C. Drain

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 BRISTOL STREET SUITE 100 COSTA MESA, CALIFORNIA (714) 444-4100